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VAbstract
Background: Abnormal thrombus formation and occlusion of a vessel is one of
the main events of cardiovascular disease. A main component of the thrombus
is the protein fibrin, which is formed by proteolytic cleavage of its precursor
fibrinogen by the serine protease thrombin. The cleavage of fibrinogen to fibrin
releases fibrinopeptides from the E-region of the molecule which leads to the
exposure of peptide sequences termed knobs A and B. The knobs A and B on
one fibrin molecule are able to spontaneously interact to binding pockets (termed
holes a and holes b) via hydrogen bonds forming half staggered protofibrils.
These protofibrils laterally aggregate and form fibrin fibers, providing the clot its
strength and stability. Recent molecular dynamic simulations have predicted that
there are additional interactions involving amino acids γGlu323 with βLys58, 
γLys356 with βAsp61, and γAsp297 with βHis67, that surround the binding 
pocket and provide additional strength and stability to the ‘classical’ knob-hole
contact. In this project I have termed these residues ‘extended D-E knob-hole
binding sites.’
Aim: The aim of this project was to probe the importance of these extended
knob-hole interactions in the process of fibrin polymerisation, clot structure and
clot mechanics, using recombinant fibrinogen variants with mutations that
abolish these electrostatic interactions.
Methods: Four recombinant human fibrinogen variants and WT proteins were
produced. The following variants with single point mutations in the γ-chain of 
extended knob-hole binding region were produced: γD297N, γE323Q and 
γK356Q. A triple variant, γDEK (γD297N/γE323Q/γK356Q) with mutations in all 
residues involved was also produced. Each variant was tested for integrity by
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circular dichroism and SDS-PAGE. Turbidity and atomic force microscopy were
used to study polymerisation kinetics, laser scanning confocal microscopy and
scanning electron microscopy were used to study clot structure. Light scattering
methods were used to study intrafibrillar protein structure, and clot mechanics
was studied using an in-house micro-rheometer.
Results: Longitudinal protofibril growth was disrupted for all variants except
γK356Q at early stages of polymerisation, but normalised at later time points. 
Vmax was reduced for all variants. γDEK and γE323Q produced denser clots, 
whereas γD297N and γK356Q were similar to WT. All variant clots had 
significantly thinner fibers compared to WT. All variants were slower to lyse, with
the exception of γD297N. Clot visco-elastic analysis showed that γDEK was 
more readily deformable (loss tangent, tanδ), at low frequencies but single 
mutant variants were unchanged at all frequencies compared to WT.
Conclusion: I produced pure and intact recombinant human fibrinogens with
mutations at the extended knob-hole binding sites. These data provide clear
evidence for the role of extended D-E interactions in supporting the classical
knob-hole binding during fibrin formation. Furthermore, the extended D-E
interactions were shown to alter clot structure and clot mechanics. Additional
studies with these variants in the presence of cells and other vascular
components may further elucidate the importance of extended knob-hole
interactions in haemostasis and thrombosis.
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1Chapter 1 - Introduction
21.1 Cardiovascular disease and coagulation
Approximately 17.5 million people died of cardiovascular diseases (CVD) in 2012
globally (Mendis, 2017) with over 4 million deaths per year in the European Union
(Townsend et al., 2016). This emphasises that CVD is an important area for
research to further understand the aetiology of the disease in order to develop
new methodologies and technologies to improve patient outcomes. The literature
suggests that the rate of cardiovascular disease progression is in decline and is
attributed to increased options for one to partake in a healthier lifestyle (Roth et
al., 2015). One of the main contributors to cardiovascular disease is thrombosis
(Previtali et al., 2011), with half a million deaths per year in Europe associated
with venous thrombosis alone (Rosendaal, 2016).
Thrombosis is the formation of abnormal blood clots within a vessel. Arterial
thrombosis occurs in high pressure arteries, whereas venous thrombosis forms
in the deep veins under low shear stress (Cilia La Corte et al., 2011). Arterial
thrombosis, responsible for myocardial infarction and ischemic stroke can occur
from the formation, build-up and rupture of atherosclerotic plaques (Zaman et al.,
2000) detailed in Figure 1-1, or through the formation of a platelet plug when
collagen fibers are exposed to flowing blood due to endothelium damage
(Tomaiuolo et al., 2017). Formation of the atherosclerotic plaque is initiated when
low density lipoprotein (LDL) can no longer be transported normally from the
blood in the lumen of a vessel via transcytosis by endothelial cells (Magalhaes
et al., 2016). The endothelial cells of the vessel become damaged, which can be
caused by many factors such as hypertension (Dharmashankar and Widlansky,
2010; Puddu et al., 2000), smoking (Messner and Bernhard, 2014; Johnson et
3al., 2010), high blood glucose levels (Esper et al., 2008; Hadi and Suwaidi, 2007),
and hypercholesterolemia (Landmesser et al., 2000; Stapleton et al., 2010).
The damage that is caused by these factors increases the permeability of the
endothelial wall giving arise to an influx of LDL molecules to the surrounding
vessel intima. Damaged endothelial cells also express receptors where
monocytes can bind, allowing them to undergo morphological changes and
migrate through the endothelial wall (Gerhardt and Ley, 2015). Free radicals
excreted by the monocytes oxidise the LDL (Xing et al., 1998). The presence of
oxidised LDL and monocytes enables the recruitment of more monocytes to the
tissue that in turn produces more free radicals, causes further oxidation of LDL
molecules, leading to the accumulation of monocytes and oxidised LDL in the
tissue. Monocytes differentiate into macrophages in the tissue and engulf the
oxidised LDL (Seo et al., 2015). They eventually become saturated, becoming
foam cells, which then undergo apoptosis, the accumulation of cell debris and
oxidised LDL forms a lipid core (Tabas, 2010). The atherosclerotic plaque can
rupture under physical stresses, and can release tissue factor originally from the
apoptosis of macrophages within the plaque (Tatsumi and Mackman, 2015). This
initiates the coagulation cascade with the end product being a clot known as an
occlusive thrombus (Hagedorn et al., 2010). When an occlusive thrombus forms
in the coronary arteries, downstream oxygen levels become dramatically
reduced (Tremoli et al., 1999) often leading to death of cardiomyocytes and
ultimately heart failure (myocardial infarction) (Talman and Ruskoaho, 2016).
Thrombi can also break off from the site of formation travelling to a vessel
downstream blocking the flow of blood, this process is known as embolisation.
In arterial thrombosis, the thrombi that form are termed ‘white thrombi’ as they
4are rich in platelets and fibrin due to the flowing blood coming into contact with
tissue factor on the surface of the atherosclerotic plaque (Jerjes-Sanchez, 2005).
Physical damage to the endothelium can also cause a platelet plug to occur,
Figure 1-2. The first step of this process is when the damage to the endothelium
causes the sub endothelial tissue (containing collagen) to be exposed, leading
to von Willebrand factor (vWF) from the bloodstream binding to collagen fibers
(Peyvandi et al., 2011). Platelets are able to bind to collagen through this
immobilised vWF but also through receptors on the platelets such as α2β1 
(Wang et al., 2003) and GPVI (Jung et al., 2008). Platelet adhesion to collagen
triggers a cascade of events that activate the platelets causing a morphological
change and platelet aggregation where extruding filopodia can be observed, this
process is commonly known as ‘platelet spreading’ (Aslan et al., 2012). Platelet
spreading increases the surface area of the platelets. The accumulation and
aggregation of platelets at the site is called a platelet plug. Following activation
and spreading, platelets release contents of their α-granules such as fibrinogen, 
factor V, vWF (Paul et al., 1999) and ADP, ATP, serotonin, calcium and
polyphosphate from dense granules (Woulfe et al., 2001). The release of ADP
serves as a positive feedback loop for more platelet aggregation to occur.
Platelets are linked together by fibrinogen via the platelet receptor αIIBβ3
(Podolnikova et al., 2014). One of the final events of haemostasis and
coagulation is the conversion of fibrinogen to fibrin by serine protease thrombin
(Rocco, 2008), giving arise to the fibrin network that stabilises the clot
(van Kempen et al., 2014).
5Figure 1-1 Mechanisms of atherosclerosis (1) Endothelial cells become compromised making the endothelial cell barrier more
permeable and allowing influx of low density lipoprotein (LDL) to the surrounding tissue. (2) Upon damage, endothelial cells express
receptors where monocytes bind and undergo morphological changes to migrate through the endothelial barrier. (3) Monocytes
secrete free radicals. (4) The free radicals oxidise LDL molecules. (5) The presence of oxidised LDL and monocytes enables the
recruitment of more monocytes which secrete more free radicals. Eventually, monocytes undergo morphological changes and
become macrophages. (6) Macrophages engulf free oxidised LDL and are termed foam cells due to their foamy appearance, they
undergo apoptosis and become incorporated into an atherosclerotic core/plaque which can rupture causing clot formation within
the vessel.
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6Figure 1-2 Vessel following platelet plug formation Damage to the endothelium causes the endothelial cells and collagen to be
exposed. Platelets (blue) are able to bind, through immobilised vWF, (not shown), but also through receptors on the platelets such
as α2β1 and GPVI, leading to activation of platelets (spikey blue cells). Activation triggers intracellular signalling events causing 
them to increase in surface area and spread. Platelets are linked together by fibrinogen via the platelet receptor αIIBβ3. Fibrin 
(yellow strands) produced by the coagulation cascade forms a network around the platelet plug.
Site of endothelial injury
Red Blood Cells
7Venous thrombosis is caused by three factors that have been defined as the
Virchow’s triad (Esmon, 2009): stasis (or the disturbance of normal laminar flow
of the blood), hypercoaguability and endothelial dysfunction. Stasis, the
complete stopping or slowing down of the blood flow, can be caused by reduced
mobility and increases one’s risk due to the accumulation of coagulation factors
(Wessler, 1962). Endothelial dysfunction can disrupt coagulant and anti-
coagulant functions in addition to platelet adhesion and activation (Poredos and
Jezovnik, 2017). The hypercoagulability of the blood can be caused by a number
of factors such as pregnancy (James, 2009), surgery (Ulrych et al., 2016),
increased hormone levels (Tchaikovski and Rosing, 2010) and deficiencies in
coagulation inhibitors (Esmon, 2009). The use of heparins has been the standard
treatment of venous thromboembolism for many years as heparins are efficient
at preventing further thrombus growth through the inhibition of factor Xa and
thrombin by enhancing antithrombin (Ageno and Huisman, 2000).
Two pathways can initiate the coagulation cascade, the tissue factor pathway
and the contact factor pathway, The contact and tissue factor pathway merge
where factor Xa cleaves prothrombin to thrombin. Thrombin then converts
fibrinogen to fibrin, but also activates factor XIII which cross-links fibrin
monomers to create a cross-linked fibrin network. The tissue factor pathway is
initiated by the exposure of tissue factor by damaged vessels (Mann et al., 1998),
whereas the contact factor pathway is initiated when factor XII is activated
through contact with a negatively charged surface (Naudin et al., 2017). In both
pathways, clotting factors become activated by proteolytic cleavage by other
clotting factors upstream in the cascade and both pathways consolidate to a
common pathway. In this instance, factor Xa cleaves prothrombin to thrombin
8(Cabral and Ansell, 2015), which in turn cleaves soluble fibrinogen that self-
assembles into an insoluble fibrin polymer (Doolittle, 1984). Simultaneously
thrombin also activates factor XIII, which forms γ-glutamyl lysine bonds that 
‘cross-link’ the fibrin network, stabilising the clot network further (Ariëns et al.,
2002).
Coagulation occurs in two phases, initiation and propagation (Smith et al., 2015).
Coagulation is initiated when membrane bound tissue factor within the sub
endothelial matrix is exposed and causes binding to factor VII in the blood
forming activated FVII (FVIIa) (Mackman, 2009). The binding of these factors
forms a protease complex that proteolytically activates factors FIX and FX,
producing active forms FIXa and FXa. Factor Xa produces small amounts of
thrombin through the cleavage of prothrombin. This small amount of thrombin
that is generated is not enough to cleave fibrinogen to fibrin, however it is able
to cleave FXI to FXIa which, in turn cleaves FIX to FIXa, which cleaves additional
FX to FXa, producing even more thrombin. During the propagation phase the
small amount of thrombin generated is able to activate factors FV and FVIII to
their activated forms FVa and FVIIIa respectively which also cleave larger
amounts FX to FXa by functioning as cofactors for FXa and FIXa respectively on
the platelet surface (Yang and Walsh, 2005; Sinha et al., 1983). Ultimately this
leads to the generation of thrombin in large enough quantities to initiate fibrin
polymerisation.
9Figure 1-3 Diagrammatic representation of coagulation The contact and
tissue factor pathway merge where factor Xa cleaves prothrombin to
thrombin. Thrombin then converts fibrinogen to fibrin, but also activates
factor XIII which cross-links fibrin monomers to create a cross-linked fibrin
network. Image reused from (Crooks and Hart, 2015) with permission
from European Respiratory Review.
1.2 Fibrinogen
Fibrinogen was originally known as factor I (Alami et al., 1968) and its primary
function is to provide the mechanical strength and stability to clots (Kim et al.,
2014; Glidden et al., 2000; Zhmurov et al., 2011). Other physiological roles
include inflammation (Alexander et al., 2011; Hennigs et al., 2014; Davalos and
Akassoglou, 2012), angiogenesis (Staton et al., 2003; Sahni and Francis, 2000;
Hadjipanayi et al., 2015) and very recently it was found that fibrin is involved in
wound protection through the production of a fibrin sheet (Macrae et al., 2018).
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In the blood of a healthy individual, fibrinogen circulates in the body at
approximately 1.5g to 3.5g per litre (Takeda, 1966), this amount can increase
rapidly during inflammation as fibrinogen is an acute phase response
inflammatory protein (Jain et al., 2011). Others have reported that fibrinogen
levels can increase up to as much as 8g per litre in pathophysiological conditions
(Machlus et al., 2011).
A great deal of structural information has been gathered by crystallography
efforts (Spraggon et al., 1997; Everse et al., 1998; Yee et al., 1997). Fibrinogen
is a large elongated trinodular glycoprotein (Fowler and Erickson, 1979) that is
approximately 340kDa in size and is has three dimeric polypeptide chains
(AαBβγ)2 that organise into two identical halves (Doolittle, 1984), Figure 1-4A.
The Aα-chain is 610 residues, whereas the Bβ and the most common splice 
variant of the γ-chain (γA) are 461 and 411 residues respectively (Henschen et
al., 1983). The γ’ variant is created by an alternative splicing event that replaces 
γA codons 408-411 with a negatively charged 20 amino acid sequence 
(Wolfenstein-Todel and Mosesson, 1981). γ’ is an proportionally uncommon 
splice variant where the heterodimeric γ’ γA form contributes to approximately 
15% of fibrinogen found in human plasma whereas the homodimeric γ’ γ’ form 
contributes less than 1% (Wolfenstein-Todel and Mosesson, 1980).
Each polypeptide chain of fibrinogen Aα, Bβ and γ are encoded by their own 
gene, FGA, FGB and FGG respectively (Chung et al., 1980) and are located on
chromosome four, bands q23-q32 (Kant et al., 1985). The polypeptide chains are
all expressed in hepatocytes (Tennent et al., 2007) where the Bβ and γ chains 
are glycosylated (Nickerson and Fuller, 1981). Firstly, the γ-chains form pre-
complexes with the Aα and Bβ chains forming Aα-γ and Bβ-γ complexes, then 
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the missing chain (either Bβ or Aα) combines to form AαBβγ half molecules. An 
in-depth discussion on fibrin assembly can be found in (Redman and Xia, 2001).
The two half molecules then co-complex to form a complete hexameric
fibrinogen monomer (AαBβγ)2 before being secreted from the cell (Hirose et al.,
1988) (Yu et al., 1984). Each of the fibrinogen chains has a signal peptide that is
cleaved from the relative chain during the translocation process to the
endoplasmic reticulum and the disulphide bonds are formed before secretion
(Zhang and Redman, 1996). All sequence nomenclature discussed in the body
of this work will be that of the mature product after removal of the signal peptide.
The N termini of the chains begin in the central globular central ‘E’ region where
they extend outwards in a helical coiled coil fashion, and end in two distal ‘D’
regions, Figure 1-4A. The longer α-chain, however, which is not resolved by X-
ray crystallography, is thought to protrude from the D-region and fold back
towards the E region. Fibrinogen has 58 cysteine residues, Figure 1-4B, the two
pair of disulphide rings hold separate chains of the molecule together and at each
end of the coiled coiled regions. There are five interchain disulphide bonds that
hold the two halves of the molecule together (Huang et al., 1993).
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Figure 1-4 Molecular dynamic representation of human fibrinogen (A)
Crystal structure PDB 3GHG was used to map structural elements of the
fibrinogen molecule. Chains Aα were highlighted in red, βb in blue and γ-
chains in green. Items in grey such as knob A and knob B sequences and
αC sequences in (A) are modelled onto the crystal structure and represent 
portions of the molecule that were not resolved in the crystal structure. (B)
Schematic of fibrinogen depicting disulphide bonds across all three
polypeptide chains shaded yellow). Image reused with permission from the
journal ‘Structure’ reference number 4445910717620. (Zhmurov et al.,
2016)
1.3 Fibrin polymerisation and clot formation
As highlighted in Figure 1-5 fibrinogen is converted to fibrin by the serine
protease thrombin. Thrombin cleaves two fibrinopeptides, fibrinopeptide A (FpA)
from the N-terminal region of the Aα chain which is 16 residues in length and 
fibrinopeptide B from the N terminal region of the Bβ chain which is 14 residues 
in length (Pechik et al., 2006). FpA is released faster than FpB due to higher
affinity of FpA for thrombin (Mullin et al., 2000a), however during the
polymerisation process the rate of FpB release increases, suggesting that the
formation of protofibrils accelerates FpB release (Riedel et al., 2011). The
removal of the fibrinopeptides has a crucial effect, the unmasking of knobs A (by
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FpA removal) and knobs B (by FpB removal) which can then bind to permanently
exposed holes on adjacent fibrin molecules (Averett et al., 2008). Knobs A and
B do not appear in the crystal structures as they are semi flexible. Synthetic
peptides that replicate the N-terminal sequence of knobs A and B have been
made. GPRP (binding to hole-a in the γC pocket) and GHRP (binding to b-hole 
in βC pocket) have been crystallised into the D-regions, indicating the residues 
involved in the knob-hole interactions (Pratt et al., 1997). Due to the dimeric
properties of the molecule there are two A:a knob-hole and two B:b knob hole
complexes that are able to form and do so in a half staggered fashion. The
spontaneous polymerisation continues and forms structures called protofibrils
which essentially are longer oligomers. Upon reaching a critical length (0.5µm)
(Storm et al., 2005), those protofibrils begin to laterally aggregate to form fibrin
fibers which in turn form the fibrin matrix as seen in Figure 1-6.
The traditional view of polymerisation dynamics is that A:a interactions drive
longitudinal growth forming oligomers and protofibrils whereas B:b knob-hole
interactions are responsible for the lateral aggregation of protofibrils into fibrin
fibers (Geer et al., 2007). Evidence for this is that particular snake venom
enzymes that cleave only FpA yield clots that have thinner fibers (Shen et al.,
1977). Dysfibrinogenaemia such as fibrinogen Metz demonstrates clots can be
formed with only FpB cleavage, although the fibrin also yields clots that are have
thinner fibers (Galanakis et al., 1993).
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Figure 1-5 Fibrin(ogen) Polymerisation (A) Fibrinogen structure, Aa chains
(red) Bβ-chains (blue) and γ-chains (green), fibrinopeptides, FpA and FpB 
(orange and purple respectively). Thrombin cleaves FpA situated in the E
region and exposes knobs A which bind to permanently exposed holes-a
located within E regions of other monomers forming fibrin oligomers, and at
later time points fibrin protofibrils. (B) Fibrinopeptides B are cleaved by
thrombin when the protofibrils reach a critical length exposing knobs B.
Knobs B located on the E-region bind to permanently exposed holes-b
located within the D-region. The binding of knobs B with holes-b in
conjunction with release and interaction of αC regions causes the 
protofibrils to laterally aggregate and form fibrin fibers.
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Figure 1-6 Scanning electron microscopy image of a purified fibrin clot
Thrombin cleaves fibrinogen to form a fibrin clot and was imaged at
20,000x magnification. Image Nathan Asquith, University of Leeds.
Recent discoveries have shown that the αC domains of fibrin(ogen) also play a 
role in polymerisation. The αC domains cannot be resolved in the crystal 
structures because they are semi flexible regions. However, they have been
recently imaged and characterised by AFM (Protopopova et al., 2017;
Protopopova et al., 2015). The αC domains have also been implicated in 
polymerisation (Weisel and Medved, 2001). It has been observed by AFM that
the αC domains usually interact with the central E domain when the molecule 
remains as fibrinogen. However, when converted to fibrin there is a large
conformational change where the αC dissociate from the E domain (Weisel and 
Medved, 2001), Figure 1-7.
The Ariëns laboratory has shown that recombinant variants missing the αC 
connector have significantly different clotting times, clot structure (McPherson,
unpublished), and when γ-chain cross-linking is inhibited clot stiffness still 
increases showing the importance of αC regions and α-chain crosslinking in the 
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mechanical properties of fibrin. (Duval et al., 2014). Others have also shown
remarkable differences using recombinant variant α251 to investigate the role of 
the α-chain in polymerisation (Collet et al., 2005b). Here the authors showed that
truncated recombinant α251 variant (that is missing the α-chain globular domain) 
impacted greatly on polymerisation through lateral aggregation, but this variant
was similar to WT for longitudinal protofibril assembly as measured by turbidity.
Additionally this variant produced clots that were 30% more deformable than WT
control clots, even though the clot network was denser, suggesting that αC 
domains in WT fibrinogen interact with each other to increase rigidity.
Figure 1-7 Atomic force image of a single fibrin monomer. Soft tapping mode
in air was used to obtain the topology profile of a single fibrin monomer on
a freshly cleaved mica surface. The high resolution capabilities of the AFM
allowed the imaging of D and E globular regions in addition to the αC 
connector. Image taken by Nathan Asquith.
1.4 Factor XIII
1.4.1 Factor XIII structure and secretion
FXIII is a tetramer composed of two A subunits, that provides the catalytic activity
of the protein, and two B subunits (Nagy et al., 1988). The molecular weight of
the full protein structure (FXIII-A2B2) is 320kDa (Ashcroft et al., 2000). Very little
E- Region
D- Region
αC 
connector
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information is known about the structure of the full molecule, however others
have postulated that both the factor XIII B subunits protect the catalytic core A
subunits (Ivaskevicius et al., 2010). Patients that are deficient in either A- or B
subunit demonstrate an increased bleeding phenotype. (Karimi et al., 2009).
Factor XIII A subunit is secreted by many cell types such as monocytes,
macrophages and megakaryocytes (Cordell et al., 2010), the B-subunit is
secreted from hepatocytes in the liver (Ariëns et al., 2002). More recent work has
provided evidence that arterial macrophages provide the majority of plasma
FXIIIA (Beckers et al., 2017).
1.4.2 Factor XIII function
As clot formation occurs, thrombin cleaves fibrinogen to fibrin, simultaneously
thrombin also activates factor XIII (factor XIIIa) during clot formation, FXIIIa forms
γ-glutamyl-lysine bonds between γGln398/399 of one fibrin monomer with γ406 
on an adjacent fibrin monomer. The α-chains of fibrin are also crosslinked at sites 
221, 237, 328, 366 (glutamine acceptor sites) with residues 508, 539, 556, 580
and 601 (lysine donor sites) (Ariëns et al., 2002). The crosslinking process
increases the stiffness of fibrin clots in vitro (Ryan et al., 1999a) and it is
hypothesised that this stiffness in vivo would lead to clots that are less prone to
embolise (Weisel, 2004a). Factor XIIIa also crosslinks fibrinolytic inhibitors to
fibrin such as α2-antiplasmin (Carpenter and Mathew, 2008).
1.5 Prevention of clot formation and clot lysis
Naturally occurring anticoagulants are substances that can prevent coagulation
and therefore reduce thrombus formation (Harter et al., 2015). In a healthy
vessel, endothelial cells and megakaryocytes secrete tissue factor pathway
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inhibitor (TFPI) (Maroney and Mast, 2008). It has been identified that the K1
domain within TFPI binds to the active site of TF-FVIIa complex in the presence
of calcium ions and co factor FXa (Mast Alan, 2016), whereas the K2 domain
binds directly to FXa.
Thrombomodulin is expressed on the endothelial membrane which forms a
complex with thrombin and reduces the conversion of fibrinogen to fibrin through
the activation of protein C and subsequent inactivation of factor Va and factor
VIIIa (Sadler, 1997). Antithrombin inhibits factor IXa, Xa and XIa, and also inhibits
thrombin (factor IIa) in a more significant manner. Antithrombin does this by
forming a covalent complex with these enzymes (Maaroufi et al., 1997). Heparin,
a therapeutic anticoagulant, enhances the efficiency of antithrombin via a
conformational change and exposure of exosites enabling antithrombin to
inactivate thrombin at a greater rate (Gray et al., 2012).
In vitro peptides that mimic partial knob A and knob B sequences have been
designed. GPRP competes with knob A for the hole-a; GHRP competes with the
B knob for hole-b in fibrin monomers. Therefore knob-hole binding cannot take
place and fibrin fibers do not form. These peptides have been used to aid in the
determination of the crystal structure of fibrin monomers (Everse et al., 1998).
In vitro, digestion of fibrinogen can be performed with cyanogen bromide,
yielding DesAB-NDSK fragments (N-terminal Disulphide knot fibrinogen) which
contains the E region and coiled coil connectors (Litvinov et al., 2005). Trypsin
has also been used to produce fragments of fibrinogen for X-ray crystallography
analysis (Spraggon et al., 1997). Fibrinogen can also be digested by plasmin
(Slater et al., 2018), which generates fragments X, Y, D and E in a time
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dependent manner. Initially digestion will generate fragment X which is
essentially fibrinogen but with truncated alpha chains, at later stages fragment Y
is formed which is the further loss of one D region, upon further digestion of
fragment Y, fragments D and E are obtained. Digestion of cross-linked fibrin
removes α-chain cross links to produce fragment X (240kDa) (Ferguson et al.,
1975) where further digestion leads to the production of fragments YD and D-
dimer (Gaffney, 2001). D-dimer includes two cross-linked D regions non-
covalently bonded to an E region by knob-hole bonds (Gaffney and Joe, 1979),
Figure 1-9.
1.6 Fibrinolysis
In blood, once the fibrin network has stemmed the loss of bleeding and is no
longer required it is broken down into smaller fragments, this is known as the
fibrinolytic process. The fibrinolytic process involves the degradation of fibrin
fibers by serine protease plasmin. Plasmin is formed by the conversion of
plasminogen to plasmin mainly by tissue plasminogen activator (tPA) (Didiasova
et al., 2014), urokinase plasminogen activator (uPA) (Lacroix et al., 2007) or
streptokinase (SK) (Sherry, 1954). The tPA circulating in the blood is derived
from endothelial cells The plasminogen and tPA bind to C-terminal lysines (via
kringle domains) on the fibrin fibers where plasminogen becomes activated by
tPA. As new C-terminal lysines become exposed they provide additional binding
sites for plasminogen and tPA contributing to a positive feedback mechanism
and enhancing the fibrinolytic process. Interestingly, fibrin also acts as a co-
factor for tPA mediated plasminogen activation. It has been previously reported
that the affinity for tPA for plasminogen increases 1000-fold when bound to fibrin
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increasing the fibrinolytic activity 2 to 4-fold (Zamarron et al., 1984). As
mentioned in section 1.5 the digestion of fibrin by plasmin produces fibrin
degradation products. The main difference between fibrinogen and fibrin
degradation products being that the covalent crosslinks of factor XIIIa are
present in fibrin leading to the formation of structures such as D-dimer. As D-
dimer is a degradation product of fibrin, it has been widely used as a tool in the
clinic to detect levels of intravascular fibrin deposition (Bates, 2012).
This fibrinolytic process can be inhibited by different mechanisms, α2-
antiplasmin for example can decrease the digestion of fibrin by the formation of
a complex with plasmin or by becoming crosslinked to the fibrin fibers via FXIIIa
making the network more resistant to digestion (Sakata and Aoki, 1980). Lysis
can also be prevented by plasmin activator inhibitor (PAI-1) through the binding
of PAI-1 with either tPA or uPA (Gorlatova et al., 2007). TAFI (thrombin activable
fibrinolysis inhibitor) hinders fibrinolysis by the removal of C-terminal lysines from
fibrin, which reduces tPA mediated plasminogen activation within the clot
(Bouma and Mosnier, 2006). Mechanical and structural properties of the fibrin
mesh can also influence the fibrinolytic properties. For example, density of the
fibers, number of branch points and fiber thickness can all influence lysis rates.
The accepted dogma is that denser networks with thinner fibers are slower to
lyse and less dense networks with thicker fibers are faster to lyse (Weisel and
Litvinov, 2017)
21
Figure 1-8 Clot formation and fibrinolysis Clot formation (left, green lines) and
fibrinolysis (right) The fibrinolytic process can be inhibited by several
molecules (red lines) including PAI (plasminogen activator inhibitor), α2-
antiplasmin and TAFI (thrombin activatable fibrinolysis inhibitor).
Figure 1-9 Schematic of digestion of cross-linked fibrin by plasmin
Cleavage of a fibrin oligomer (yellow = D-region, orange = E-region and
green = αC domains) by plasmin initially removes cross-linked α-chains and 
then cuts the coiled coils at the positions indicated with a dotted line. Fibrin
degradation products are produced such as DD-E complex (d-dimer) and
fragment YD.
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1.7 Fibrin clot structure
Fibrin at the nanoscale has been imaged for at least the past 40 years as
demonstrated the rotary shadow image of fibrinogen on a mica surface, Figure
1-10. In brief, Fowler was able to spray a glycerol/fibrinogen solution onto a mica
surface and dried it using a vaccum evaporator, the samples were then sprayed
with platinum and imaged using a scanning electron microscope, (Fowler and
Erickson, 1979). Modern technology such as atomic force microscopy allows the
imaging of αC domains in fibrin (Protopopova et al., 2017).
Fibrin monomers, Figure 1-10, undergo spontaneous polymerisation, and
eventually lead to the formation of fibrin fibers, Figure 1-11. The fibers form
branch points, become entangled with one another, and trap other blood
components such as cells and other plasma proteins, Figure 1-12.
Figure 1-10 Rotary shadowed fibrinogen Fibrinogen prepared on freshly
cleaved mica, and dried using a vacuum and observed using SEM at
100,000 magnification. The typical trinodular shape of fibrinogen can clearly
be observed. (Fowler and Erickson, 1979)
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Figure 1-11 Transmission electron micrograph of human fibrin Human
fibrinogen was cleaved with thrombin, fibers were negatively stained and
imaged using an electron Microscope. The image from the authors clearly
demonstrates the 22.5µm banding pattern of fibrin fibers. Image courtesy
of Marco Domingues, University of Leeds.
The polymerisation that is initiated upon cleavage of fibrinogen monomers to
fibrin monomers, allows fibrin to stack into half staggered protofibrils that was
observed by Krakow et al., using scanning electron microscopy (Krakow et al.,
1972). Another group has explored the use of negative staining techniques in an
attempt to confirm that fibrin fibers are in fact made from half staggered
protofibrils (Weisel, 1986). In this technique, areas that have lower protein
density (coiled-coil regions) absorb stain and therefore appear dark, whereas the
opposite is true for areas of high protein density (globular D and E regions) and
therefore appear bright as demonstrated in a TEM image taken by Dr. Marco
Domingues, University of Leeds, Figure 1-11.
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Figure 1-12 Scanning electron micrograph of a fibrin clot prepared from
whole blood. Red arrow represents red blood cell, green arrow represents
fibrin fibers and blue arrow indicates the presence of fibrin sheet covering
the clot. Image courtesy of Fraser Macrae, University of Leeds.
Once the fibers are formed they intertwine and form a complex three dimensional
network (Baradet et al., 1995). In addition to the formation of a fibrin fibrillary
network, a recent study by the Ariëns laboratory has shown that fibrin also
produces a sheet covering the clot through Langmuir film formation at the air-
liquid interface, Figure 1-12 . Each fibrin mesh within the clot can have varying
characteristics such as different fiber thickness (Pretorius et al., 2011), fibrin fiber
density (Li et al., 2017), pore sizes (Blombäck et al., 1989), and mechanical
properties. In physiological conditions, the fibrin network and the fibrin sheet
prevent loss of red blood cells (Kim et al., 2013).
In the literature many authors have investigated the role of differing substances
and conditions on the clot network. An increase in pH or a decrease in
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temperature of the fibrinogen solution (Nair et al., 1986) was investigated by
turbidity. It was found that the development of the clot was delayed. A reduction
in temperature did not significantly reduce the mass length ratio of a fibrin fiber
(μ0, proportional to fiber thickness) but this mass length ratio decreased with the
increase in pH. In addition to turbidity, other techniques can be used to study
fibrin polymer architecture. The Ariëns group showed that light scattering can be
used effectively to probe the average fiber radius within a fibrin clot (Domingues
et al., 2016). I showed that an increase in thrombin concentration decreased the
radii of fibrin fibers as previously seen by others (Blombäck et al., 1989). It has
been reported that polyphosphates also play a role in regulating clot structure,
in the presence of calcium. Clots that were formed with the inclusion of
polyphosphate had a three-fold higher turbidity in addition to an increase in fiber
thickness measured by SEM (Smith and Morrissey, 2008), however the Ariens
laboratory demonstrated that fiber thickness was unchanged in the presence of
polyphosphate but closely knit ‘fibrin knots’ were present in SEM micrographs
(Mutch et al., 2010). It was shown that increasing the concentrations of fibrinogen
forms clots that are more dense (Ryan et al., 1999b). The binding of calcium ions
to fibrin protofibrils forms clots that are have thinner fibers than clots that are in
the presence of Fluorine ions (Di Stasio et al., 1998). The presence of calcium
ions on clot structure were investigated using thrombin and reptilase. In the
presence of calcium, with both enzymes the clots formed faster, the maximum
optical density was increased, and larger fiber mass/length ratios were observed,
indicating thicker fibers for clots (Carr et al., 1986). Electron microscopy studies
on the effect of cysteine show increased cardiovascular disease risk, clot
structures were denser with many branch points (Lauricella et al., 2006;
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Mujumdar et al., 2001). Even complex branched polysaccharides such as
dextran can have an impact on clot structure, by increasing fiber thickness (Carr
and Gabriel, 1980). More recently, clots that were formed ex vivo from blood
samples taken from patients treated with dextran showed that these clots were
subject to increased fibrinolysis (Jones et al., 2008).
1.8 Intra-fibrillar fibrin structure
Once protofibrils reach a critical length, they laterally aggregate to form fibrin
fibers, (Weisel and Litvinov, 2017). However, the exact mechanism to how this
occurs is not fully understood. The fibrin fiber diameter and consequently fibrin
fiber packing arrangements have a direct effect on fiber stiffness and therefore
could influence the formation of an embolus in vivo (Li et al., 2016). Previous
studies by other groups do not necessarily agree with each other on the packing
arrangements of fibrin fibers, some groups have shown that protofibrils within a
fiber are packed in a ordered fashion (Caracciolo et al., 2003) whereas others
have shown that fibers may not be homogeneous throughout (Guthold et al.,
2004). Light scattering is typically used to determine the amount of protofibrils,
the distance between protofibrils and hence overall protein density of fibrin fibers
(Carr and Hermans, 1978; Yeromonahos et al., 2010). It is an indirect measure
of fiber radius and the models are based on the assumption that all fibers are of
equal thickness inside the clot, however the clot may be in fact heterogeneous.
As discussed in section 1.3, fibrin polymerises in both the longitudinal space and
lateral space. Using a combination of crystal structures and light scattering data
a multi-bundle model of protofibril packing within fibrin fibers was proposed,
hypothesising that protofibrils are packed homogenously within the fiber (Yang
27
et al., 2000). This model was critiqued and a new model was proposed based on
the relationship between stretch modulus of fibrin fibers and fibrin diameter (Li et
al., 2016) The authors argue that if a fibrin fiber really does have protofibrils that
are packed homogenously then the stretch modulus (Y) would be independent
to fibrin diameter, Figure 1-13A. They propose a “bicycle wheel spokes” model
Figure 1-13B where the stretch modulus decreases as fiber diameter increases.
However, their experimental observations using lateral force pulling AFM show
that stretch modulus decreases in an even more dramatic manner with
increasing fibrin diameter than predicted by the “bicycle wheel spokes” model.
They explained that this would lead to a model where fibrin fibers have a dense
core leading to a less dense periphery (Figure 1-13C) as demonstrated in their
later publication (Li et al., 2017). The work by Li et al, shows that protofibril
packing may be more complex than the homogenous fiber density as proposed
by (Carr and Hermans, 1978).
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Figure 1-13 Theoretical schematics of different packing possibilities for
fibrin fibers (Panel A) Homogenous protofibril model proposed by where
stress modulus is independent of fibrin diameter. (Panel B) Bicycle wheel
spokes protofibril model where the stretch modulus (Y) decreases as fiber
diameter (D) increases. (Panel C) Heterogeneous protofibril model where
stretch modulus decreases rapidly with increasing radius. Figure based on
Figure 6 in (Li et al., 2016)
1.9 Fibrin mechanics
Fibrin fibers are one of the strongest naturally occurring polymers in nature,
which makes it a perfect candidate to stem a damaged vessel wall and to prevent
the loss of blood, while the damage is repaired, despite the large shear forces
present in the blood (Weisel, 2004a). Although, in normal physiological
conditions it may seem like a good idea to have a strong polymer to prevent
blood loss, in pathological conditions of thrombosis this may be detrimental. The
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formation of pathological fibrin clots (thrombi) lead to conditions such as
myocardial infarction (MI) (Delewi et al., 2012), ischemic stroke (Stoll et al., 2008)
or VTE (venous thrombo embolism) (Phillippe, 2017). Therefore the visco-elastic
properties of thrombi, with fibrin(ogen) as the key modulator, are key to
preventing bleeding, and may contribute to the risk of thrombosis or embolization
of thrombi.
Many previous studies have shown that clots formed in vitro, from the plasma
taken from patients who had experienced myocardial infarction, are denser than
those of control subjects (Fatah et al., 1996). Others have also observed that ex
vivo plasma from patients with premature coronary heart disease form denser
fibrin networks that are more stiff (Collet et al., 2006). The authors found an
increase of storage modulus from 21.2 to 31.2 dynes/cm2 (+47.2% ).
Micro-rheology studies of fibrin clots have been performed by many groups in
the past (Nelb et al., 1976; Ferry et al., 1951; Shen and Lorand, 1983;
Domingues et al., 2016). Shear rate describes the flow of a liquid through a
vessel, in the case of haemostasis and thrombosis this is the blood shear rate
within arteries, veins and capillaries. The shear rate is influenced by the diameter
of the vessel (Casa et al., 2015) There is a direct relationship between the
viscosity, wall shear rate and wall shear stress where; Wall shear stress =
viscosity x wall shear rate. Build-up of athlerosclerotic plaques can narrow
vessels, increasing the shear rate within the vessel and therefore the shear
stress on the endothelium wall. Shear stress is important because it can
influence biological processes such as platelet adhesion (Ruggeri et al., 2006).
Fibrin clots are exposed to shear rates that range from approximately 10s-1 (in
veins) to 2000s-1 in (arteries) (Sakariassen et al., 2015). In pathophysiological
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conditions such as atherosclerosis, the shear rate in arteries can reach up to
40,000s-1 (Sakariassen et al., 2015). Molecular simulations of shear conditions
have been performed previously by Kononova et al., who calculated that knob-
hole bonds must be exposed to tensile forces ranging from 150-400pN
(Kononova et al., 2013). Therefore clots must be able to withstand
(patho)physiological stresses and not undergo permanent deformation. If the
stresses are too great, the whole clot, or fragments, breaking off and traveling
through the rest of the circulatory system, a process known as embolisation is
possible. Thromboelastometry is used in the clinic for the prediction of need of a
blood transfusion (Crochemore et al., 2017), it measures the visco-elastic
properties of a patient’s whole blood sample and outputs parameters such as
maximum clot firmness (Zaky, 2017). The basic principle involves the change in
rotational torque of a pin during blood clotting. Weisel has discussed the difficulty
of associating ex vivo tests like thromboelastometry to in vitro biophysical data
obtained with rheometers or other biophysical methods to determine visco-
elastic properties of clots. The in vitro biophysical methods generate visco-elastic
moduli G' (Gprime) and G" (Gdouble prime), whereas it is not clear how the parameters
obtained by thromboelastometry relate to these biophysical measures (Weisel,
2004a).
The G' (storage modulus), is defined as the amount of energy that is stored in a
system. In work on fibrin clots, the G' is often used in the literature to describe
clot or fiber stiffness (Konings et al., 2011; Longstaff et al., 2013; Piechocka et
al., 2010). The G" (loss modulus) is defined as the amount of energy that is
dissipated from a clot, and is often used to represent the amount of permanent
deformation or in other words viscosity (Schmitt et al., 2011; Mason and Weitz,
31
1995). Fibrin clots are neither purely elastic or viscous, but they are visco-elastic,
and therefore one must consider both moduli at the same timescale. Therefore
the tanδ is calculated, which is the ratio of G"/ G', which indicates the amount of 
non-elastic deformation relative to the stiffness. A predominately viscous
material would have a tanδ > 1, whereas a predominantly elastic material would 
have a tanδ <1 and a material where the tanδ =1 signifies that neither the storage 
or loss modulus is dominating, (Collet et al., 2005b). Clots with a high G' and
lower G'' are stiffer and experience less permanent deformation, usually
attributed to many branch points and increased fiber thickness. Clots with lower
G' and high G'' are more readily deformable due to fewer branch points and
thinner fibers (Ryan et al., 1999b). It has been shown that specific unfolding of
molecular domains of the fibrinogen molecule such as the coiled coils (Lim et al.,
2008; Brown et al., 2007) and D-domains (Guthold et al., 2007) can impact on
the mechanical properties of the fibrin clots. Interestingly, it has been observed
that clot density (the number of fibers in a certain area of the clot) can impact on
clot stiffness where an increase in clot density leads to an increase in G' (Ryan
et al., 1999b).
A magnetic micro-rheology apparatus was designed and created by Rob
Harrand, University of Leeds (Harrand.R, 2007) and was further optimised to
study the mechanical properties of fibrin clots by Peter Allan, University of Leeds
(Allan.P, 2012). My studies utilise the same device and analysis procedure for
the calculation of visco-elastic measurements of fibrin clots. The analysis is
based on the theory of visco-elastic properties of semi-flexible polymer solutions
suggested by groups who described three relaxation mechanisms of fibrin
(Morse, 1998a; Morse, 1998b; Morse, 1999; MacKintosh et al., 1995). Briefly,
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moduli at the low frequency range are dictated by the alignment of fibers,
intermediate frequencies are dictated by the twisting of fibers, and high
frequencies are dictated by molecular deformation events. Following raw data
collection, a mathematical procedure is then performed as previously described
to calculate the G*, G' and G'' from time dependent compliance (Evans et al.,
2009).
Mechanics at smaller scales, such as at the fibrin fiber level, and at the fibrin
monomer level have also been investigated by others. At the fiber level, lateral
force AFM has been used. Here, a single fibrin fiber has being pulled using a
cantilever and has shown the great extensibility of fibrin fibers adding insight to
the roles that particular protein domains play in fibrin deformation (Guthold et al.,
2007). The authors suggest that the load of small strains can be endured by fibrin
monomers through knob-hole bonds, while at medium strains the α-helical coiled 
coils unfold, and then at high strains they hypothesised that globular domains
such as the γC nodule unfold. 
1.10 Fibrinogen disorders
A large amount of research on fibrin and the disorders associated with it has
been performed over the years (Neerman-Arbez et al., 2016; Asselta et al., 2007;
Fish and Neerman-Arbez, 2012), this section will detail some variants that give
rise to afibrinogenaemia and dysfibrinogenaemia.
Fibrinogen disorders are usually congenital and can either completely lack the
presence of fibrinogen and are known as afibrinogenaemia. The lack of
fibrinogen causes patients with afibrinogenaemia to commonly display excessive
bleeding and to treat these episodes they can receive cryoprecipitate
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(concentrated fibrinogen). Dysfibrinogenaemia patients do have the fibrinogen
protein but contain one or more point mutations. The mutations are usually within
the mature product often changing the function of the fibrinogen, impacting on
polymerisation, clot structure and the patient’s ability to clot normally. It has been
reported that from all the known dysfibrinogenaemia 55% are asymptomatic,
25% are associated with bleeding tendency and the remaining 20% are
associated with thrombosis (Hayes, 2002)
Interestingly, a dysfibrinogenaemia named Fibrinogen Miami (Bβ D61G) has 
been described in the literature. The variant described contained a mutation of
the opposite interacting residue to γK356 that is being investigated in my work. 
The current hypothesis is that βbD61 interacts with γK356. The patient who had 
this dysfibrinogenaemia also showed tendancy to bleed and delayed
polymerisation kinetics, (Galanakis et al., 1996) providing evidence that the K356
and BβD61 extended knob-hole interaction also plays an important role in clot 
formation in a physiological setting. The first dysfibrinogenaemia to be
discovered was fibrinogen Detroit in 1969 (Mammen et al., 1969), with mutation
AαA19S changing a basic amino acid with a neutral amino acid in knob A that is 
exposed after thrombin cleavage of fibrinopeptide A. The patient’s
polymerisation rates were delayed and the literature describes the patient’s
thromboelastograms as ‘grossly abnormal’. A database detailing other
afibrinogenaemia and dysfibrinogenamias has been created in an effort to
compile all the known fibrinogen variants and their relevant literature. The
database can be found using the website http://site.geht.org (last accessed
15/10/18 for this work). As can be seen from the database, hundreds of
fibrinogen variants have been discovered to date, but in this work I focus on
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describing variants that surround the knob A cleavage site, variants that effect
the hole-a binding pocket and variants that effect the D:D interface.
Other variants beside fibrinogen Detroit also play a role in influencing knob-hole
interactions or FpA release. Heterozygous AαR16H variant (fibrinogen 
Manchester) exhibits slower FpA than FpB release, which as expected gave
arise to delayed polymerisation kinetics (Lane et al., 1983). FpA release is
completely prevented from AαR16C, whilst FpB is still released, (Henschen et
al., 1984). There are a plethora of additional naturally occurring mutations
affecting fibrinopeptide A release including, AαD7N Fibrinogen Lille resulting in 
no FpA release (Denninger et al., 1978). Fibrinogen Magdeburg I AαL9P 
mutation that results in delayed FpA release (Meyer et al., 2003b). Fibrinogen
Mitaka II, AαE11G, reduces fibrinogen binding with thrombin resulting in delayed 
FpA release (Niwa et al., 1993). Fibrinogen Saint-Germain I, AαG12V, displayed 
impaired release of FpA and FpB by thrombin (Mathonnet et al., 2002).
Other residues have also been shown to be implicated in defects within the a
hole pocket. Variants γD330V fibrinogen Ales (Lounes et al., 2000), fibrinogen
Kyoto III γD330Y (Terukina et al., 1989) both disrupt extended ionic interactions
involving AαR19, resulting in impaired polymerisation. 
Known mutations around the FpB cleavage site are rarer than mutations around
the FpA cleavage site, so much so that only one variant at the FpB cleavage site
has been discovered and characterised. The variant has a mutation at position
14 of the β-chain where an arginine is substituted for a cysteine. This variant has 
been described by more than one group and therefore has several names,
Christchurch II, Christchurch III, Ijmuiden, and Seattle (Brennan et al., 1997;
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Branson et al., 1983; Koopman et al., 1992). The mutant fibrinogen displayed
normal FpA release but abnormal FpB release resulting in altered polymerisation
(Brennan et al., 1997) and reduced maximum OD which indicates a difference in
clot structure (Branson et al., 1983).
1.11Knob-hole interactions
1.11.1 Concept of knob-hole interactions
Although the cleavage of fibrinopeptides and the imaging of monomers and
fibers had already been described (Lorand and Middlebrook, 1952) (Fowler and
Erickson, 1979) (Van Zandt Hawn and Porter, 1947), it was still unknown where
knobs A and B bound on adjacent fibrin molecules. The binding pockets were
discovered somewhat 20 years ago through co-complexes that were formed
between competitive inhibitors of knobs A and knobs B (Spraggon et al., 1997).
Further crystallography efforts using fragment D and GPRP peptide revealed that
γGln329, γHis340, γAsp364, and γArg375 are the residues responsible for the 
binding of the peptide (Kostelansky et al., 2002). As these efforts were not using
full fibrin molecules, it is expected that this interface will involve other residues
that accommodate the binding pocket.
Since then there has been a strong interest in regards to the binding of knobs A
and knobs B with holes a and b respectively. These key interactions in fibrin have
been termed ‘knob-hole interactions’. Particular interest has been attributed to
distinguish their individual roles in fibrin polymerisation and ultimately how this
results in altered clot structure and mechanics, (Bowley et al., 2008) (Lord, 2011).
It should be noted that these knob-hole bonds are not covalent and are mainly
electrostatic in nature (Spraggon et al., 1997). With the advances in recent
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technologies such as optical tweezers and atomic force microscopy, it has been
much easier to probe fibrin(ogen) at the nanoscale. Complementary to these two
techniques, computational studies have also proven useful to determine
interactions involving knob-hole bonds at the sub-molecular level, providing key
insights into the regulation of knob-hole binding (Litvinov et al., 2018).
The full hole-a (residues within and surrounding the binding pocket) is thought to
span a 70 residue stretch of residues γ295-365 as predicted by molecular 
dynamic simulations (Kononova et al., 2013). It has been shown by others that
mutations in hole-a can have significant effects on clot structure and
polymerisation. The importance of the structural integrity of hole a can be seen
where GPRP peptide prevented oligomer formation even though FpA was
cleaved normally (Everse et al., 1998). Residue γD364 is one of the residues 
located in the binding pocket, and a variant γD364A was made to investigate the 
importance of the binding (Bowley et al., 2008). Surprisingly, a GPRP mimic that
replicates knob A still bound to in the binding pocket even though ionic
interactions between knobs A and hole a was disturbed. Additionally, turbidity
and γ-γ dimer formation analysis using γD364A failed to measure any significant 
fibrin polymerisation.
1.11.2 Force rupture of A:a knob-hole interactions
The force rupture of A:a knob-hole bonds were determined by Averett et al. The
digestion of fibrin was performed using cyanogen bromide which yields a DesAB-
NDSK fibrin fragment, containing the central E fragment of the molecule with
both knobs A and B exposed. The authors focussed their attention on the force
rupture of the A:a bonds as they are deemed the most important and influential
on polymerisation of fibrin and the formation of the fibrin clot, (Averett et al., 2009;
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Averett et al., 2008). Briefly, AFM cantilevers were functionalised with DesAB-
NDSK fibrin fragment. Glass surfaces were prepared with recombinant
fibrinogen and BSA. The functionalised tip (containing knobs A) was used to
approach the functionalised fibrinogen surface (containing holes a) and the
retraction of the tip allowed the force unbinding and unfolding mechanisms to be
determined, Figure 1-14B. Using this technique, the authors describe four
molecular deformation events that contribute to the complete dissociation of the
A:a knob-hole bond. They measured the amount of force that was required to
extend and dissociate the NDSK fragment and the fibrinogen molecule. In the
first instance, the fibrinogen that is bound to the glass surface re-orientates. The
second and third steps that they described were unfolding events that occur in
the γ-nodule, potentially weakening the A:a interaction. The final deformation 
event described was the dissociation of knob A from hole a.
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Figure 1-14 Schematic of rupture of A:a knob-hole bonds. Representation of
the functionalised AFM tip with DesAB NDSK (N-terminal disulphide knot)
fibrin fragment and functionalised surface with fibrinogen and BSA. (B) A
molecular cartoon representation of the globular D region of the fibrinogen
molecule. The β- nodule (blue) and γ-nodule (red). Knob A (green) binds to 
the polymerisation pocket and the AFM is utilised to calculate unfolding and
unbinding kinetics. Image reused from (Averett et al., 2009) with permission
from the Biophysical Journal, reference number 4441860996422.
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1.11.3 Catch-slip bonds in fibrin
Further simulations in combination with optical trap measurements have probed
the importance of some of these residues in the role of calcium binding and how
this regulates the atomic mechanics of knob-hole bonding (Litvinov et al., 2018).
Fibrinogen has a total of four calcium binding sites, two of which are low affinity
binding sites (γ2 and β2) and two of which are high affinity binding sites (γ1 and 
β1) (Marguerie et al., 1977). The γ1 and γ2 sites are located on the γ-chain of 
fibrinogen, whereas sites β1 and β2 are located on the β-chain of the molecule. 
The γ1 binding site directly involves residues γAsp318, γAsp320, γPhe322 and 
γGly324 (Yee et al., 1997). The γ2 binding site has been shown to involve the 
residues γ294, γ296, γ298, and γ301 (Everse et al., 1999).
Optical trap pulling experiments of fibrin from fibrinogen showed that rather than
decreasing with force as expected, the strength of A:a knob hole bonds
increased as pulling force increased up to 30pN, and then the strength of the
bond decreased hereafter. The binding of 3mM calcium reduced the A:a bond
strength (Litvinov et al., 2018).
The molecular simulation part of the article (Litvinov et al., 2018) describes the
importance of a movable flap motif that is adjacent to the γ2 binding site, and 
regulates the opening and closing of the hole-a. Some residues of the flap, γ291, 
γ294, γ297 and γ301 are normally positioned so that the hole-a is in a loose, 
open state that causes more frequent dissociation of knob A. In pulling
experiments tension is applied to this region and the movable flap undergoes
conformational change and causes interactions between γ297-γ304 in the flap 
and residues in knob A. Consequently, loop I (residues γ315-330) also undergo 
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conformational change leading to further electrostatic interactions between γ321-
γ323 and knob A, causing the hole-a to become more tightly bound to knob A 
(catch bond). In the optical trap experiments the authors showed that the catch
bonds did not occur when 3mM CaCl2 was present in the solution. They argue
that the crystal structures show γ297 and γ301 interact with calcium and 
therefore the movable flap cannot undergo conformational change and form the
catch bond. This provides evidence that knob-hole bonds could be regulated
through calcium binding, altering the kinetics of the polymerisation of fibrin.
1.12Extended knob-hole interactions
1.12.1 Concept of extended D-E knob-hole interactions
Weisel first postulated that additional binding contacts must occur in addition to
the traditional A:a knob-hole interactions (Weisel, 2012). Using the cross-linked
double D fragment, it has been reported that the GPRP mimic of knob A has a
dissociation constant of Kd 25µM with hole a. However, GHRP mimic and hole
B has a Kd of 140µM. (Everse et al., 1998). Geer et al., found that larger DesAB
NDSK fibrin fragments dissociated with fibrinogen at a Kd of 5.8µM There was
no difference in dissociation between desAB fragments with fibrin and DesA
fragments with fibrin suggesting that the binding was driven by residues involved
in A:a interactions (Geer et al., 2007). This shows that larger fibrin fragments
dissociate less frequently than the knob A and hole a complex providing
evidence that there are residues beyond the classical knob-hole interaction sites
that mediate knob-hole binding. X-ray Crystallographic studies of fibrin(ogen)
have provided a wealth of data in understanding not only the structure of
fibrinogen but also the binding contacts made during polymerisation of the
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molecule. However, these methods rely on the preparation of a crystal and
imaging of the molecule when it is in a static state, and therefore provide limited
information regarding the dynamic structure of proteins , particularly during the
interactions between these proteins or peptides.
In 2013, computational molecular dynamic simulations provided evidence that
extended knob-hole interactions may occur (Kononova et al., 2013). The authors’
goals were to provide computational evidence for the molecular transitions that
occur at the sub-molecular level. In their study, in the first instance molecular
pulling simulations of the co-complexed γ-nodule fragment of fibrin(ogen) and 
the peptide mimics GPRP and GHRP. They simulated the pulling of the knobs A
and knobs B mimics away from the γ- nodule. They found that the average bond 
lifetimes A:a and B:b bonds was similar.
The authors performed another additional simulation but this time of a fibrin
oligomer (consisting of double D interacting with E region of what would be
another monomer), Figure 1-15. The advantage of performing this simulation
was that the contacts between other residues and not only the immediate knob-
hole interactions were also computed and analysed for binding. The authors
found that the traditional A:a knob-hole binding pocket was enhanced by
electrostatic interactions between the D region of one monomer and the E region
of another monomer that flanked the traditional knob-hole interaction site. The
three pairs of electrostatic interactions (as highlighted in Figure 1-15) were
between γGlu323 & βLys58, γLys356 & βAsp61 and γAsp297 & βHis67. Their 
data showed that the binding interface may be more complicated than originally
thought.
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Figure 1-15 A computational reconstruction of the alignment of fibrin
molecules (A) A cartoon representation shows the β- and γ-nodules of DD 
fragment alongside a fibrin monomer before equilibration of the simulation
(B) Shows the same structures but after the 250ns simulation has taken
place, the zoomed in window shows in detail the switch in conformation in
γ-nodule binding pocket. Three pairs of electrostatic interactions beyond 
the classical knob-hole interactions occur between γAsp297 - βHis67, 
γLys356 - βAsp61 and γGlu323 – βLys58 (circled black). This image was
adapted from (Kononova et al., 2013) with permission from the Journal of
Biological Chemistry.
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1.12.2 Known variants in the vicinity of the extended knob-hole
region
In this section I will be describing variants that are located in within proximity to
the extended knob-hole interactions.
1.12.2.1 γD297 
Fibrinogen Baltimore I is sequentially the closest fibrinogen variant to γD297 
found within the clinic. Baltimore I incorporates a mutation at position γ292 
changing a glycine to a valine residue. It was one of the first congenital
fibrinogens to be discovered and is known for its longer than normal clotting time
that could be corrected by adding calcium chloride. Baltimore I shows a reduction
in γ-chain synthesis which must lead to the observed delayed polymerisation 
possibly via reduced fibrinogen concentration (Bantia et al., 1990).
Non clinical studies have also been performed by others researching residues
very close to γ297 in the sequence alignment. γD298A-D301A recombinant 
variant was created to investigate the importance of the γ2 calcium binding site 
that is located in moveable flap γ294-301 (Kostelansky et al., 2007). Their
experimental investigations found that polymerisation was only effected very
slightly with the D298A-D301A mutation, suggesting that the γ2 binding site plays 
a minor role in polymerisation.
1.12.2.2 γE323 
No mutations were found in the literature for position 323 in the γ-chain. 
However, mutations have been reported for amino acids just a few residues up
and downstream. Fibrinogen Beijing at γ322 (Hua et al., 2015) contains a
mutation where phenylalanine is substituted for isoleucine, no phenotype was
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determined by the authors. However, fibrin polymerisation was found to be
delayed when cleaved by thrombin, the authors postulate that this was caused
by the importance of residue 322 as its backbone has been reported to be
involved in calcium binding at the γ1 calcium binding site. D320A, fibrinogen 
Athens III which was asymptomatic (Galanakis et al., 2014) and fibrinogen
Krakow, N325I, resulted in delayed polymerisation, denser clot network and
more resistant to lysis (Undas et al., 2009).
The extended A:a binding pocket consists of residues γ295-365 (Kononova et
al., 2013) which includes the γ1 calcium binding site residues γ311-336 (Varadi 
and Scheraga, 1986; Dang et al., 1985; Yee et al., 1997). Although not observed
in the clinic, others have indicated that residue γE323 could also play a role in 
the binding of calcium in the γ1 binding site (Pratt et al., 1997). They observed
readjustment of the hole-a binding pocket when GPRP binds in the crystal
structure. They notice a rearrangement of hydrogen bonds and salt links that
stabilise the binding, and predicted that γK338 and γE323 form a salt link when 
GPRP is unbound, however when bound there is a slight shift resulting in the
interaction of K338 with the peptide.
1.12.2.3 γK356 
No mutations were found in the literature for position 356 in the γ-chain either, 
although some mutations have been found within proximity to this residue of
interest. Fibrinogen Homburg VII contains a mutation where tyrosine γ354 is 
substituted for a cysteine residue (Meyer et al., 2003a). The resulting
polymerisation in plasma was delayed with clots displaying a much denser
network and thinner fibers as compared to WT. The authors concluded that these
effects could be attributed to abnormal packing of residues as this area has been
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previously shown to have an importance in this mechanism (Yang et al., 2000).
Other dysfibrinogenaemia sequentially upstream of γ356 have also been 
implicated in fibrin polymerisation and clot structure. Fibrinogen Milano VII
where γ358 serine was substituted to cysteine resulted in delayed polymerisation 
kinetics (Steinmann et al., 1994). The authors also observed that when the
fibrinogen was immunoblotted, albumin was found to be covalently bound to this
variant via disulphide bonding. Also when bound albumin was removed using
β2-mercaptoethanol, the fibrinogen still produced abnormal polymerisation 
kinetics.
Additionally, packing analysis of DD fibrin fragments with bound ligands has
shown the possibility of extra residues at play (Yang et al., 2000). The authors
created four D:D structures; DD-GP (DD with GPRP ligand bound to holes-a)
DD-GH (DD with GHRP ligand bound to holes-b) DD-BOTH (DD with GPRP
ligand bound to holes-a and GHRP bound to holes-b), and DD-NL (Both holes
empty, no ligands). Structures that had one or both ligands occupying the holes
displayed different lateral packing interactions when compared with crystals
where holes were left empty. This suggests that the binding of knobs A and B
induce a conformational change which could possibly lead to heightened
polymerisation of the fibrin. The authors proposed that the two stretch of residues
responsible were γ350-360 and γ370-380 (termed γC-γC contacts), which 
contains the γ356 residue.   
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1.13 Aims
Molecular simulation studies have predicted that extended interactions
underpinning and extending the classical knob-hole interactions during fibrin
polymerisation involve electrostatic binding between three pairs of amino acid
residues, i.e. γGlu323 with βLys58, γLys356 with βAsp61 and γAsp297 with 
βHis67. My aim was to probe the importance of these extended knob-hole 
interactions on fibrin polymerisation, clot structure and clot mechanics, using
recombinant fibrinogen variants with mutations that abolish the electrostatic
interactions.
1.14 Objectives
My specific objectives were:
1. To generate fibrinogen variants of the extended knob-hole region using
site directed mutagenesis, transfection of mammalian cells and
purification by affinity chromatography. Variants of the γ-chain produced 
were: γD297N, γE323Q, γK356Q and γD297N/E323Q/K356Q (γDEK 
triple mutant), Figure 1-16.
2. To validate the integrity of the recombinant fibrinogen preparations
through CD spectroscopy and SDS-PAGE.
3. To determine the role of the extended knob-hole residues on fibrin clot
formation. Turbidity was used to study lag time of clot formation, maximum
polymerisation rate and maximum optical density. Atomic force
microscopy was used to study the early polymerisation stages of clot
formation.
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4. To investigate the effects of the mutations within the recombinant variants
on clot structure. Whole clot density was measured by Scanning Electron
Microscopy (SEM) and LSCM (Laser Scanning Confocal Microscopy).
Fiber thickness was also studied by SEM. Clot fibrinolytic properties were
investigated using LSCM. Intrafibrillar fiber structure was analysed using
light scattering approaches.
5. To examine the effect of the altered polymerisation and clot structure on
the visco-elastic properties of the fibrin clots using an in-house micro-
rheology device (‘magnetic tweezers’).
6. To collaborate with Professor Valeri Barsegov (University of
Massachusetts, Lowell, USA) on the role of extended D-E interaction sites
at the sub-molecular and atomic scales of fibrin polymerisation.
Figure 1-16 Molecular computation of γ nodule in fibrinogen co-complexed 
with knobs A Residues residing in the γ-chain were chosen for mutation 
based on their proposed function in extended knob-hole interactions
(circled in red). γAsp297, γLys356 and γGlu323 were chosen to be mutated 
as previous experience from the Ariens laboratory with γ-chain mutants 
demonstrated good levels of expression. Mutations of the β-chain would 
have been performed in the event that the γ-chain mutants did not express. 
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Chapter 2 - Materials and
Methods
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2.1 Materials
2.1.1 Molecular biology
The QuickChange site directed mutagenesis kit and XL-10 gold competent
bacteria were purchased from Agilent Technologies (Stockport, UK).
Mutagenesis primers and SOC medium were purchased from ThermoFisher-
Scientific (Loughborough, UK). LB broth was made consisting of 10g/L tryptone
LabM (Bury, UK), 5g/L Yeast extract (LabM) and 5g/L NaCl (Thermo-Fisher
Scientific, Loughborough, UK) and Ultrapure water (resistivity of 18.2MΩ at 25oC,
Millipore (Watford, UK)). LB agar was purchased from LabM. Ampicillin was
purchased from Sigma-Aldrich (Dorset, UK) and reconstituted at 100µg/mL and
stored in 1mL aliquots. 10cm culture dishes were purchased from Corning
(HighWycombe, UK). 50mL Falcon tubes were purchased from Greiner Bio-One
(Stonehouse, UK). Parafilm was purchased from Starlabs (Milton Keynes, UK).
2.1.2 Cell culture
Growth medium consisted of DMEM F12 Ham (ThermoFisher-scientific), 5%
foetal bovine Serum (Labtech; Heathfield, UK), 5% nu-serum (VWR
International; Lutterworth, UK), 1x antibiotic-antimycotic (Sigma-Aldrich; Poole,
UK). Serum free medium was made from DMEMF12 Ham and 1x Antibiotic-
antimycotic. Selection medium was made from growth medium as detailed above
with the addition of 800µM L-histidinol (Sigma-Aldrich). ITS medium consisted of
DMEM F12 ham complemented with 1x antibiotic-antimycotic, 4µg/mL Aprotinin
(Sigma Aldrich), ITS supplement (Insulin, 5μg/mL, transferrin, 5μg/mL, sodium 
selenite, 5ng/mL, Roche; Welwyn Garden City, UK). 2x HEBS solution was made
using 150mM Na2HPO4, pH7.05 (Sigma- Aldrich), 2.5mM HEPES solution
(Sigma-Aldrich) and 14mM NaCl (ThermoFisher-Scientific). Geneticin, Cell
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culture grade glycerol, 10mL syringes and cryotubes were purchased from
ThermoFisher Scientific. Dubecco’s phosphate Buffered Saline (PBS),
ethylenediaminetetraacetic acid (EDTA), 1x Trypsin-EDTA 0.25% solution,
Calcium Chloride, sterile filtered water, phenylmethylsulphonyl fluoride (PMSF),
cytodex microcarrier beads and dimethyl sulphoxide (DMSO) were all purchased
from Sigma-Aldrich. 0.1M EDTA-PBS was made from 1xPBS supplemented with
EDTA to a final concentration of 0.1M. Tissue culture treated 24 well plates,
10cm dishes, 6cm dishes, 75cm2 flasks with vents and 850cm2 roller bottles with
vents were purchased from Corning. 0.2µm Filters were purchased from VWR
International. Freezing mix was made consisting of 10% DMSO and 90% Foetal
Bovine Serum.
2.1.3 Precipitation and purification
Protease inhibitor cocktail (stored at 4oC) made from 5mM epsilon-aminocaproic
acid (ε-ACA), 5mM benzamidine, 1µM pepstatin, 1µM leupeptin, 100µM PMSF, 
and 20mM 2-ethanesulphonic acid (MES) buffer pH5.6 all purchased from
Sigma-Aldrich. Saturated ammonium sulphate was made by dissolving 1.52kg
ammonium sulphate (Sigma-Aldrich) in heated 2L ddH2O and stored at 4oC.
Pellet resuspension mix pH 7.4 (stored at 4oC) consisted of 5mM ε-ACA, 5mM 
benzamidine, 5µM pepstatin, 5µM leupeptin, 100µM PMSF, 10U/mL Soybean
Trypsin Inhibitor (Sigma-Aldrich), 1mM EDTA, 300mM NaCl, 200mM Tris-Base
pH 7.4 (ThermoFisher-Scientific).
IF-1 mAb 10mg was purchased from Kamiya Biomedical (Seattle, Washington,
USA) and CnBr Activated Sepharose 4B 1.5mg was purchased from VWR
(Lutterworth, UK) and packed into a XK16/20 column (GE Healthcare, Little
Chalfont, UK) and was attached to the ÄKTA avant (GE healthcare). Purification
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was initiated and the protocol was pre-programmed by Cédric Duval, University
of Leeds.
The following buffers were made for use during affinity chromatography of
recombinant fibrinogen variants:
Equilibration buffer pH 7.4 consisted of 20mM Tris-base, 300mM NaCl, 1mM
CaCl2. Wash buffer I pH 7.4 consisted of 20mM Tris-base, 1M NaCl, and 1mM
CalCl2. Wash Buffer II pH 6.0 was made from 300mM Na-acetate, 300mM NaCl
and 1mM CaCl2. Elution buffer pH 7.4 consisted of 20mM Tris-base, 300mM
NaCl and 5 mM EDTA. Dialysis buffer pH 7.4 was made from 50mM Tris-base
and 100mM NaCl. All buffers were stored at 4oC.
2.1.4 Fibrinogen ELISA
Coating buffer pH 7.2 consisted of 2.5mM disodium phosphate (Sigma-Aldrich),
7.5mM sodium dihydrogen phosphate (Sigma-Aldrich), 145mM NaCl. Blocking
buffer was made using 1x dilution buffer and 1% bovine serum albumin
(ThermoFisher-Scientific). Dilution Buffer was made from 1x coating buffer, 0.2%
Tween 20 (Sigma-Aldrich), 355mM NaCl. Citrate-phosphate buffer pH5.0 was
made from 25mM citric acid (Sigma-Aldrich) 50mM Disodium phosphate (Sigma-
Aldrich). Some 2mg o-phenylenediamine dihydrochloride tablets and hydrogen
peroxide were purchased from Sigma-Aldrich. F96 maxiSorp nunc immuno
plates were purchased from SLS (Nottingham, UK). Polyclonal Rabbit Anti-
Human Fibrinogen antibody was purchased from Agilent Technologies. detecting
sheep anti-human fibrinogen antibody was purchased from Enzyme Research
Laboratories (Swansea, UK).
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2.1.5 SDS-PAGE and circular dichroism spectroscopy
SDS-PAGE samples were prepared using 2.5µg protein, 1x LDS running buffer
and 1x sample reducing agent purchased from ThermoFisher-Scientific and tris
buffered saline (50mM Tris-base, 100mM NaCl). MES running buffer was
purchased from Sigma-Aldrich. Samples were loaded into NuPage 4-12% Bis-
Tris Gels (ThermoFisher-Scientific) alongside precision plus protein standards
(Bio-Rad, Hempstead, UK). Gels were inserted into Xcell sure lock gel tanks (Life
Technologies) and 200V was applied across the gel for 90 mins using a Biorad
power pack 300 (BioRad). Gels were stained with Gel Code® Blue Stain reagent
(ThermoFisher-Scientific) and then de-stained using ddH2O. All reagents were
stored at 4oC. The gel was imaged using Gbox imaging system (Syngene,
Cambridge, UK).
Circular Dichroism (CD) spectra samples were prepared by diluting recombinant
human fibrinogen variants to 0.2mg/mL in 200µL total volume and stored on ice
for the duration of the experiment. The variants were placed in a cuvette with a
1 mm path length (Hellma Analytics, Southend on Sea, UK) and the near UV
spectrum was measured using Chirascan instrument (Applied Photo Physics,
Surrey, UK).
2.1.6 Functional analysis of fibrin clots
Fibrin clots for turbidity measurements, magnetic tweezers and confocal
microscopy experiments were performed using recombinant human fibrinogen
generated in house, CaCl2 (1M stock stored at room temperature), 0.1U/mL
human thrombin (reconstituted to 250U/mL with ddH2O stored at -80oC (Merck-
Millipore, Watford, UK) and tris-buffered saline (50mM Tris 100mM NaCl) stored
at 4oC. Scanning electron microscopy clots were made using 0.5mg/mL, 10mM
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CalCl2 and 1U/mL thrombin. Clots used during AFM imaging were made using
0.02mg/mL Fibrinogen, 0.05 U/mL Thrombin and 2mM CaCl2.
Additional turbidity measurements were completed using 0.5BU/mL reptilase
(Stago Diagnostics, Reading, UK) and 5mM CaCl2. Reptilase lyophilised powder
was stored at 4oC and reconstituted by adding 2mL ddH2O to a final
concentration of 10BU/mL prior to conducting experiments. Clots formed for
magnetic tweezers had the addition of 1:250 v:v 4.5µm diameter paramagnetic
beads (Thermo-Fisher Scientific), these were also stored at 4oC. Clots made for
confocal microscopy had the addition of 5% Alexa 488-labelled recombinant
fibrinogen by using the Alexa Fluor™ 488 labelling kit (Thermo-Fisher Scientific).
Human Glu-plasminogen for confocal lysis experiments was purchased from
Enzyme Research Laboratories, and was reconstituted in 1mL ddH2O following
the manufacturer’s instructions yielding a final concentration of 11µM, dispensed
in 10µL aliquots and stored at -80oC. Tissue plasmin activator (tPA) was
purchased from pathway diagnostics (Dorking, UK) diluted to 1380nM by diluting
in 1mL ddH2O and stored at -80oC in 10µL aliquots.
2.2 Mutagenesis
2.2.1 Primer design and mutagenesis
The mutagenesis primers were designed using the Agilent primer design
program (https://www.genomics.agilent.com/primerDesignProgram.jsp), and
ordered from Thermo-Fisher Scientific at 200nmol and SDS-PAGE purified. The
full primer sequences can be found in Table 3-1. The QuickChange site–directed
mutagenesis kit (Thermo-Fisher Scientific) was used to mutate the human γA-
chain cDNA contained within the expression vector (pMLP-γA, Figure 2-1) A mix 
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of 1x reaction buffer, 20ng pMLP- γA expression vector, 125ng of forward and 
reverse primers, dNTP mix and 2.5U PfuUltra High Fidelity DNA polymerase in
50µL total volume was used in a thermal cycler (MJ Research, Waltham, MA,
USA) set to the parameters shown in Table 3-2
Figure 2-1 Plasmid map of pMLP-γAPlasmid map created using Snapgene
Viewer (GSL Biotech; Chicago, USA). The map displays the SV40 promoter
and SV40 poly(A) signal (yellow) the insertion of Fbg-γA (red) between 
restriction sites SalI (1420bp) and NotI (2834bp). This plasmid contains an
ampicillin resistance promoter (light green) and the ampicillin resistance
gene (dark green) and an origin of replication (pink).
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When the PCR cycling had completed, non-mutated parental strands were
digested by the addition of 10U Dpn-1 restriction enzyme and then incubated in
the thermal cycler as described in 3.2.1
Table 2-1 PT200 Dpn-1 digestion parameters
Segment Cycles Temperature (oC) Time (Minutes)
1 1 37oC 60
2 1 4oC 10
2.2.2 Bacterial transformation
LB Agar was autoclaved and supplemented with 100µg/mL ampicillin to produce
(LB-Agar Amp+), 15mL of LB-Agar Amp+ were poured onto three 10cm dishes. XL10
gold bacteria were defrosted slowly on ice and a 50mL falcon tube was pre-
chilled on ice, meanwhile SOC medium was defrosted and warmed to 42oC in a
water bath. XL10 gold bacteria (50µL) and Dpn-1 treated DNA (1µL) from section
2.2.1 was transferred to the pre-chilled tube (now a transformation reaction). The
transformation reaction was mixed gently and returned to the ice to incubate for
30 minutes, quickly transferred to 42oC and gently mixed for 45 seconds, then
transferred to ice and incubated for a final two minutes. SOC medium (300µL)
was then added to the transformation reaction and incubated at 37oC, while
shaking (220rpm) for one hour. Three different volumes of transformed cells
were plated at 37oC (50µL, 100µL and 150µL) onto LB-agar Amp+ dishes which
were wrapped in parafilm and incubated for 16 hours at 37oC. The following day,
LB-agar Amp+ dishes were checked for colony growth and stored at 4oC.
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2.2.3 DNA extraction
Six colonies from the transformation step 2.2.2 were picked using a wire loop
(Starstedt, BrandErbisdorf, Germany) and individually inoculated into 10mL LB-
broth (in a 50mL falcon tube, Starstedt) containing 100ug/mL ampicillin (LB-broth
Amp+) and incubated overnight in a G25 shaking incubator (New Brunswick
Scientific, NJ, USA) at 37oC, 220rpm. The following day, the cultures were
centrifuged at 4600g for 10 minutes using a Rotana 460R (Hettich, Germany)
and the supernatant was discarded. The QIAprep® Spin Miniprep Kit (Qiagen;
Manchester, UK) was used for plasmid DNA extraction from the pellets produced
and the manufacturer’s instructions were followed with the exception that the
DNA was eluted using DNAse-free water (Thermo-Fisher Scientific) instead of
buffer ‘EB’. The concentration of the eluted DNA preparation was determined at
A260nm using a Nanodrop ND 1000 (Fisher Scientific; Loughborough, UK) and
the DNA was then stored at -20oC. This DNA was used for partial and then full
sequencing of the fibrinogen γ-chain cDNA to check that the correct point 
mutation(s) had been performed. The vector containing the correct DNA
mutation(s) confirmed by sequencing was used to perform a second
transformation reaction. One colony was chosen, suspended in 5mL of LB-broth
Amp+ in a 50mL falcon and incubated for 4 hours at 37oC 220rpm. The cell mixture
was then added to 200mL of LB-broth Amp+ in a 1L conical flask and incubated
overnight at 37oC, 220rpm. DNA extraction using the PureYield™ Plasmid
maxiprep system (Promega; Southampton, UK) was performed. All steps were
performed using the manufacturer’s instructions. The concentration of the DNA
preparation was determined at A260nm using the Nanodrop ND 1000, the DNA
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was stored at -20oC, and used for full fibrinogen γ-chain cDNA sequencing and 
transfection into mammalian cells.
2.2.4 Sequencing
In the first instance, the FbgGg-F1 primer was used to partially sequence the γ-
chain DNA sequence within the area of the desired point mutations. Plasmids
containing the desired point mutations had their entire γ-chain cDNA fully 
sequenced with the primers listed in Table 2-2. All sequencing was contracted to
DNA Sequencing and Services, Dundee University (https://www.dnaseq.co.uk).
Table 2-2 Primers for DNA sequencing
Primer Name Primer Sequence
pMLP-F1 5'-CCTTTCTCTCCACAGGTGTC-3'
FbgGg-F1 5'-TGCTACTTTGAAGTCCAGGAAAA-3'
FbgGg-F2 5'-GTACTGCAGACTATGCCATGTTC-3'
pMLP-R1 5’-GCTGCAATAAACAAGTTAACAACAA-3’
2.3 Cell culture
2.3.1 Thawing cells
Chinese Hamster Ovary (CHO) cells were previously transfected with fibrinogen
Aα- and Bβ- chains by the Ariëns laboratory. The method was based on the 
works of (Lord et al., 1993; Binnie et al., 1993). The previously transfected cells
were removed from liquid nitrogen storage. The cells were rapidly thawed in a
water bath (Grant Instruments Cambridge, UK) set to 37oC, transferred to a
15mL falcon tube containing 9mL of Growth Medium, and centrifuged at 280g
(Hettich, Tuttlingen, Germany) for 4 minutes. The supernatant was discarded
and the cells were suspended in 10mL growth medium, 1mL of this suspension
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was added to a T75cm2 tissue culture flask containing 12mL growth medium,
and incubated (Panasonic Biomedical, Loughborough, UK) at 37oC, 5% CO2.
2.3.2 Routine splitting of cells
Cell culture medium was discarded from 75cm2 flasks containing CHO cells at
80% confluency, 10mL of 0.1M PBS-EDTA was used to wash the cell monolayer
and was replaced by 1mL of Trypsin-EDTA. Following 2 minutes incubation at
37oC with the trypsin, the cells were checked for detachment using a light
microscope (Olympus, Hamburg, Germany) and suspended in 10mL of growth
media. This splitting of the flasks was performed every 2-3 days at a 1 in 10
dilution.
2.3.3 Transfection – calcium phosphate method
When 80% confluent, cells were split in a 1 in 10 dilution between three 10cm
dishes (one dish for each of the two transfection reactions listed in Table 2-3 and
one for a control). Geneticin (Thermo-Fisher Scientific) was added to the dishes
at a final concentration of 400µg/mL and the dishes were incubated overnight at
37oC, 5% CO2.
The medium was replaced with fresh growth medium and incubated for 2 hours
at 37oC, 5% CO2. Two transfection reactions were performed for the same
mutation, where one contained 10µg and the other reaction contained 20µg of
DNA as demonstrated in Table 2-3.
Table 2-3 Transfection reaction mix
Transfection 1 Transfection 2
10µg DNA 20µg DNA
1µg pMSV-his 2µg pMSV-his
2.5M CaCl2 2.5M CaCl2
Make up to 500µl with ddH2O
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The DNA mixture was added slowly, in a dropwise fashion to 500µL of bubbling
2x HEBS buffer. Following the addition of the DNA the mixture was allowed to
stand for 30 minutes to enable the formation of a phosphate-DNA co-precipitate.
The phosphate-DNA co-precipitate was then added evenly, dropwise across the
dish and incubated for 4 hours at 37oC, 5% CO2. A glycerol shock step was then
performed by discarding the growth medium, adding 2mL of 10% glycerol (VWR)
that was previously sterile filtered using a 0.22µm filter (VWR) and incubating the
cells for 3 minutes at room temperature. The cells were then washed three times
with PBS and incubated in growth medium for 24 hours at 37oC and 5% CO2.
The three dishes were then split into 10 dishes (5 dilutions in duplicate), the
dilutions were 1 in 50, 1 in 100, 1 in 150, 1 in 200 and 1 in 400. The control dish
was split 1:100 and 1:400. The following day the medium was removed and
replaced with selection medium and incubated for 48 hours at 37oC, 5% CO2.
Selection medium for all dishes were replenished every 2-3 days until single
isolated cells appeared.
2.3.4 Colonies selection
Cells were selected for using L-histidinol for approximately two weeks. Single
cell colonies had formed from the selection process and 24 colonies per
transfection condition were selected (48 clones in total). The clones were
trypsinised for 5 minutes, picked using a glass cloning cylinder, and transferred
to a 24-well plate (one clone per well) containing 500µL of selection medium.
At 80% confluence, the supernatant from each well in the 24-well plates was
removed and frozen at -80oC as separate aliquots, for the quantification of
fibrinogen expression by ELISA. Each clone was split into two 5 cm dishes and
incubated at 37oC, 5% CO2 until confluent. At 80% confluence, one dish from
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each pair was trypsinised by the addition of 0.5mL 0.25% Trypsin-EDTA, 9.5mL
selection medium was added and the cell suspension was centrifuged (280g, 4
minutes). The supernatant was discarded and the pellet was suspended in 4mL
freezing mix, aliquoted 1mL per cryotube and frozen at -80oC using a ‘Mr Frosty’
apparatus (Nalgene; Loughborough, UK), before being moved to liquid nitrogen
storage the next day. The other dish was split 1 in 10 in selection medium. When
80% confluent, the medium was changed to serum-free medium and incubated
for a period of 1 week at 37oC, 5% CO2, before the medium was harvested and
stored at -80oC for ELISA.
2.3.5 Roller bottle expression and precipitation
The top 50% highest fibrinogen expressing mutants in regular culture conditions
were selected for expression for 1 week in 10cm dishes using serum free
medium. The highest expression clone in these serum free conditions as
determined by fibrinogen ELISA was selected for roller bottle expression. A
cryovial of the highest expressing clone was removed from liquid nitrogen
storage, thawed and re-suspended as described in section 2.3.1. The
supernatant was removed and the cell pellet was suspended in 10mL of growth
media and split equally into two 10cm dishes containing 10mL growth medium.
Cells were routinely split to obtain 40 confluent 10cm dishes of the same
passage.
When confluency had been reached two 10cm dishes were washed with 10mL
of 0.1M EDTA-PBS followed by 1mL of Trypsin-EDTA. Following 2 minutes
incubation at 37oC with the trypsin the supernatant was suspended in 20mL of
growth media and added to a roller bottle supplemented with 180mL of growth,
and incubated at 37oC until confluent. The growth medium was replaced every
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2-3 days until confluence was reached. When the roller bottles had reached
confluence, 20g of micro carrier beads were added to 1L of PBS and autoclaved.
Supernatant PBS from sedimented autoclaved microcarrier beads was removed,
replaced with 1L basal DMEM F-12 medium and the beads were allowed to
sediment, this was repeated three times. 100mL of medium was removed from
each roller bottle and replaced with 50mL of bead mixture and 50mL complete
growth medium, and incubated for 2-3 days at 37oC, 5% CO2. After the 3 days
had elapsed the medium from the roller bottles was removed and replaced with
with 100mL serum-free medium and incubated overnight at 37oC 5% CO2. The
following day, the serum-free medium was removed and replaced with 200mL of
ITS medium and incubated for 2-3 days at 37oC, 5% CO2. The supernatant was
then collected for a period of 8 weeks by the removal of approximately 100mL
ITS medium per roller bottle every 2-3 days and replaced with 100mL fresh ITS
medium. The collected supernatant was filtered using filter paper (Whatmann,
Little Chalfort, UK) and 150µL 100mM PMSF was added per 100mL harvested
supernatant and 1mL harvested medium was aliquoted for fibrinogen ELISA. The
remaining supernatant was then frozen at -40oC.
2.4 ELISA
Anti-Fibrinogen antibody was diluted at 1:4000 in coating buffer and used to coat
(100µL/well) a 96-well immuno-plate. The plate was covered and incubated
overnight at 4oC. Following removal of the antibody, 150µL/well of blocking buffer
was added and incubated at room temperature for 60 minutes on a shaker at
50rpm. Recombinant human fibrinogen was used to create a standard curve of
0.06-1000ng/mL in dilution buffer. The blocking buffer was removed and the
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plate was washed 3x with 300µL/well of washing buffer. Standard or neat sample
(100µL) were distributed, in duplicate, and incubated at room temperature for
120 minutes on a shaker set at 50rpm.The plate was washed 3x with 300µL/well
washing buffer. The anti-fibrinogen/HRP antibody was diluted 1:16000 in dilution
buffer, 100µL/well was added to each well, and the immuno-plate was incubated
at room temperature for 60 minutes on a shaker. The plate was washed 3x with
300µL/well washing buffer and 5µL of 34% H2O2 was added to an OPD and
citrate buffer solution (8mg of 1,2-phenylenediamine dihydrochloride in 12mL
citrate phosphate buffer), before being distributed 100µL/well and allowed to
develop. The reaction was stopped with 100µL/well buffer 3M H2SO4. The plate
was then read at 490nm using a Spectramax plate reader (Molecular Devices;
California, USA). The log concentrations of the standards used in the ELISA were
plotted against their corresponding ODs and a standard curve was constructed.
A linear line of best fit was applied and the fitted equation was used to calculate
the concentration of fibrinogen for each clone.
2.5 Precipitation and purification
2.5.1 Precipitation
Prior to precipitation, the frozen medium was thawed and 3L were added per 5L
flask in conjunction with 90mL of protease inhibitor cocktail. Whilst stirring at
50rpm 2L of saturated ammonium sulphate was filtered into the medium,
dropwise, and left overnight without stirring. The final concentration of
ammonium sulphate was 40%. The precipitate (recombinant fibrinogen and other
proteins) precipitate was collected by centrifugation at 14,500g, 45 minutes, 4oC
using a Beckman High Speed Centrifuge (Beckman Coulter; California, US). The
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excess ammonium sulphate was removed, pellets were dissolved in 9.6mL of
pellet resuspension, incubated on ice for 30 minutes, then centrifuged for
30minutes at 43,000g, 4oC. The supernatant was collected and stored in 5mL
aliquots at -80oC.
2.5.2 Affinity chromatography and dialysis
The frozen supernatant 2.5.1 was defrosted and CaCl2 was added to a 10mM
final concentration. IF-1 immunoaffinity chromatography was performed as
previously described (Takebe et al., 1995), using an ÄKTA Avant 25 (GE
Healthcare, Little Chalfort, UK). Following injection of the supernatant onto the
column using equilibration buffer, non-specific binding was eliminated using
wash I and wash II buffers, and the purified fibrinogen was recovered using
elution buffer. Fibrinogen was then dialysed overnight using a D-tube™ dialyser
mega 10mL (Millipore) against dialysis buffer made as described in 2.1.3. The
purified fibrinogen was then concentrated by centrifugation at 4600g using Pierce
100,000 MWCO spin columns (Sigma-Aldrich) and the fibrinogen concentration
was determined at A280nm (15.1 extinction coefficient) using the Nanodrop
ND1000 before storage in 10 µL aliquots at -80oC.
2.6 Protein concentration and dialysis
2.6.1 Concentration of recombinant fibrinogen variants
The purified fibrinogens were concentrated using Pierce 100,000 MWCO spin
columns and the fibrinogens were then dialysed overnight against dialysis buffer
as mentioned in 2.5.2 and the fibrinogen concentration was determined at
A280nm using the Nanodrop ND1000) before being stored at -80oC.
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2.7 SDS-PAGE
For SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis)
analysis samples were prepared using 2.5µg protein, 1x loading buffer, 1x
sample reducing agent and TBS (50mM Tris, 100mM NaCl) to the final volume
of 25µL. The samples were heated to 70oC for 10 minutes, incubated on ice for
2 minutes and then centrifuged at 14500rpm in a microfuge for 15 seconds. MES
running buffer (500mL) was prepared and added to the gel tank and the samples
were loaded (25µL) into a NuPage 4-12% Bis-Tris gel alongside 5µL of precision
plus protein standards and 200V was applied for 1 hour. After completion the gel
was washed with ddH2O and stained in Gel Code® Blue Stain reagent for 1 hour
at room temperature. The gel was then washed with ddH2O for 1 hour and the
water was replaced every 15 minutes, a final wash was performed overnight in
ddH2O at 4oC. The gel was imaged the following morning using G:Box (Syngene,
Cambridge, UK) in conjunction with Genesys computer software, (California,
US).
2.8 Circular dichrosim
Circular Dichroism (CD) spectra samples were prepared by diluting recombinant
human fibrinogen variants to 0.2mg/mL in 200 µL total volume and stored on ice
for the duration of the experiment. The variants were placed in a cuvette with a
1 mm path length (Hellma Analytics, Southend on Sea, UK) and the near UV
spectrum (190-270nm) was measured using Chirascan instrument (Applied
Photo Physics). CDNN convolution software was used to calculate percentage
folding for all variants.
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2.9 Turbidity
Turbidity is a technique that is based on the changes of light scattering of a
sample and in this particular case, fibrin matrices. During polymerisation,
fibrinogen, a soluble transparent protein is converted to fibrin by thrombin
resulting in a fibrin matrix which is insoluble and translucent/opaque. In brief,
light is scattered and the amount of un-scattered light can be detected by the
plate reader, Figure 2-2. In this work turbidity was measured over time by taking
multiple light scattering readings of multiple samples at a time in a 384 well
microtiter plate to generate a turbidity curve (opacity increase over time), Figure
2-3.
Figure 2-2 Diagram to demonstrate the principal of turbidity (light
scattering). When light travels through a solution it scatters (known as the
incidence point (Io)). The detector is then able to measure the amount of
transmitted light (I) and determine the absorbance of the solution (Aλ). This
was adapted to a 384 well microtiter plate in the case of this work. Different
patterns of light scattering by fibrin matricies reflect differences in clot
structure.
The optical density can be calculated using the following equation;
ܣఒ = log(ூ௢ூ)
Equation 2-1 Absorbance calculation Where the absorbance (Aλ) equals the
log of the intensity of the indicdence light (Io) divided by the intensity of the
transmitted light (I).
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Figure 2-3 Typical profile of a fibrin polymerisation curve (1). Denotes the
lag phase when FpA and FpB are being cleaved and formation of
protofibrils, (2) represents fiber growth and (3) the plateau signifies the
clot’s maximum optical density and correlates with the average fibrin fiber
diameter.
Figure 2-3 shows a typical fibrin polymerisation curve, in the early stages (1) a
lag phase is typically observed where there is no increase in the optical density
followed by a rapid increase (2) which then reaches a plateau (3). The lag phase
corresponds to the cleavage of both FpA and FpB and the formation of
protofibrils, the exponential rise in optical density results from lateral aggregation
of protofibrils that form fibrin fibers. Previous studies have shown that the
maximum OD (MaxOD) is directly related to the average cross sectional area of
fibers (Carr and Hermans, 1978).
2.9.1 Cleavage with thrombin
All turbidity experiments were performed in 384 well plates using a Powerwave
micro-plate reader (Bio-Tek; Swindon, UK). All fibrinogen variants, were diluted
to 1mg/mL in TBS, pH 7.4 and 50µL were added in duplicate to a 384 well plate
(Greiner). A reaction mix (50µL/well) comprising of 10mM CaCl2 and 0.2U/mL
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thrombin in TBS, pH 7.4 was added, to achieve a final concentration of 0.5mg/mL
of fibrinogen 5mM CaCl2 and 0.1U/mL thrombin in a total volume of 100µL and
immediately transferred to the micro-plate reader. The absorbance of each well
was measured at 340nm wavelength every 12 seconds for 2 hours at 37oC. Data
analysis was performed using both Microsoft Excel, for the averaging of data,
and GraphPad Prism for the statistical analysis and graphing of the data. Three
outputs were analysed from the turbidity profiles of each fibrinogen variant; lag
phase, maximum optical density (OD) and maximum polymerisation rate. The
lag time was interpreted manually and chosen to be the last point before an
exponential increase in optical density. The maximum OD was taken to be the
highest absorbance value. The maximum polymerisation rate was calculated
using a macro on excel designed by Fraser Macrae, University of Leeds. The
macro analyses the most steep part of the turbidity curve which is equivalent to
the Vmax. The results of lag phase and MaxOD were analysed for statistical
significance with the use of a One-Way ANOVA test with multiple comparisons
using WT as a control column
2.9.2 Cleavage with reptilase
Cleavage of fibrinogen with reptilase was also performed as in 2.9.1 with the
exception of 0.5U/mL (final concentration) reptilase was used instead of 0.1U/mL
thrombin.
2.10 Micro-rheology using magnetic tweezers
2.10.1 Magnetic micro-rheometer equipment
The magnetic micro-rheometer was already built and designed by Robert
Harrand, a past Ph.D student at the University of Leeds, (Harrand.R, 2007). In
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brief, four magnetic poles (named up, down, left and right) are housed on a stage
each connected to an individual BOP 20-5M amplifier (Kepco, Inc., NY, US)
providing voltage to generate the magnetic field. Underneath the stage sits a
Olympus IX-71 inverted microscope with CCD camera (Olympus, UK) equipped
with a 40x ultra long working distance air objective. Images are recorded at 25Hz
and processed by a PXI-8186 with particle tracking software (National
Instruments; Texas, US) that the user can export as a .txt file of the X and Y
displacement. All equipment, except for the amplifiers are housed on a vibration
reduction optical table.
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Figure 2-4 Micro-rheometer setup (A) Olympus IX-71Microscope with 40x ultra
long air objective and CCD camera attached. An iron frame housing
electromagnets and the sample holder which are positioned above the
objective. (B) The sample holder surrounded by four electromagnets that
houses the capillary tube, paramagnetic beads are pulled and imaged using
the microscope objective on the underside of the iron frame which is
connected to the CCD camera.
2.10.2 Calibration
The magnetic tweezers micro-rheology setup is a very sensitive piece of
equipment as the position of the electromagnets can have a great effect on the
measurements taken, due to this the voltage applied from the amplifiers may not
induce the correct force, therefore before every study the electromagnets are
correctly positioned and the setup is calibrated.
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To calibrate the magnetic tweezers apparatus a material that had a known
viscosity was used as the medium with the addition of paramagnetic beads
(4.5µm diameter) trapped in the solution. These were inserted into Hildenberg
capillaries (Hildenberg GmbH, Germany) and the ends were blocked with
Vaseline to prevent dehydration. In the case of this work, 99% glycerol (Sigma-
Aldrich) was used at a dilution of 1:300 (V:V) beads to glycerol. The amount of
force that the magnetic bead was subjected to can be then calculated using
Equation 2-2 (Allan.P, 2012);
ܨ = 6ߨߙߟݒ
Equation 2-2 Stoke’s Law  F = the constant applied force, η = fluid viscosity 
and v = velocity of the particle.
The Labview 7.1 software was then used to locate a magnetic bead whose
movements would not be influenced by the edges of the capillary tube or another
magnetic bead. Voltages between 0 and 3 volts with 0.2V increments were
applied to displace the magnetic bead followed by voltages of 3 to 5 volts with
0.5V increments for all electromagnets, for force calibration. Using the output
data, the force calibration curves were plotted for all electromagnets and fitted
with a curve determined by Equation 2-3 (Allan.P, 2012).
ܨ = ܣଵ− ܣଶ1 + ቀܸ
଴ܸ
ቁ
௣
Equation 2-3 Force calibration fitting F = force, V = voltage and A1, A2, V0
and p are fitting parameters.
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The equation was rearranged so that voltage became the subject and this was
reprogrammed back to LabView7.1 to allow experiments to be performed using
a particular force.
2.11Force measurements
To perform force measurements of WT and the four recombinant fibrinogen
variants, clots were made of each type using 0.5mg/mL fibrinogen, 5mM CaCl2
1:250 (v:v) superparamagnetic beads and 0.1U/mL thrombin in a total volume of
25µL in an Eppendorf tube. Immediately following the addition of thrombin a
VitroCom microcell (50mm length, 0.5mm diameter, VitroCom, New Jersey, US)
was inserted and approximately 15µL of the forming clot was drawn into the
capillary, the ends of the capillary were then blocked with vaseline to prevent
dehydration. Each clot was manually rolled for 15 minutes to ensure the beads
did not sediment onto one side of the capillary walls and the clot was allowed to
fully form overnight at room temperature in a humidity chamber. Experiments
showing the superparamagnetic beads do not have an effect on clot structure
have been conducted previously (Allan.P, 2012).
The following day the capillary was housed on the sample stage and using the
Labview7.1 software an appropriate superparamagnetic bead was located and
a force of 40pN was applied using the ‘right’ electromagnet. The deformation of
the fibrin clot was measured for a period of ten minutes, ten beads were
measured per clot and three clots per recombinant variant were measured.
There was a significant time difference between when triple mutant γDEK variant 
was measured and when the single mutant variants were measured, requiring
the magnetic tweezer apparatus to be re-calibrated before measurements were
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taken. Therefore, WT clots were measured in both instances due to different
calibration settings. The time dependent displacement (the 10 minute pulling) of
the bead is related to time dependant compliance J (t) as can be seen in Equation
2-4 (Allan.P, 2012);
ܬ(ݐ) = 6ߨܽݔ(ݐ)
ܨ
Equation 2-4 Time dependent compliance is related to the time dependent
particle displacement J(t) = time dependent compliance, a = radius of the
paramagnetic bead and x(t) = time dependent particle displacement and F
= Force.
Figure 2-5 Time dependent compliance Each black dot represents a data point
of the time dependent compliance J(t) of the super paramagnetic beads.
The red line displays the compliance fitting applied as calculated by
Equation 2-6.
The compliance fitting to the experimental data was attempted to be plotted by
fitting Equation 2-5 in GraphPad Prism 7. However, using GraphPad 7 it is not
possible to fit this equation therefore an approximation was used as in Equation
2-6, designed by Dr. Marco Domingues, University of Leeds.
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ܬ(ݐ) = ܬ଴ + ෍ ܣ௡௡
ଵ
(݁ି௧/ఛ೙)
Equation 2-5 Compliance fitting Equation 1
The equation that is solved to obtain the fitting parameters of the time
dependent compliance.
ܻ = 1
ܭ଴
൬1 − ܭଵ
ܭ଴ + ܭଵ൰݁ି௫/ఛ+ ݔ݅ݒ ܿݏ ݋݅ݏݐݕ
Equation 2-6 Compliance fitting equation 2
The equation that is inputted into GraphPad Prism 7 as an approximation
of Equation 2-5. K1, K0 ,viscosity and tau are fitting parameters. Y= J(t) from
Equation 2-4 and x = time.
Peter Allan in his Ph.D thesis describes how to convert the time dependent
compliance J(t) to frequency dependent moduli through the aforementioned
equations and mathematical transformations developed by Professor Steve
Evans, Molecular and Nanoscale Physics group, University of Leeds (Evans et
al., 2009). After these equations have been solved the G' and G" moduli using
can be extracted from the data using Equation 2-7.
ܩ∗(߱) = ܩᇱ(߱) + ݅ܩᇱᇱ(߱)
Equation 2-7 The equation that is used to generate all G' and G" data points
using Octave 4.2 software.G* is the complex modulus, G’ is storage
modulus and G’’ is the loss modulus
Equation 2-7 was executed using the mathematical software Octave 4.2 and
generated curves for G’ and G’’ as shown in Figure 2-6
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Figure 2-6 Frequency dependent moduli G' and G"
The storage modulus G' (blue) and the loss modulus G" (red) plotted
against frequency (ω) using values calculated from the equation in Equation 
2-7
For all micro-rheology experiments 10 beads were measured per fibrin clot and
were pulled with a force of 40pN, these results were averaged to generate a G'
(storage modulus) and G" (loss modulus) value for each clot between 0 and
25Hz. The values for each clot type were averaged to obtain G’ and G’’ as a
function of frequency (between 0 and 25Hz) for all fibrinogen variants. Three
frequencies of 0.1, 1 and 10Hz were chosen to make comparisons between each
fibrinogen variant, these were chosen because they represent the timescales
where deformation events occur when force is exerted on the fibrin clot. G’ and
G’’ values were analysed for statistical significance with the use of a One-Way
ANOVA test with multiple comparisons using WT as a control column. The loss
modulus (overall visco-elastic property of the fibrin clots) was then calculated by
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dividing the G" by G'. The tan delta (δ) were analysed for statistical significance 
with the use of a One-Way ANOVA test with multiple comparisons using WT as
a control column.
2.12 Laser scanning confocal microscopy
2.12.1 Alexa Fluor labelling of fibrinogen variants
The Alexa Fluor 488 protein labelling kit was used to label approximately 100µg
of each recombinant fibrinogen variant. Due to incompatibility of Tris buffers with
the labelling kit each recombinant variant was dialysed against 1x PBS pH 7.4.
The manufacturers’ instructions were completed in full. Afterwards the degree of
labelling was quantified using a Nanodrop ND-1000 using A280 for the detection
of protein and A494 for the detection of bound label. The degree of labelling was
then calculated using the absorbance from the Nanodrop using the following
formula; (ܣଶ଼଴ × 10) − ((ܣସଽସ × 10) × 0.11)1.51
Equation 2-8 The degree of labelling. Where A280 is the value for the amount
of absorbance detected at 280nm and A494 is the amount of absorbance
detected at 494nm. 0.11 is the correction factor value of labelling provided
by Thermofisher Scientific and 1.51 is the molar extinction coefficient of
fibrinogen.
2.12.2 Fibrin clot formation in hydrated conditions
Fibrin polymerisation and clot formation was initiated in a total volume of 40µL in
an Eppendorf tube. The tube was immediately mixed and 30µL of the volume
was transferred to a channel in a VI flow, uncoated sterile µ-slide (Thistle
Scientific, Glasgow, UK), placed onto the piezo stage of the LSCM microscope
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(Carl Zeiss, Cambridge, UK) and the clots were formed for a period of one hour
with the first image being taken 1 minute after formation. For all confocal imaging
an inverted Zeiss 880 LCSM with a 40x 1.4 DIC M27 oil immersion objective was
used. Multiple scans of different focal planes (slices) were used to reconstruct a
3D image of each clot (z-stack), for clot formation experiments a z-stack was
imaged every 30 seconds to create a series of images to visualise clot formation
over time. For settings of the LSCM during clot formation experiments refer to
Table 2-4.
Table 2-4 LSCM settings for clot formation experiments
Setting Value
Laser Power 3%
Laser 488
Stack size X = 212.13µm Y = 212.13µm Z = 15µm
Slices 21
Slice Depth 0.75µm
Series Time 30 seconds
Gain 762
Pinhole 34µm
The computer software ZEN was used to process the z-stacks, they were
flattened into a 2D image and a 5fps avi. video file was created of clot formation
over time.
2.12.3 Final clot structure Imaging
Fibrin clots were formed as described in 2.12.2. Images of the final clot structure
(1 hour after polymerisation initiation) were taken with a Zeiss 880 LCSM using
the following parameters described in 5.2.2.3
The software package ZEN was used to process the z-stacks, they were
flattened into a 2D image. Fiber density of the clots was determined by imaging
three areas of each clot and a micrograph generated for each area. Three lines
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spanning the entire length of the micrograph (212.13µm) were drawn horizontally
and three lines vertically and the number of fibers that crossed these lines on
were counted. The clot density between WT, γDEK, γD297N, γE323Q and 
γK356Q were compared with the use of a One-Way ANOVA test with multiple 
comparisons using WT as a control column.
2.12.4 Clot lysis
Fibrin clots were formed as described in 2.12.2 and subsequently lysed by
adding 20µL of 6nM tPA and 0.4µM Plasminogen.
The computer software ZEN was used to process the z-stacks, they were
flattened into a 2D image and then converted into a 5fps avi. video file. The image
window was calibrated to the known distance of the stack size which was
212.13µm using the computer image analysis software Fiji, ImageJ (Schindelin
et al., 2012). Now that the window had been calibrated, it was possible to
calculate the rate of lysis by the distance of the window (measured by drawing a
line between the lysis front in the first and last stacks) divided by the time elapsed
for the complete disappearance of the lysis front.
Figure 2-7 Measurement of the distance travelled over time by the lysis
front. (A) The window is calibrated to 212.13µm length. (B) The clot is partially
lysed at this particular frame with the direction of the lysis front indicated by the
yellow. Ten seconds elapsed between the capture of each stack, so it was
possible to calculate how much time had elapsed for the distance travelled. This
information was used to calculate how fast the lysis front was travelling over time
(µm/s).
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The clot density between the recombinant variants were compared with the use
of a One-Way ANOVA test with multiple comparisons using WT as a control
column.
2.13Scanning electron microscopy
Scanning Electron Microscopy (SEM) is another imaging technique that can be
used to study the structure of fibrin clots, it differs somewhat compared to LSCM
as SEM is a surface imaging technique providing limited depth information, while
LSCM provides full 3D visualisation through the reconstruction from z-stacks. In
addition, SEM requires sample fixation, dehydration and critical point drying,
while LSCM is performed on full hydrated samples. However, SEM delivers much
greater imaging resolution and remarkable detail, resolving structures in the
range of 1-10nm with the best microscopes, LSCM on the other hand provides
no better resolution than light microscopy allows, for example 100-200nm being
the limit of its resolving power. Some fibrin fibers are less than 100nm in
diameter, and therefore SEM is an important addition to LSCM in the study of
fibrin clot structures.
Fibrin Clots using all fibrinogen variants and WT were made to the final
concentration of 0.5mg/mL fibrinogen, 5mM CaCl2 and 1U/mL, thrombin in a total
volume of 80µL. Eppendorf lids were pierced seven times with a needle and
subsequently wrapped in parafilm in preparation to house the fibrin clot. The
formation of the fibrin clot was initiated by the addition of thrombin, the mixture
was gently vortexed and transferred to the Eppendorf lid reaction chamber
Figure 2-8 and allowed to form in a humidity chamber for 2 hours.
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Figure 2-8 SEM clot formation in an Eppendorf lid The pierced reaction
chamber is where the fibrin clot is formed. The parafilm seal is required to
prevent leakage during clot formation, it can be removed at later stages
when the clot has fully formed to expose the pierced side of the reaction
chamber for the washing and fixing stages.
Following clot formation, the clots were washed in 50mM sodium cacodylate
buffer (pH 7.4) for 20minutes three times (to remove excess salt). Clots were
fixed with 2% Gluteraldehyde for a period of two hours and then washed another
three times in 50mM sodium cacodylate buffer (pH 7.4) and dehydrated using
an acetone dehydration series (30, 50, 60, 70, 80, 90, 95 and 100% acetone, 15
minutes per acetone concentration, 30 minutes for 100% acetone). The clots
were transferred to fresh 100% acetone and left overnight. The following morning
clots were critical point dried (performed by Martin Fuller of the Astbury Center,
University of Leeds). In brief, the liquid acetone within the samples was replaced
with liquid CO2 under 800psi, the samples were heated to 35oC under 1200psi
which allows the CO2 to evaporate removing all excess liquid, samples were
mounted onto 13mm diameter aluminium SEM imaging stubs and coated with
0.5nm thick layer of iridium using an Agar High resolution sputter coater (Agar
Scientific, Stanstead, UK). Each clot type was made three times and each
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individual clot was imaged at a minimum of two locations at x2000, x5000,
x10000 x 20000 and x50000 magnifications using Hitashi SU8230 scanning
electron microscope. Images at x20000 for all clot types were chosen to be used
to calculate average fiber diameters. The images were imported into ImageJ
software, a 9 x 6 line grid overlay was superimposed onto the image, creating 54
intersections across the image, the fibers that were closest to the intersections
were measured for fiber thickness. The results were tabulated using GraphPad
Prism 7 and the fiber thickness between WT, and the recombinant variants were
compared with the use of a One-Way ANOVA test with multiple comparisons
using WT as a control column.
2.14 Atomic force microscopy
Atomic Force Microscopy (AFM) was used to study different stages of the
polymerisation process and to investigate the effect of the abolition of the
electrostatic extended D-E interactions on protofibril formation and assembly. A
mica disc was cleaved and treated with 50µL 5mM NiCl2 to positively charge the
surface. Fibrin Clots of all fibrinogen variants and WT were made to the final
concentration of 0.02mg/mL fibrinogen, 0.05U/mL Thrombin and 2mM CaCl2 in
a total volume of 45µL. All samples were mixed gently using a pipette and
allowed to clot until either 10, 20, 30 minutes had elapsed, after the clotting time
was reached the polymerisation reaction was stopped by the addition of 135µL
of TBS buffer and 3µL was transferred to the treated mica disc. The surface was
then washed with 150µL of ddH2O and dried using nitrogen gas, the sample was
washed and dried in the same manner one more time. Samples were then
imaged using a Nanoscope V MultiMode 8 (Bruker, Coventry, UK) in soft tapping
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mode in air with Bruker Tespa-V2 tips. Images were then flattened by the third
order, and streaks were removed during processing using Nanoscope Analysis
v1.5 (Bruker). The modified file was then exported to ImageJ for further
processing. Using ImageJ a macro “AFM Crop” was written to automatically crop
and set the scale (4µm) to allow for accurate measurement of protofibrils.
Protofibril length was measured using the measuring tool in the software, and
the results were tabulated using GraphPad Prism 7. Histograms of protofibril
formation were made using Origin Pro (Origin Lab, Northampton, MA USA).
2.15 Protofibril packing
Fibrin clots (0.5mg/mL fibrinogen 5mM CaCl2 and 0.1U/mL thrombin) of both WT
and fibrinogen variants were made to a volume of 100µL in a polystyrene cuvette
(Eppendorf) with 1cm path length and immediately closed with parafilm to
prevent dehydration of the fibrin clot. The clots were formed for 24 hours at room
temperature before measuring the light scattering properties. After complete clot
formation the clots were scanned between 500 < λ <780nm in a λ 35 UV-Vis 
spectrophotometer (Perkin-Elmer, Cambridge, UK). The average fiber diameter
of the fibrin fiber can be determined from the wavelength dependent turbidity of
fibrin clots which has already been established by (Carr and Hermans, 1978) and
more recently by (Yeromonahos et al., 2010). Firstly the wavelength dependent
absorbance was determined as demonstrated in Figure 2-9.
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Figure 2-9 UV-Vis spectra in the fully formed fibrin clot Scan between 500 <
λ <780nm) Example taken from K356Q fibrinogen variant. 
The obtained optical density values were converted into turbidity values ‘ ’߬ using
the following equation described in (Yeromonahos et al., 2010).
߬= 1 − (݁ି஺.௟.୪୬(ଵ଴))
Equation 2-9 Wavelength dependent turbidity Wavelength dependent
turbidity transformed into turbidity values where A= Abosrbance and l= path
length.
It has previously been estimated by both (Carr and Hermans, 1978) and
(Yeromonahos et al., 2010) that for a solution of randomly orientated fibers the
turbidity is as described in Equation 2-10;
߬ߣହ = 2ߨଷܥ ௦݊ߤ
ܰ
൬
݀݊
݀ܿ
൰
ଶ4415൬ߣଶ− 184154ߨଶܽଶ ௦݊ଶ൰
Equation 2-10 Turbidity of a solution of randomly orientated fibers N =
Avogadro’s number, λ = the incident wavelength (cm), μ = the fiber protein 
mass/length ratio (Da.cm-1) and a = fiber radius (cm), C = initial fibrinogen
mass concentration (g.mL-1) ns = 1.33 which is the solvent refractive index
and dn/dc = 0.17594cm3/g and is the solution refractive index change with
protein concentration (Domingues et al., 2016) (Perlmann and Longsworth,
1948).
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The average number of protofibrils that were contained in a fibrin fiber and the
average radius of the fibers were calculated by plotting λ߬5 as a function of λ2.
Fitting the linear Equation 2-10 to the experimental data makes it possible to
calculate the mass length ratio (µ) as the mass length ratio is equivalent to the
slope of the fitting (Yeromonahos et al., 2010). The intercept of gradient allows
the calculation of the square of the average radius by rearrangement of Equation
2-10. The average number of protofibrils per fiber was calculated using the
mass/length ration (µ) using Equation 2-11.
ܰݑ݉ ܾ݁ ݎ݋݂ ܲݎ݋ݐ݋݂ ܾ݅ ݅ݎ ݈ݏ= μ
μ଴
Equation 2-11 Number of protofibrils µ0 =1.44x1011 Da/cm = mass/length ratio
of a single protofibril and µ is the mass/length ratio of a fiber.
The average protein density can also be calculated using Equation 2-12.
ߜ= ൬ μ(ߨ ଶܽ)൰
ܰ
Equation 2-12 Average protein density Where δ = average protein density, µ 
= mass/length ratio of the fibrin fiber, a =radius of a single fibrin fiber, N =
Avogadro’s constant.
The distance between protofibrils can also be used as seen in Equation 2-13
ݖ= ටμ଴
ߜ
Equation 2-13 Distance between protofibrils. z = the average distance
between protofibrils, µ0 is the mass/length ratio of a single protofibril, and δ 
is the average protein density.
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Chapter 3 - The production of
human recombinant
fibrinogen variants in a CHO
cell system
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3.1 Introduction
This chapter describes the molecular biology, cell culture and protein purification
methods used to produce functional recombinant human fibrinogen variants with
mutations in the extended knob-hole binding sites.
Recombinant human fibrinogen variants have been used to investigate clot
polymerisation (Mullin et al., 2000b), structure (Collet et al., 2005b) and
mechanics (Piechocka et al., 2017) in the past. Today, recombinant techniques
still remain a powerful tool to investigate the importance of individual residues or
domains of the fibrinogen molecule. For example, the Ariëns laboratory has
previously made variants to investigate the roles of γ- and α-chain crosslinking 
in fibrin (Duval et al., 2014). The work in this chapter will describe how the
recombinant protein was produced, purified and characterised. This chapter has
four sections;
1. Molecular Biology (Site-Directed Mutagenesis, Sequencing)
2. Mammalian Cell Culture Fibrinogen Production
3. Precipitation and Purification
4. Characterisation
Four recombinant human variants of fibrin have been produced using this
method, these variants are; single point-mutation variants, yD297N, yE323Q and
yK356Q. A fourth variant (γD297N/γE323Q/γK356Q) containing all three above 
mutations above was also created. These variants were developed to investigate
the possible role of extended D-E electrostatic interactions between fibrin
monomers, by changing the charged residues that facilitate the interaction in the
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WT, to uncharged residues that disrupt the electrostatic interactions in each of
the variants.
3.2 Methods
3.2.1 Site directed mutagenesis
The primers described in Table 3-1 were used in conjunction with cycling
parameters described in Table 3-2 for mutagenesis of pMLP-γA expression 
vector (Figure 2-1) using the QuickChange mutagenesis kit to produce three
constructs with a single point mutation and a fourth construct containing all three
point mutations (refer to section 2.2.1 for further details).
Table 3-1 Primers designed and used for site-directed mutagenesis
Primer Name Primer Sequence
FbgG-D297N-R 5'-aaaaacttgtcactaggatcattgccaaaatcaaagccatcaaag-3'
FbgG-D297N-F 5'-ctttgatggctttgattttggcaatgatcctagtgacaagttttt-3'
FbgG-E323Q-R 5'-gcacagttgccttgaaacttatcattgtcattgtccca-3'
FbgG-E323Q-F 5'-tgggacaatgacaatgataagtttcaaggcaactgtgc-3'
FbgG-K356Q-R 5'-cattaggagtagatgcttgtgagtaagtgccaccttg-3'
FbgG-K356Q-F 5'-caaggtggcacttactcacaagcatctactcctaatg-3'
Table 3-2 Cycling parameters used in site directed mutagenesis
Segment Cycles Temperature (oC) Time (s) Cycling Stage
1 1 95 30 Initial Denaturation
2 16
95 30 Denaturation
55 60 Annealing
68 340 Extension
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3.2.2 Bacterial transformation and DNA extraction
XL-10 gold bacteria were transformed as described in 2.2.2. using the mutated
pMLP-γA expression vectors produced in 3.2.1. Bacterial colonies were selected 
using ampicillin resistance and DNA extraction was performed on these colonies
as described in 2.2.3. The harvested mutated cDNA was sent for sequencing to
Dundee University as described in 2.2.4 and 2.2.2.
3.2.3 Cell culture
Chinese Hamster Ovary (CHO) cells were used for expression of the wild type
and all four recombinant human fibrinogen variants. Routine cell culture was
performed as described in 2.3.2. CHO cells were then co-transfected with the
sequenced cDNA produced in 3.2.2 and a plasmid containing the coding region
of L-histidnol (selection marker) using a calcium phosphate transfection method
described in 2.3.3. Two different transfection conditions, described in Table 3-3,
were chosen in order to maximise the chances of cDNA successfully being
incorporated into the cells.
Table 3-3 Conditions for CHO cell transfections
Transfection 1 Transfection 2
10µg DNA 20µg DNA
1µg pMSV-his 2µg pMSV-his
2.5M CaCl2 2.5M CaCl2
Cells were selected against L-histidinol resistance until the appearance of
colonies, which were picked and cultured as described in 2.3.4. The supernatant
was removed and frozen at -80oC as described in section 2.3.4 for determination
of the rate of fibrinogen expression in serum-free conditions using fibrinogen
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ELISA as described in section 2.4 The highest expressing clone was selected
and grown for eight weeks in roller bottles.
3.2.4 Precipitation and purification
Prior to precipitation, frozen medium from protein expression was thawed and
mixed with a protease inhibitor cocktail as described in section 2.5.1. The
resulting mix was then precipitated with ammonium sulphate and concentrated
by centrifugation as described in 2.5.1. Precipitated protein was stored at -80oC
until purification. The recombinant proteins were then purified by IF-1
immunoaffinity chromatography, dialysed, concentrated and the concentration of
fibrinogen was determined by absorbance at A280nm using the Nanodrop
ND1000 as described in sections 2.5.2 to 2.6.
3.2.5 Characterisation
A reducing SDS-PAGE was performed to compare bands between recombinant
WT fibrinogen and the fibrinogen variants as described in section 2.7. Circular
Dichroism was performed to confirm expected secondary structure folding and
convolutions were produced using CDNN software as described in section 2.8.
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3.3 Results
3.3.1 Sequencing results of γD297N, γE323Q γK356Q & γDEK 
recombinant human fibrinogen variants
To confirm that the correct cDNA sequences were obtained for each variant and
that no undesired mutations were present, the cDNA for each construct was sent
to Dundee University for sequencing. The results of the cDNA comparison of WT
to the fibrin variants confirmed the desired point mutations in all mutants without
any other unwanted random mutations. The genomic sequences converted to
protein sequence for alignment of variant sequences using Clustal Omega
(tables 3-4 to 3-7). In the alignments, the desired mutation is highlighted in
yellow. In the case of the γDEK mutant, sequential mutagenesis was performed 
and the cDNA was sent for sequencing to confirm no random mutations had
occurred before the next mutation was introduced. The clustal omega alignments
below depict the single point mutations being 26 residues longer in length than
previously stated, this is because the alignment also includes a 26 residue long
signal peptide that is cleaved during secretion, highlighted in blue.
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Table 3-4 Clustal Omega protein alignment of Wild Type (WT) γ-chain 
fibrinogen and γD297N mutant 
WT MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQT 60
D297N MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQT 60
************************************************************
WT KVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIM 120
D297N KVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIM 120
************************************************************
WT KYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQ 180
D297N KYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQ 180
************************************************************
WT DIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEG 240
D297N DIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEG 240
************************************************************
WT FGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKY 300
D297N FGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKY 300
************************************************************
WT RLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGW 360
D297N RLTYAYFAGGDAGDAFDGFDFGNDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGW 360
**********************:*************************************
WT WMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTI 420
D297N WMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTI 420
************************************************************
WT GEGQQHHLGGAKQAGDV* 437
D297N GEGQQHHLGGAKQAGDV* 437
******************
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Table 3-5 Clustal Omega protein alignment of Wild Type (WT) γ-chain 
fibrinogen and γE323Q mutant 
Table 3-6 Clustal Omega protein alignment of Wild Type (WT) γ-chain 
fibrinogen and γK356Q mutant 
WT MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQT 60
E323Q MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQT 60
************************************************************
WT KVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIM 120
E323Q KVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIM 120
************************************************************
WT KYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQ 180
E323Q KYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQ 180
************************************************************
WT DIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEG 240
E323Q DIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEG 240
************************************************************
WT FGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKY 300
E323Q FGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKY 300
************************************************************
WT RLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGW 360
E323Q RLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFQGNCAEQDGSGW 360
************************************************:***********
WT WMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTI 420
E323Q WMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTI 420
************************************************************
WT GEGQQHHLGGAKQAGDV* 437
E323Q GEGQQHHLGGAKQAGDV* 437
******************
WT MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQT 60
K356Q MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQT 60
************************************************************
WT KVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIM 120
K356Q KVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIM 120
************************************************************
WT KYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQ 180
K356Q KYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQ 180
************************************************************
WT DIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEG 240
K356Q DIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEG 240
************************************************************
WT FGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKY 300
K356Q FGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKY 300
************************************************************
WT RLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGW 360
K356Q RLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGW 360
************************************************************
WT WMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTI 420
K356Q WMNKCHAGHLNGVYYQGGTYSQASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTI 420
*********************:**************************************
WT GEGQQHHLGGAKQAGDV* 437
K356Q GEGQQHHLGGAKQAGDV* 437
******************
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Table 3-7 Clustal Omega protein alignment of Wild Type (WT) γ-chain 
fibrinogen and γD297N/E323Q/K356Q (γDEK) mutant 
WT MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQT60
D297N-E323Q-K356Q MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDERFGSYCPTTCGIADFLSTYQT60
************************************************************
WT KVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIM120
D297N-E323Q-K356Q KVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIM120
************************************************************
WT KYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQ180
D297N-E323Q-K356Q KYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQ180
************************************************************
WT DIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEG240
D297N-E323Q-K356Q DIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEG240
************************************************************
WT FGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKY300
D297N-E323Q-K356Q FGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKY300
************************************************************
WT RLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGW360
D297N-E323Q-K356Q RLTYAYFAGGDAGDAFDGFDFGNDPSDKFFTSHNGMQFSTWDNDNDKFQGNCAEQDGSGW360
**********************:*************************:***********
WT WMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTI420
D297N-E323Q-K356Q WMNKCHAGHLNGVYYQGGTYSQASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTI420
*********************:**************************************
WT GEGQQHHLGGAKQAGDV* 437
D297N-E323Q-K356Q GEGQQHHLGGAKQAGDV* 437
******************
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3.3.2 Protein purification and integrity checks
Following the collection of the CHO cell supernatant the medium was frozen at -
80oC until required for protein concentration and purification. Precipitation and
concentration of the medium was performed as described in section 2.5,
whereas the purification of the medium was described in section 2.6. The
purification of the recombinant variants was successful using the affinity
chromatography technique in conjunction with the IF1 antibody. A representative
chromatogram from the purification process using the AKTA Avant can be found
below, Figure 3-1. This chromatogram is of triple point variant γDEK. The 
chromatogram displays an inset (A) of all steps in the cycle of the purification
process including; injection, wash I, wash II, elution and equilibration steps,
whereas (B) is a zoomed in version of the same chromatogram detailing the
elution of the fibrinogen molecules and the resulting absorbance peak. In this
case fractions A2 to B8 contained fibrinogen therefore they were pooled,
concentrated and dialysed as described in section 2.6
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Figure 3-1 Affinity chromatography chromatogram of γD297N-E323Q-K356Q (A) Inset of the complete purification process that
contains all steps of the cycle (injection, wash I, wash II, elution and equilibration). The green box indicates the area chosen for
zoomed in chromatogram (B). ‘Fibrinogen peak’ that arises from the elution of the recombinant fibrinogen molecules.
A
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3.3.3 SDS PAGE
Following production and purification, the integrity of the fibrinogen expressed
was determined by loading the fibrinogen variants onto a reducing SDS-PAGE
gel, as described in section 2.7. Figure 3-2 shows reducing gel for each of the
single point-mutation variants whereas Figure 3-3 shows the reducing gel for the
γDEK triple variant. The reduction of the fibrinogen molecules on the gel allowed 
clear visualisation of all three fibrinogen chains with separation of the Aα-. Bβ-. 
and γ-chains. The gels also showed that there was no degradation amongst any 
of the fibrinogen variants. Furthermore, as expected each corresponding
polypeptide band was of the same molecular weight when compared to WT.
Figure 3-2 Reduced SDS-PAGE gel of recombinant wild type and single
mutant recombinant variants Molecular weight Marker (MW), ranging
from 37-100kDa. Bands were stained with Gel Code® Blue Stain reagent.
No difference in the variants’ molecular weight to WT was observed, and all
bands for all variants were intact with no signs of degradation.
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Figure 3-3 Reduced SDS-PAGE gel of recombinant wild type and triple
mutant recombinant variant γDEK. Molecular weight marker (MW),
ranging from 37-100kDa. Bands were stained with Gel Code® Blue Stain
reagent. No difference in molecular weight from any of the chains was
observed compared to the WT, and all bands for γDEK were intact with no 
signs of degradation.
3.3.4 Circular dichroism (CD) spectroscopy
Far-UV CD spectroscopy measures the amount of circularly polarised light
absorbed by proteins. In this thesis, Far-UV CD was specifically performed at the
180-270nm range, here the peptide bonds of the protein are the chromophore
which generate a different CD signal when they are either located in an α-helix , 
β-turn or random coil structure (Johnson, 1990). Due to large amounts of noise 
at the extremities of the range provided, the CD spectra were truncated and only
measurements from 190-250nm were analysed. To investigate whether there
were any local changes in the folding of secondary structures, CD spectroscopy
was performed and spectra were produced using CDNN software. When the
spectra were calculated using CDNN software differences were observed for all
variants, Figure 3-5. CDNN convolution software showed that for γDEK there 
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was a 5% decrease in helical content, 3 % increase in antiparallel, 1% increase
in parallel, 0.4% increase in β turn content and 1% increase in random coil 
content. For γD297N, there was a 1.1% increase in helical content, 1.1% 
increase in antiparallel content, 0.2% in parallel content, 0.4% increase in β turn 
content and a 0.5% decrease in random coil content. For γE323Q there was a 
0.6% increase in helical content, 0.1% increase in antiparallel, 0.1% increase in
parallel, 0.3% increase in beta turn and 1% decrease in random coil content. For
γK356Q there was a 2.8% increase in helical content, 0.9% increase in 
antiparallel, 0.3% increase in parallel, 0.3% increase in beta turn and 0.2%
increase in random coil. Therefore SDS-PAGE and CD spectroscopy indicated
that the fibrinogen variants produced had intact chains and overall had correctly
folded secondary structure, since the observed differences in secondary
structure were minimal.
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Figure 3-4 Raw CD spectroscopy curves of recombinant wild type and recombinant variants Spectra (190-250nm) measured in
millidegrees (mdeg). WT (blue N=5) γDEK (red N=4) γD297N (orange N=3) γE323Q (green N=3) γK356Q (Purple N=3). There 
were changes between WT and mutant curves.
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WT
361.2
80.5
80.1
170.1
310.4
DEK
31.22.2
10.91.2
8.70.2
17.40.0
31.90.5 ***
****
**
***
D297N
34.91.4
9.10.6
8.20.1
17.40.0
30.50.6
****
E323Q
36.61.4
8.10.6
8.10.2
17.30.0
30.00.6
***
K356Q
34.82.0
8.91.1
8.30.2
17.30.1
30.80.7
***
Figure 3-5 CD spectroscopy data. Calculated using CDNN software.
Secondary structure composition ranged from helix (31-36%), antiparallel (8-
11%), parallel (8-9%), β turn (17%) and random coil (30-32%) percentage 
content.
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3.4 Discussion
Mammalian cells, e.g. CHO cells, are an important tool that can be used to
express recombinant human proteins. Due to the importance of cardiovascular
disease and the role of haemostasis and thrombosis in this devastating disease,
several clotting factors have previously been expressed using a recombinant
system to enable investigations into mutant variants. Factor VIII cDNA was
cloned in 1984 which led to the production of recombinant factor VIII in 1992 as
the product Recombinate® (Kingdon and Lundblad, 2002). Similarly, recombinant
factor IX has been produced through recombinant CHO cell culturing with the
first drug being licensed in 1997 (Swiech et al., 2017).
The first functional recombinant fibrinogen was expressed in baby hamster
kidney (BHK cells) in 1989 (Farrell, 1989). The system used in this work is based
on a CHO cell system (Lord et al., 1993), and this work demonstrates that it is
possible to make several variants in a relatively short amount of time. The system
by Lord’s group has been characterised extremely well, recombinants have been
developed to give insight of the traditional knob-hole regions (Okumura et al.,
1997), fibrinogen-platelet interactions binding sites (Rooney et al., 1998), role of
αC domains in fibrinogen (Gorkun et al., 1998) and calcium binding (Hogan et
al., 2000). Site directed mutagenesis was used on an expression vector already
containing the coding sequence for the human γ-chain fibrinogen, these 
plasmids were duplicated on a large scale using XL 10 gold bacterium and when
harvested they were sent for sequencing to Dundee University. The data in this
chapter shows that the expected cDNA sequence was obtained, successful
transfection was performed, using a calcium phosphate based method, that
produced clones that expressed good yields of recombinant fibrinogen measured
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directly from the supernatant using an ELISA method. The highest expressing
clone was successfully used to produce fibrinogen in roller bottles.
The following amount of protein was produced per fibrinogen, in the case of WT
this was produced by Helen McPherson, University of Leeds. γK356Q was grown 
for a shorter period of time with fewer roller bottles due to the fact that maximum
capacity had already been reached in the incubator by other projects.
Table 3-8 Yields of recombinant WT and variant human fibrinogen
Variant Total Supernatant (L) Total Yield (mg)
WT 72 122.4
γDEK 48 1.5
γD297N 48 15.2
γE323Q 48 5.0
γK356Q 9 4.5
SDS-PAGE and circular dichroism spectroscopy were both performed as
integrity checks of the expressed variants. SDS-PAGE confirmed that the
fibrinogen produced, for all variants, was made from all three intact Aα- Bβ- an 
γ-chains with no signs of degradation. SDS-PAGE does not give any information 
on the quality of the secondary structures of the protein, and therefore far-UV CD
spectroscopy was used to investigate the percentage of α helix, antiparallel, 
parallel β-turn and random coil structures for each variant. Secondary structure 
was shown to be similar across all recombinant variants with minor differences
when compared to WT. Considering that fibrinogen variants have been produced
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for some thirty years it is somewhat surprising that there is no indication from the
literature of what the percentage fold of fibrinogen should be, making it difficult
to judge if there would be any impact on fibrinogen function. Following
consultation with the CD spectra laboratory manager, Dr. Nasir Khan at the
University of Leeds and Professor Valeri Barsegov, University of Massachusetts,
Lowell, it was suggested that these were small changes in local secondary
structure and that there would be no impact on the functions of the fibrinogens,
but the changes in function and structure of the fibrinogens as a consequence of
2D structural arrangement cannot be discounted. Further study could be
performed by producing other variants that lead to similar changes in CD spectra
but are not located in the knob-hole binding pocket and testing the functionality.
This was not done in this thesis because it would have been impractical from
both a time and cost perspective.
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Chapter 4 Polymerisation
kinetics of recombinant
human fibrinogen variants
using light scattering
analysis and atomic force
microscopy
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4.1 Introduction
This chapter compares the polymerisation profiles and early polymerisation
stages of the recombinant human WT fibrin(ogen) with those of recombinant
variants, γDEK (γD297N/γE323Q/γK356Q), γD297N, γE323Q and γK356Q, 
using light scattering and atomic force microscopy (AFM) methods. Parameters
such as lag phase (when only protofibril formation is occurring) and the
maximum optical density (corresponds to the cross sectional area of a fibrin fiber)
were compared between the four variants.
Light scattering techniques to study fibrin polymerisation and clot structure have
been used for several decades and are used commonly by laboratories within
the field for the same purpose (Domingues et al., 2016; Magatti et al., 2013). The
technique remains popular because of the easy preparation of a clot and the
amount of information that can be gathered. Conveniently, the technique can be
used for either purified fibrinogen samples or plasma samples from patients.
Light scattering techniques are not sensitive enough at the earlier stages of clot
formation (when protofibrils are growing longitudinally), therefore high resolution
imaging techniques such as Atomic Force Microscopy (AFM) are used. Others
have used Atomic Force Microscopy (AFM) to visualise protofibril formation and
polymerisation at these earlier stages (Protopopova et al., 2015). The Ariens
laboratory has also used AFM to study polymerisation for γA and γ’ fibrin(ogen) 
(Allan et al., 2012). Therefore it was decided that it was appropriate to use AFM
to also study and visualise polymerisation at the early stages.
In this thesis the potential presence of extended knob-hole interaction sites
beyond the classical binding pocket were investigated. As I am mutating amino
acid residues that are thought to support knob-hole binding then it would be
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reasonable to expect a delay in polymerisation at the early stages that would be
detectable using AFM and may result in protofibril packing differences that result
in changes in fiber growth, through destabilisation of these bonds. Therefore soft
tapping mode AFM was used to visualise early protofibril formation and turbidity
techniques were used to study polymerisation rate and fiber growth of these
recombinant variants. Using AFM, differences in the early kinetics were observed
where the longitudinal protofibril growth was delayed, turbidity showed larger,
significant differences where there was a decrease in the Vmax and all variants
had a decreased maximum optical density which indicates a difference in fiber
thickness and clot structure.
4.2 Objectives
To investigate whether the abolition of extended knob-hole interactions alter the
polymerisation kinetics.
4.3 Methods
4.3.1 Turbidity
Fibrin clots were prepared with 0.5mg/mL fibrinogen, 5mM CaCl2 and 0.1U/mL
Thrombin (final concentrations) and the polymerisation of the fibrin was
measured at 340nm for a period of 60 minutes, as described in 2.9.1. From the
resulting turbidity curves, the lag phase was measured by calculating the time
difference between the start of the reaction (the combination of fibrinogen and
thrombin) and when an increase in OD was detected. The maximum optical
density was calculated from the highest OD value. For comparisons of OD and
lag phase between WT and γDEK, a paired two-tailed t-test was performed at a 
significance level of p<0.05. For the single fibrin variants a comparison was made
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to WT using a One-way ANOVA at a significance level of p<0.05. When the
variants were compared at different time points for AFM experiments, a one-way
ANOVA was used with multiple comparisons to the WT at a significance level of
p<0.05.
4.3.2 Atomic force microscopy
Atomic Force microscopy was performed as described in section 2.14 on clots
(0.02mg/mL fibrinogen, 0.05U/mL Thrombin and 2mM CaCl2 formed at 10, 20
and 30 minutes after the initiation of clotting. Micrographs were taken using a
Nanoscope AFM in air in soft tapping mode. Briefly, individual images were
flattened using Nanoscope analysis software v9.2 and converted to a tiff file
using a macro designed by Dr. Stephen Baker (University of Leeds) to allow
accurate measurement of the length of individual protofibrils ‘by hand’ using
ImageJ software. Histograms were created using GraphPad Prism 7 to study
length of protofibrils and comparisons were made between WT and the
fibrinogen variants at a significance level of p<0.05.
4.3.3 Statistics
Data analysis was performed using GraphPad Prism statistical software
package. A two-tailed t-test was used for comparisons between one variant and
the WT, when more than one variant was compared a one-way ANOVA was
used with multiple comparisons with the WT as a control column. Results are
shown as mean ± SD, and were considered significant when p<0.05.
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4.4 Results
Turbidity measurements were performed to investigate the differences in kinetics
of the recombinant variants. In the first instance, turbidity was performed using
the serine protease thrombin to cleave the fibrinogen for all variants. Additionally,
turbidity was also performed with reptilase a snake venom that cleaves
fibrinogen differently to thrombin by only cleaving FpA and exposing knob-A, FpB
remains uncleaved.
The analysis of the turbidity data in Figure 4-1 and Figure 4-2 demonstrates that
there are striking and significant differences in the polymerisation kinetics. The
maximum OD was significantly reduced for γDEK (0.23±0.03Abs, -41%) 
compared to WT (0.39±0.01Abs) p=0.0162. The lag phase was significantly
increased for γDEK (132±12 seconds, +43.5%) compared to WT 
(92±14seconds) p=0.0194. Due to the differences seen here from the triple
mutant (γDEK), turbidity measurements were also performed on the fibrinogen 
variants that only consisted of single point mutations in order to identify whether
the changes are driven by just one or more of the changes that were introduced.
The analysis of the turbidity data for the single mutants in Figure 4-3 and Figure
4-4 further demonstrate significant differences in the polymerisation kinetics. The
percentage change from the WT (0.48±0.02Abs) to the variants was calculated.
The maximum OD was significantly reduced for variants γD297N (0.39±0.03Abs, 
-19% p=0.001), γE323Q (0.33±0.02Abs, -31% p=0.001), γK356Q 
(0.39±0.03Abs, -19% p=0.001) However, there were no significant changes to
lag phase for any of the single mutants.
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Polymerisation kinetics using reptilase were also performed for all single
recombinant variants, as shown in Figure 4-5. N=1 was performed due to
limitations in material quantity. Turbidity with reptilase was not performed for the
triple mutant due to limitations in material quantity. A similar turbidity trend as
seen with previous measurements with thrombin was observed. WT (0.60Abs)
had the highest maximum OD followed by the three single mutants γD297N 
(0.43Abs, -28%), γK356Q (0.43Abs, -28%). and γE323Q (0.39Abs, -35%). There 
were changes for the lag phase with γE323Q (108seconds, +12.5%), being 
extended compared to the WT (96seconds), γD297N (84 seconds, -12.5%) was 
accelerated, and there was no difference for γK356Q (96 seconds). 
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Figure 4-1 Turbidity curve of fibrin clots. WT (blue) γDEK (red) Fibrin polymerisation over a period of one hour. γDEK fibrinogen has 
an extended lag phase, slower polymerisation rate and reduced maximum optical density (OD). N=3.Dotted line represents the
mean of three experiments, shaded areas depict standard deviation between repeats.
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Figure 4-2 Maximum optical density and lag phase of fibrin clots. Altered polymerisation was seen for γDEK. A significantly reduced 
max OD was observed for γDEK when compared to WT, p=0.0162. Lag Phase was determined using Microsoft Excel to be the last 
point before exponential growth of the polymerisation curve. A significantly extended lag phase was observed for γDEK when 
compared to the WT, p=0.0194. For both graphs max OD and lag phase were compared using a paired t-test with a significance
level of p<0.05. Error bars represent standard deviation.
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Figure 4-3 Turbidity curve of fibrin clots.  WT (blue), γD297N (red), γE323Q (green), γK356Q (purple). Altered polymerisation was 
also observed for the single fibrin variants when over a period of 1 hour of polymerisation. Lag Phase was determined using
Microsoft Excel to be the last point before exponential growth of the polymerisation curve. There were no changes in lag phase, but
maximum optical density of all the single variants were significantly different. N=3, dotted line represents the mean of three
experiments, shaded areas depict standard deviation between repeats.
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Figure 4-4 Maximum optical density and lag phase of fibrin clots. Maximum OD was significantly reduced for all single mutant
variants when compared to the WT. Lag Phase was determined using Microsoft Excel to be the last point before exponential growth
of the polymerisation curve. No significant differences in lag phase were observed. For both graphs max OD and lag phase were
compared using an one way ANOVA with a significance level of p<0.05. Error bars represent standard deviation.
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Figure 4-5 Turbidity of fibrin clots with reptilase. WT (blue), γD297N (red), γE323Q (green), γK356Q (purple). The overall turbidity 
profile of clot formation over 1 hour. (A) Shows different kinetics for the single mutant variants vs WT. (B) Maximum OD was reduced for
all single mutant variants when compared to the WT. Lag Phase was determined using Microsoft Excel to be the last point before
exponential growth of the polymerisation curve. Lag phase was varied for the single mutants with γD297N being accelerated compared 
to WT, γE323Q was extended compared to WT and γK356Q remained unchanged compared to WT.  
114
The Vmax (ᴧAbs/min) was measured to study the rate of polymerisation of the 
recombinant variants. Due to abolition of the electrostatic interactions, the knob-
hole bonds should be less stable causing higher dissociation, slower
polymerisation rate and slower protofibril/fiber formation. γDEK polymerisation 
rate, Figure 4-6, was significantly impaired (0.0375±0.005Abs/min, -46.1%)
compared to WT (0.070±0.001Abs/min) p=0.004. Polymerisation rate for
γD297N (0.065±0.014Abs/min, -35.6%) γE323Q (0.057±0.013, -43.6%) and 
γK356Q (0.072±0.017, -28.1%) variants were significantly lower compared to the 
WT (0.100±0.023Abs/min), Figure 4-7.
Figure 4-6 Maximum polymerisation rate of WT and γDEK fibrin clots
Polymerisation rate was decreased for γDEK when compared to WT, error bars 
depict standard deviation at P<0.05 using two tailed t-test analysis.
115
Figure 4-7 Maximum polymerisation rate of WT, γD297N γE323Q and 
γK356Q. Polymerisation rate was significantly decreased for all single mutants,
error bars depict standard deviation at P<0.05 using one-way ANOVA analysis.
Based on the altered polymerisation kinetics as analysed by the turbidity
experiments, Atomic Force Microscopy was used to visualise protofibril formation
at the very early stages following clotting initiation by thrombin. Clots for the WT
and all variants were allowed to form for either 10, 20 or 30 minutes, and then
added to freshly cleaved mica for AFM imaging. Figure 4-8 shows the
progressive longitudinal polymerisation of protofibrils over time for WT and each
recombinant variant. At the 10 minute timepoint delayed polymerisation was
observed for the recombinant variants except γK356Q, while at longer time 
points 20 and 30 minutes most variants were longer in length Table 4-1.
However, it was decided that analysis of only average protofibril length was
insufficient as the amount of protofibrils within each sample may also change,
therefore distribution curves of protofibril length for each variant were made as
seen in Figures 4-9 to 4-12.
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Table 4-1 Average length (mean) of protofibrils during polymerisation
Significance at p<0.05 is represented by an asterisk (*) when variants are
compared to their matching WT time point.
Recombinant
Variant
Time point
10 Minute 20 Minute 30 Minute
WT 183.3 ± 43.5 nm 244.7 ± 31.3nm 238.0 ± 19.4nm
γDEK 163.1 ± 0.7nm 213.1 ± 40.3nm 268.5 ± 46.7nm
γD297N 149.0 ± 8.1nm 287.0 ± 14.8nm 276.6 ± 31.0nm
γE323Q 176.5 ± 26.9nm 258.2 ± 45.3nm 302.7 ± 33.8nm
γK356Q 225.4 ± 24.8nm 282.4 ± 42.1nm 346.4 ± 22.5nm *
Following image processing, protofibrils were measured by hand using Image J
software. Origin Pro Software (OriginLab Corporation, Northampton, MA, USA)
was used to plot the distribution of protofibrils over time for the WT and each
variant as demonstrated in Figure 4-9 to Figure 4-12. For WT and all fibrin
variants there was an increase in the number of larger species at later 20 minute
and 30 minute time points although the larger differences of protofibril length
were seen between 10 and 20 minutes time points. However for a more direct
comparison between variants, each variant was plotted on the same histogram
for the same time point, 10minutes (Figure 4-10), 20 minutes (Figure 4-11) and
30 minutes (Figure 4-12). All fibrin variants median length increased between the
10 minute and 20 minute time points, γDEK (163.1→193.4nm), γD297N 
(149.0→291.3nm), γE323Q (172.3→235.2nm), γK356Q (211.7→302.3nm). 
Between 20 and 30 minutes WT (251.6→232.9nm) and γD297N 
(291.3→261.1nm) median length plateaued, however median protofibril length 
increased for γDEK (193.4→250.9nm), γE323Q (235.2→295.5nm) and γK356Q 
(302.3→337.6nm) between these time points. 
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Figure 4-8 Atomic force micrographs Protofibril formation of WT and
recombinant variants. Clotting was stopped at 10, 20 and 30 minutes after
initiation of polymerisation, added dropwise to a cleaved mica surface and
imaged in a 4µm x 4µm area. Images taken in dried conditions during soft
tapping mode in air.
WT
10min 30min20min
γDEK
γD297N
γE323Q
γK356Q
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Figure 4-9 Distribution of protofibrils WT (A) γDEK (B) γD297N (C) γE323Q 
(D) γK356Q (E) 10minute time point (orange), 20 minute time point (green) and 
30 minute time point (purple). For WT protofibrils formed at 10 minutes were
shorter than 20 and 30 minutes, average protofibril length at 20 minutes was
similar to 30 minutes time point. For γDEK protofibrils were shorter and less 
abundant at 10 minutes compared to 20 and 30 minute time points. For γD297N 
10 minutes had the shortest and least abundant amount of protofibrils whereas
20 and 30 minutes were similar. γE323Q had an increasing amount of and an 
increased length of protofibrils as time points progressed. γK356Q had many 
short fibers at 10 minutes but fewer and longer protofibrils at 20 and 30 minutes.
Normal distribution curves were plotted on each graph where bin size was limited
to 50 per group.
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Figure 4-10 Distribution comparison of protofibril length (nm) following 10
minutes clot formation  WT (Orange), γDEK (green), γD297N (purple), 
γE323Q (yellow), and γK356Q (blue). Inlet represents the same data but 
with a shorter x axis. All fibrin variants, except from γK356Q had fewer and 
shorter protofibrils than the WT. The triple mutant (γDEK appeared to have 
the shortest protofibrils followed by γD297N, γE323Q. Normal distribution 
curves were plotted on each graph where bin size was limited to 50 per
group.
Figure 4-11 Distribution comparison of protofibril length (nm) following 20
minutes clot formation  WT (Orange), yDEK (green), γD297N (purple), 
γE323Q (yellow), and γK356Q (blue). At the 20 minute time point γDEK still 
had the shortest protofibrils followed by WT,γE323Q, γK356Q, γD297N. 
Normal distribution curves were plotted on each graph where bin size was
limited to 50 per group.
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Figure 4-12 Distribution comparison of protofibril length (nm) following 20
minutes clot formation  WT (Orange), γDEK (green), γD297N (purple), 
γE323Q (yellow), and γK356Q (blue). All variants have a longer average 
protofibril length compared to the WT. From the variants γDEK, still has the 
average shortest protofibrils followed by γD297N, γE323Q and γK356Q) 
Normal distribution curves were plotted on each graph where bin size was
limited to 50 per group.
4.5 Discussion
In this chapter, the polymerisation kinetics were studied by light scattering and
atomic force microscopy methods. The main focus in the light scattering studies
was to study the difference in maximum optical density and lag phase, whereas
for the AFM experiments protofibril growth was the main focus. Turbidity as a
function of time has commonly been used to assess the kinetics of clot formation
(Reganon et al., 1984; Duval et al., 2016). The typical shape of the turbidity curve
as discussed in section 2.9 is somewhat distorted for the recombinant variants,
as they all have a significantly reduced maximum optical density and in the case
of the triple mutant a significantly extended lag phase. The following percentage
reductions of optical density by the variants were observed; γDEK -41%, γD297N 
-19%, γE323Q -31% and γK356Q -20%. It has previously been published that 
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maximum optical density values have a direct correlation with the radial cross
section of a fibrin fiber with higher amounts of scattering representative of thicker
fibers and lower amounts of scattering representing thinner fibers (Carr and
Hermans, 1978). Therefore, based on this knowledge and other reports (Weisel
and Litvinov, 2013) I hypothesise that in the clot structure experiments the
recombinant variants should produce clots that are more dense with many more
fibers, that are thinner, more branch points and have smaller pore sizes
compared to the WT. It is worth noting that the γDEK variant has the largest 
reduction in maximum OD, followed by the three single variants perhaps
suggesting that each point mutation has a somewhat additive effect on the
reduction of the maximum optical density.
For the triple mutant (γDEK) it is interesting that the early kinetics (lag phase) 
was significantly different from that of the WT suggesting that the abolition of the
extended D-E electrostatic interactions play a key role in polymerisation of the
fibrin fibers or during protofibril formation. On the contrary, the single mutants
were not different from the WT, indicating that all three single point mutations are
required to observe an effect on lag phase, as when mutated individually no
changes were observed. Therefore, the effect of the mutations do not appear to
be cumulative or additive, rather the combination of the mutations triggers an
effect, perhaps by local conformational changes of the binding pocket.
Although it is reasonable to assume that each mutation contributes a change in
the overall polymerisation profile, one must consider the possibility that even
though the polymerisation curves for the single mutant variants are very similar
to each other, especially γD297N and γK356Q, they still may be different at the 
protofibril and intrafibril level. The varying parameters (FpA cleavage, protofibril
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initiation, protofibril growth, fiber initiation, fiber growth, fiber aggregation and
fibrin concentration) that regulate the kinetics of protofibril formation have
extensively been investigated (Weisel and Nagaswami, 1992). These authors
used computer modelling, light scattering methods and scanning electron
micrographs to describe the effects of each of these parameters and their
influence on maximum fiber size, maximum rate of assembly, lag period, and
number of fibers. Table 4-2 is based on Table 1 found in Weisel’s paper. If the
polymerisation profiles of the mutant variants are to be compared to Table 4-2
then one can see that an decrease in the parameter ‘fiber growth’ (kfg) gives rise
to a similar turbidity profile that is observed in the variants (decrease in maximum
fiber size, a decrease in maximum rate of assembly, an increase in the number
of fibers). Therefore it is likely that the point mutations that abolish the extended
D-E electrostatic interactions limit fiber growth.
Table 4-2 Parameters implicated in affecting polymerisation kinetics and
clot structure An increase in the rate constant results in an increase or
decrease in maximum fiber size, polymerisation rate, lag period and
number of fibers. This table is based on Table 1 found in (Weisel and
Nagaswami, 1992).
Polymerisation of the recombinant variants was further investigated using
reptilase, a snake venom enzyme which cleaves fibrinopeptide A only, (unlike
thrombin). This was performed to confirm that the differences in turbidity were
not just due to change in affinity of the recombinant variants with thrombin. There
Increase in the rate
constant
Maximum
Fiber Size
Polymerisation
Rate
Lag
Period
Number of
Fibers
kA - FPA cleavage ↓ ↑ ↓ ↑ 
kpi - protofibril initiation ↓ ↑ ↓ ↑ 
kpg - protofibril growth 0 0 0 0
kfi- fiber initiation ↓ ↓ 0 ↑ 
kfg - fiber growth ↑ ↑ ↓ ↓ 
kfa - fiber aggregation ↑ 0 0 ↑ 
kfc - fiber concentration ↑ ↑ ↓ ↓ 
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was not enough material of γDEK remaining for this experiment to be performed. 
These data demonstrated that the altered polymerisation kinetics that are
observed for the recombinant variants are independent of their binding affinity to
thrombin and these mutated residues are likely to affect polymerisation directly.
This data is also supported by the significant reduction in maximum
polymerisation rate that is observed for all recombinant variants.
The early stages of protofibril formation and fibril initiation were investigated
using Atomic Force Microscopy (AFM studies). In these experiments, high
resolution images are captured at the nanoscale range of protofibril formation.
Three time points were used to assess protofibril formation and fibril initiation
over time; 10 minutes, 20 minutes and 30 minutes. Clotting usually occurs within
a few minutes, however to truly observe the early polymerisation kinetics the
clotting conditions for AFM measurements must be slowed down by reducing the
fibrinogen and thrombin concentrations. This allows the imaging of protofibril
formation where very little information can be gathered from turbidity
measurements.
When studying the early stages of protofibril formation using atomic force
microscopy there was already a difference in polymerisation between the WT
and the recombinant variants at the 10 minute time point, where all variants,
except for γK356Q, have a reduced average length. For γDEK, γD297N, γE323Q 
this is expected because the extended knob-hole interactions have been
disrupted therefore the polymerisation process should be less stable leading to
fewer and/or shorter protofibrils. However it is quite surprising that γK356Q 
variant forms longer protofibrils than the WT, it may be possible that although the
extended electrostatic interaction has been abolished, the γK356Q variant is able 
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to form new contacts counter intuitively to enable it to form longer protofibrils. It
is interesting to note that a publication from the laboratory of Professor Doolitte
(Yang et al., 2000) focuses on a model of fibrin formation and through the use of
crystal structures and molecular simulations postulates that regions γ350-360 
and γ370-380 are the ‘driving force’ of γC domain lateral interactions that give 
arise to protofibril association. Maybe it is possible that γK356Q forms γC- γC 
contacts that are more favourable and cause faster longitudinal growth.
At 20 and 30 minute time points there is no significant difference between the
average length of the variant protofibrils compared to the WT. At these later time
points it appears that the variants have ‘recovered’ from their initial disruption to
longitudinal protofibril formation. It was not possible to check whether protofibrils
had accelerated polymerisation beyond 30 minutes because the mixture had
become fully clotted.
Additionally, when analysing the distribution of protofibrils, it is interesting that
the ‘normal distribution’ curve that was fitted is slightly shifted to the right for all
variants at all time points. This is because extremely large species of fibers are
influencing the overall distribution.
In summary, the turbidity profiles for all fibrin variants were very different, Max
OD was significantly reduced for all variants and lag phase was significantly
extended for γDEK , longitudinal protofibril formation was also disrupted albeit it 
recovered at later time points. This suggests that the fibrin variants have an effect
on longitudinal protofibril formation, which could influence the packing
mechanisms involved, reducing lateral aggregation and greatly impacting on
fiber growth.
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Chapter 5 - Effects of abolished
extended D-E interactions on
clot structure at different spatial
scales
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5.1 Introduction
Following spontaneous longitudinal self-assembly, protofibrils finally reach a so
called critical length and begin to laterally aggregate forming fibrin fibers which
give arise to the 3D fibrin network (Hantgan et al., 1980).
What causes the lateral aggregation of protofibrils to form fibrin fibers is still
unclear and the fact that protofibrils are required to reach a critical length before
they begin to aggregate suggests that the interactions between the protofibrils
themselves are weak and increase with longer protofibrils.
Although the exact mechanism is not known, the most accepted hypothesis is
that the binding of Knobs B and holes ‘b’ following thrombin cleavage are
responsible for lateral aggregation (Litvinov et al., 2007), in addition to the
interactions exhibited by the αC domains where they untether from the E region 
during FpA and FpB cleavage by thrombin (Tsurupa et al., 2011).
The literature suggests that it is likely that extended knob-hole interactions
should exist. It was demonstrated that a GPRP mimetic of knob A has a binding
affinity of Kd = 25µM (Everse et al., 1998) with hole a. While NDSK (N-terminal
disulphide knot) fibrin fragment binding with fibrinogen has a reported Kd of
5.8µM (Geer et al., 2007), suggesting that extra interactions besides the
conventional knob and hole complex must be at play. Recent molecular
simulations (Kononova et al., 2013; Zhmurov et al., 2016) further support this
hypothesis. Work by Kononova modelled a DD-fragment and aligned it with a
fibrin monomer, the knobs were mapped manually as these do not appear in the
crystal structure and it was proposed that the electrostatic interactions studied in
this work play a key role in supporting the A:a knob-hole bond.
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In the previous chapter the effect of the abolition of the extended knob hole
interactions on polymerisation was studied, and it was found that the disruption
of extended D-E interactions impacted mainly on fiber growth. There was a
significant difference in maximum OD between the WT and recombinant
variants. As discussed previously, it has been shown by others that results such
as Max OD generated from light scattering methods have a direct relationship
with the cross sectional area of a fibrin fiber (Hantgan and Hermans, 1979;
Yeromonahos et al., 2010). Therefore, this change in maximum optical density
during turbidity measurements is a sign that there may be differences in
protofibril packing resulting in thicker or thinner fibers. It is also likely that these
packing differences then lead to differences in the final clot structure.
Previous reports by others have already demonstrated how final fibrin clot
structure can be influenced;
 pH, temperature and ionic strength (Nair et al., 1986)
 the concentration of Ca2+ ion (Carr et al., 1986)
 the concentration of thrombin (Blombäck et al., 1989)
The effect of thrombin appears to have the most striking effect on clot structure,
lower concentrations give arise to clots that have thicker fibers, whereas higher
concentrations give arise to thinner fibers (Domingues et al., 2016).
Work from the Ariëns laboratory has shown that thrombin concentration is also
very important during fibril assembly and protofibril packing of fibrin fibers
(Domingues et al., 2016). In both hydrated (light scattering) and dehydrated
(Transmission Electron Microscopy, TEM) conditions an increase in thrombin
concentration leads to a decrease in fiber radius.
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Myself and others have shown that it is possible to produce recombinant human
variants of fibrinogen to study the importance of single residues on clot structure
(McPherson, PhD thesis; Sabban, PhD thesis, (Duval et al., 2014)). The work in
this chapter will compare the differences in clot structure between the WT and
recombinant variants that impair extended D-E interactions. To do this, clot
density, hydrated conditions were studied using laser scanning confocal
microscopy. Fiber thickness was compared in hydrated conditions (using light
scattering) and dehydrated conditions (using SEM). Protofibril packing
arrangements of single fibrin fibers were studied using light scattering, and clot
lysis was also compared using confocal microscopy.
5.2 Methods
5.2.1 Scanning electron microscopy (SEM)
Detailed methods can be found in section 2.13. In brief, fibrin clots were made to
the final concentration of 0.5mg/mL fibrinogen, 5mM CaCl2 and 1U/mL of
Thrombin in a pierced Eppendorf lid and excess salt was removed from the clots
by washing with 50mM sodium cacodylate buffer (pH 7.4) and later fixed with 2%
Gluteraldehyde. The clots were then subjected to another 50mM sodium
cacodylate wash followed by dehydration of the clots in a 30-100% acetone
dehydration series and left overnight in 100% acetone. Martin Fuller, Astbury
Center - University of Leeds, critically dried and mounted the subsequently
prepared clots onto aluminium SEM imaging stubs which were then coated with
a 0.5nm thick layer of iridium. Each clot was imaged at x2000, x5000, x10000,
x20000 and x50000 magnification. Images taken at x20000 were used to
calculate fiber thickness.
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5.2.2 Laser scanning confocal microscopy
5.2.2.1 Protein labelling
Prior to labelling, 100µg of WT and each recombinant variant was dialysed
against 1x PBS pH 7.4 and consequently labelled using Alexa Fluor 488 Protein
Labelling kit™ as described in 2.12.1.
5.2.2.2 Fibrin clot structure
Fibrin polymerisation and clot formation was initiated by the addition of a reaction
mix containing 5mM CaCl2 and 0.1U/mL thrombin to 0.5mg/mL fibrinogen variant
and 5% Alexa Fluor 488 labelled fibrinogen variant (final concentrations) to a
total volume of 40µL in an Eppendorf tube. 30µL was transferred to a channel in
a VI flow, uncoated sterile µ-slide), placed into a dark humidity chamber and
allowed to clot for 1 hour. After formation, the clots were housed onto the piezo
stage of the LSCM microscope and z stack was imaged using parameters as
described in Table 5-1.
Table 5-1 LSCM parameters for final clot structure
Setting Value
Laser Power 3%
Laser 488
Stack size X = 212.13µm Y = 212.13µm Z = 15µm
Slices 21
Slice Depth 0.75µm
Gain 762
Pinhole 44µm
The computer software ZEN™ was used to process the images and fiber density
of the clots was determined as described in 2.12.3. The clot densities between
WT, γDEK, γD297N, γE323Q and γK356Q were compared. 
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5.2.2.3 Clot lysis
Fibrin clots were formed in a µ-slide as described above in 5.2.2.2. After
formation, 20µL of 6nM tPA and 0.4µM Plasminogen was added to the fully
formed clot and allowed to permeate the network for two minutes with the slide
tilted at 45oC followed by 5 minutes with the slide flat. The slide was mounted on
the microscope and a lysis front was located and clot lysis was imaged using the
following parameters as described in Table 5-2.
Table 5-2 LSCM parameters for clot lysis
Setting Value
Laser Power 3%
Laser 488
Stack size X = 212.13µm Y = 212.13µm Z = 2µm
Slices 5
Slice Depth 0.5µm
Series Time 10 seconds
Gain 762
Pinhole 34µm
The images were processed as described in 2.12.4 and clot lysis was measured
by the rate of travel of the lysis front.
5.2.3 Protofibril packing
Fibrin clots 0.5mg/mL fibrinogen 5mM CaCl2 and 0.1U/mL thrombin of WT and
fibrinogen variants were made to a volume of 100µL and the average fibrin fiber
diameter was determined from the wavelength dependent turbidity using a
Perkin-Elmer spectrophotometer. The average fiber radius, the number of
protofibrils, and distance between protofibrils was calculated as discussed in
2.15.
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5.2.4 Statistics
Data analysis was performed using GraphPad Prism statistical software
package. A one-way ANOVA was used with multiple comparisons with the WT
as a control column. Results are shown as mean ± SD, and were considered
significant when p<0.05.
5.3 Results
Clot structure was first compared between WT and the fibrinogen variants using
Scanning Electron Microscopy, although clots were imaged at 5 different
magnifications, and x20000 micrographs were chosen for clot analysis as they
were the most suitable for comparison. The fiber network density of the mutants
were visually compared to WT (Figure 5-1) and it is very clear that the variants
were denser, with the γDEK being the most dense followed by the single mutants 
and then the WT. Fibers also looked visually different in thickness so this was
investigated using Image J. As demonstrated in Figure 5-2, there is a significant
difference in fiber thickness for all variants compared to the WT (65.0±7.2nm) ,
with γDEK being the thinnest (43.2±5.6nm) p=0.0004, followed by γE323Q 
(48.1±2.3nm) p=0.0014, γK356Q (50.6±4.2nm) p=0.0078 and γD297N 
(53.1±3.3nm) p=0.0425.
To confirm the differences in fiber density, laser scanning confocal microscopy
experiments were also performed, Figure 5-3 is an illustrative image of each
variant and shows a difference in clot structure. The fiber count per 200µm
(Figure 5-4) was quantified, γK356Q was the least dense (25±4 fibers), followed 
by WT (29±1 fibers), γD297N (29±3 fibers) , γE323Q (34±3 fibers) and γDEK 
was the most dense (40±2 fibers). To gather insight whether the difference in
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density gave rise to changes in clot breakdown, lysis rates were measured
(Figure 5-5), however none of the mutants were significantly different to the WT.
The average lysis speeds (fastest to slowest) are as follows; γD297N (0.64 ±0.11 
µm/s), WT (0.45±0.07µm/s), γE323Q (0.36±0.09µm/s), γK356Q 
(0.33±0.13µm/s) and γDEK (0.28±0.08µm/s). 
Protofibril packing analysis was then conducted in fully hydrated conditions to
study the intrafibrillar structure of fibrin fibers, there were no significant
differences in fiber radius in hydrated conditions (Figure 5-6) when comparing
WT (104±1nm) to γD297N (98±6nm), γE323Q (102±3nm) and γK356Q 
(102±1nm). It was not possible to measure γDEK due to limitations in material 
quantity. There was a large but not significant decrease in protofibril number
(Figure 5-7); for γD297N (206±82), γE323Q (270±82) and γK356Q (253±25) 
compared to WT (375±92). This reduction led to the hypothesis that if the radii
of the fibers are the same but a large reduction in the total number of protofibrils
then the packing between protofibrils for the variants must be different. The
average distance between protofibrils (Figure 5-8) was then calculated as
described in 2.15. The WT was the most densely packed with 9.7±1.0nm spacing
between each protofibril followed by γE323Q (11.2±1.4nm) γK356Q 
(11.4±0.0nm) and γD297N (12.6±2.2nm) being the least densely packed. 
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Figure 5-1 Scanning electron micrographs of purified WT and fibrin variants at x20000 magnification. WT clots were visually the
least dense followed by the extended knob-hole single variants with the triple variant being the most dense. Fibers were thinner
for the variants with γDEK being the thinnest.
γE323Q γK356Q
WT γDEK γD297N
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Figure 5-2 Thickness of WT and variant fibrin fibers in dehydrated
conditions using scanning electron microscopy. Fiber thickness was
quantified using ImageJ analysis software and a significant reduction was
observed for all fibrin variants.
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Figure 5-3 Laser scanning confocal microscopy micrographs of WT fibrin clots Alexa 488 labelled fibrin was incorporated into the
clots to allow for visualisation of clot structure in hydrated conditions. γDEK clots appeared to be the most dense followed by γE323Q 
γD297N WT and γK356Q.
WT γDEK γD297N
γK356QγE323Q
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Figure 5-4 Fiber count per 200µm Grids were overlaid on LSCM micrographs
using ImageJ analysis software, and fibers that intersected with grid lines
were counted as an indication of clot density.
Figure 5-5 Clot lysis (µm/s) After one hour of clot formation clots were lysed
and the rate of movement by the lytic front was measured using ImageJ
analysis software, γDEK, γE323Q and γK356Q were all slower to lyse, 
whereas γD297N was faster to lyse. 
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Figure 5-6 Fiber radius in hydrated conditions. Fiber radius was calculated
by the proportion of light scattering by the variant fibrin networks. None of
the clots were significantly different compared to WT.
Figure 5-7 Number of protofibrils in hydrated conditions The proportion of
light scattering for each variant was also used to calculate the total number
of protofibrils contained within a fiber for each fibrin variant. None of the
mutants were significantly different to the wild-type, however the average
number of protofibrils per fiber appeared borderline reduced for the
variants.
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Figure 5-8 Average distance between protofibrils A non-significant increase
in the distance between protofibrils were observed for all variants which
indicated fibers that were less densely packed.
5.4 Discussion
In this chapter, final clot structure in hydrated and dehydrated conditions, clot
lysis and the intrafibrillar structure was studied using SEM, LSCM and light
scattering methods.
Upon visual inspection of the SEM micrographs it is obvious that the recombinant
variants give arise to an altered clot structure being denser and comprising of
thinner fibers. It is probably worth noting that the triple mutant (γDEK) gives arise 
to the most different clot structure compared to WT followed by γE323Q then 
γD297N and γK356Q (which are similar to each other). The order of which the 
variants that are most different to the WT are in agreement with the turbidity
profiles as discussed in the previous chapter. This data supports the notion that
the disruption of electrostatic extended D-E interactions is a combination effect
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with γE323Q being more potent than γD297N and γK356Q but when all 
mutations are combined in γDEK they have a more profound and significant 
effect.
Hydrated conditions using LSCM however do not match this pattern so clearly.
γDEK formed the densest clots followed by single variant γE323Q agreeing with 
the SEM data, but γK356Q was less dense than the WT, albeit by a small margin, 
whilst γD297N appears to be the same as the WT. The main difference between 
these two sets of data is the environment in which the fibrin fibers form, in
scanning electron microscopy clots are formed, washed, fixed, dehydrated and
critically dried all before imaging is performed, whereas in confocal microscopy
clots are allowed to form and imaged 1 hour after formation without any additional
sample preparation required. One could argue that the dehydration process in
scanning electron microscopy may influence the final results, especially fiber
thickness, making confocal microscopy the more reliable data set. However one
must also be mindful of the interpretation of the confocal data because it is not
known for certain that all the variants will behave in a similar manner when bound
with Alexa Fluor label. On the other hand, experiments performed in the Ariëns
laboratory (unpublished have shown that there is no difference for polymerisation
kinetics by turbidity when comparing WT with bound label and WT without label.
Regardless, when both experimental methods are taken into consideration, the
triple mutant clearly displayed a different phenotype and was the densest overall,
with the single mutants density range in-between γDEK and WT. These changes 
in clot structure further supports the hypothesis that extended D-E knob-hole
interactions play a role in thrombus formation. What is causing this striking
difference in the clot structure? Two factors could play such a role, the
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longitudinal kinetics of oligomer formation through knob-hole interactions, and
aggregation and branching. The previous chapter demonstrates that in the early
stages of protofibril formation there is a delay in polymerisation at earlier
timepoints (10minutes), but the variants at later timepoints (30 minutes) appear
to ‘catch up’ and no difference in the length of protofibrils between WT and
variants is observed, therefore lateral aggregation and branching in these
variants could be altered. As can be seen from both the SEM (Figure 5-1) and
confocal micrographs (Figure 5-3), variant clots typically have many more branch
points (where protofibrils that form fibrin fibers diverge from each other, Figure
5-9).
Figure 5-9 Scanning electron micrograph of WT fibrin at x50000
magnification Box highlighted in grey shows fibrin fiber branching. The red
circle shows the intersection where the branching takes place.
Therefore there might be some influence on the formation of branch points in the
fibrin variants, as kinetics that favour lateral aggregation form clots that have
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thicker fibers with fewer branch points, while kinetics that are less favourable to
lateral aggregation give arise to clots that have thinner fibers with many branch
points (Weisel and Litvinov, 2017). This hypothesis is supported by the finding
that the variants have significantly thinner fibers compared to the WT.
Fibrin clots are degraded by the fibrinolytic system after they have performed
their function. In brief, plasminogen is converted to plasmin by either urokinase-
type plasminogen (uPA) activator or tissue-type plasminogen activator (tPA), the
plasmin then cuts the fibrin network into degradation products (Longstaff and
Kolev, 2015).
Clot lysis is a very important function in haemostasis as increased lysis can
cause increased bleeding (Szczepaniak et al., 2015) Clot structure can have a
large impact on the rate of as shown by Collett et al, who demonstrated that
fibrinogen Dusart (a congenital dysfibrinogenemia), associated with abnormal
polymerisation and thrombotic embolism, had a tight clot network configuration
and slower lysis rates (Collet et al., 1993). Additionally Carr and Alving directly
studied the effect of fibrin structure on lysis and found lysis was faster for clots
composed of thicker fibers (Carr and Alving, 1995). These two pieces of work
show similar results to my studies where dense fibrin networks take a longer
amount of time to lyse.
Clot lysis (Figure 5-5) was investigated using a LSCM to visualise the progress
of a lysis front over time, tPA in combination with plasminogen were added to a
fully formed clot network. None of the single mutants were significantly different
to the WT, however most of the recombinant variants were slower to lyse than
the WT, which is to be expected because they all have a denser network.
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Surprisingly, γD297N variant is actually faster to lyse than the WT, this is 
somewhat unexpected because γD297N has a similar clot density to the WT and 
therefore one would expect lysis rates to be also similar.
In a recent article (Bannish et al., 2017), the author highlighted that the fibrin
fibers are approximated only 20% protein and the rest contains water, meaning
there is space for small molecules such as tPA to diffuse within the fibers
themselves. Perhaps γD297N clots contains fibers that are less densely packed 
which leads to unexpectedly quicker lysis. Perhaps more repeats for this data
would help come to a clearer conclusion as the current data only stands at n=3.
Protofibril packing analysis was then conducted to study the intrafibrillar structure
of fibrin fibers. Recently, others have already investigated the role of thrombin
concentration and the concentration of γ’ variant on protofibril packing 
(Domingues et al., 2016). In this thesis, the effects of extended knob-hole
interactions on protofibril packing were investigated. In contrast with previous
scanning electron microscopy data described above the fiber radii for the
variants were not different. However, there was a large but not significant
decrease in protofibril number. This is interesting because if the radii remains
unchanged between the WT and the variants but there is a large decrease in
protofibril number the packing must be different. The average distance between
protofibrils was increased by 2-3nm. It was hypothesised earlier that perhaps this
increased distance between protofibrils would account for why γD297N would be 
quicker to lyse, however this explanation is not entirely consistent with the data
because both γE323Q and γK356Q have increased distances between 
protofibrils yet their lysis times were slower.
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To summarise, γDEK variant produces the most dense clots as observed by 
SEM and LSCM, with two out of three single mutant variants being denser and
the final single variant being similar to the wild type, suggesting that to observe
differences in clot structure all extended D-E interactions need to be abolished.
In the lysis experiments, most variants were overall slower to lyse as discussed
earlier in this chapter, which is to be expected as they have denser structures,
however variant γD297N was faster to lyse. Fiber thickness was significantly 
reduced for all variants and light scattering studies showed that these fibers were
reduced in packing density showing that the abolition of the extended D-E
interactions translates to a difference in fiber thickness and clot structure.
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Chapter 6 - The role of extended
D-E knob hole interactions in
clot mechanics
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6.1 Introduction
In the body, thrombi can be exposed to a range of tensile forces (150-400pN) as
predicted by molecular simulations of shear conditions in the blood (Kononova
et al., 2013). Fibrin provides the mechanical strength for the thrombi by forming
an interconnecting network of fibrin fibers (Collet et al., 2005a). Because of this
central role in thrombi formation and prevention of bleeding, fibrin clot mechanics
have been extensively studied by others for many years (Ma et al., 2017; Ryan
et al., 1999b; Ferry and Morrison, 1944). The multiscale mechanics of fibrin fibers
have now been predicted by the Ariëns laboratory and others (Allan.P, 2012;
Brown et al., 2009) identifying key strain related deformation events in fibrin. A
study has investigated the microstructural arrangement and clot mechanics
through the use of fractal dimensions in conjunction with other diseases such as
lung cancer (Davies et al., 2015). Single fiber mechanics have been studied to
elucidate the molecular mechanism(s) of fibrin fiber extension (Guthold et al.,
2007). These authors suggest that an adjustment in the alignment of the fibrin
monomers can bear the load of small strains, whilst at medium strains the α-
helical coiled coils become unravelled acting as springs and at high strains a
deformation of the γC domains is thought to occur. Clinically, an indication of clot 
mechanics can be made by thromboelastrometry. Here a rotating pin (connected
to an optical detector system) is inserted into a cup of blood and continuously
rotated, when the blood is clotting the rotational torque of the pin is slowed and
this can indicate the ‘clot firmness’ (Zaky, 2017). The output parameters such as
clot firmness that are generated in thromboelastometry (Kelly et al., 2018) are
not directly comparable to studies investigating visco-elastic properties of fibrin
clots at the nanoscale where frequency dependent moduli G’ and G’’ (Ma et al.,
146
2017; Duval et al., 2014) are calculated, increasing the difficulty of associating in
vitro and ex vivo work (Weisel, 2004b).
Chapter 5 demonstrated that the variants inhibiting extended D-E interactions
significantly changed the clot structure, suggesting that it is possible that the
extended interactions will also influence mechanical properties.
The methodology in this thesis was based on work conducted previously in the
Ariëns laboratory. Here, a piece of micro-rheology apparatus (named ‘magnetic
tweezers’) was created by Robert Harrand and optimised for the study of the
mechanical properties of fibrin clots by Peter Allan, University of Leeds. Using
this apparatus, non-crosslinked fibrinogen purified from plasma fibrinogen γA/γ’ 
splice variant fibrinogen was approximately 2.7 times less stiff than homozygous
γA/γA fibrin (Allan et al., 2012). A key difference with this new, novel method is
that visco-elastic properties could be determined using active particle tracking
and mathematical transformation (Evans et al., 2009). Two moduli can be
‘extracted’, the storage modulus (G') which is the amount of energy that is stored
in a system (also known as clot stiffness) and the loss modulus (G") which is the
amount of energy that is lost from the system (also known as clot viscosity)
(Mason and Weitz, 1995). However fibrin clots are not only purely elastic nor
purely viscous, therefore the tan delta (a ratio of G"/G') will be calculated to give
the overall visco-elastic properties of the fibrin clots.
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6.2 Methods
6.2.1 Clot preparation
Fibrin clots were prepared with 0.5mg/mL fibrinogen, 5mM CaCl2, 1:250 (v:v)
paramagnetic beads and 0.1U/mL Thrombin (final concentration) in an
Eppendorf tube. Immediately following clot initiation, the clotting mixture and
drawn up in a capillary tube by capillary action, the ends of the tube were sealed
with Vaseline to prevent dehydration and the clots were rotated very slowly by
hand for 10 minutes to prevent the sedimentation of paramagnetic beads on the
capillary wall. The clots were then stored in a humidity chamber at room
temperature overnight prior to force measurements the following day.
6.2.2 Micro-rheology
The clots were placed on an in-house built micro-rheometer and the creep
response was measured for a period of 10 minutes. A minimum of ten beads per
clot were measured as described in 2.11. Time-dependant compliance was
calculated from the time dependant displacement of the bead and a best fit of
the data was plotted using Equation 2-6. The compliance was then converted
into frequency dependent moduli using the mathematical procedure of Evans
(Evans et al., 2009) as described in 2.11. The storage modulus (G'), loss
modulus (G") was then used to compare the mechanical properties of the
recombinant variants.
6.2.3 Statistics
Data analysis were performed using GraphPad Prism statistical software
package. A one-way ANOVA was used with multiple comparisons with the WT
as a control column. Results are shown as mean ± SD, and were considered
significant when p<0.05
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6.2.4 Results
The mechanical properties of the fibrin clots were measured by the entrapment
of paramagnetic beads into the fibrin network, three parameters were ultimately
measured, the G', G" and tanδ (G"/G'). These parameters were measured from 
very short frequencies (0.004Hz) to long frequencies (25Hz). The G' and G"
response from the entire frequency range can be observed in Figure 6-1 for
γDEK triple mutant, and in Figure 6-2 for the single fibrin variants. Three 
frequencies were selected (0.1Hz, 1Hz and 10Hz) to make comparisons and
perform statistical analysis between the variants as these frequencies span a
frequency range where key deformation events in fibrin networks occur. All
comparisons below are to the WT control samples.
Table 6-1 Storage modulus (G') of WT and γDEK variant 
G'
Frequency WT γDEK 
0.1 Hz 0.44±0.01 Pa 0.38±0.10 Pa
1 Hz 0.71±0.05 Pa 1.01± 0.15 Pa *
10 Hz 1.10±0.23 Pa 1.69±0.45 Pa
Table 6-2 Storage modulus (G') of WT and single variants
G'
Frequency WT γD297N γE323Q γK356Q 
0.1 Hz 0.64±0.09 Pa 0.86 ±0.14 Pa 0.98 ±0.40 Pa 1.56 ±0.24 Pa **
1 Hz 0.98±0.07 Pa 1.68 ±0.34 Pa 1.71 ±0.61 Pa 2.23 ±0.50 Pa *
10 Hz 3.0±0.69 Pa 3.57±0.12 Pa 4.05±0.50 Pa 5.42 ±0.83 Pa **
As shown in Table 6-1 significant differences of storage modulus (G') were
observed for  γDEK at 1Hz level in addition to significant differences across all 
frequencies for γK356Q single variant as demonstrated in Table 6-2. 
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Table 6-3 Loss modulus (G") of WT and γDEK variant 
G"
Frequency WT γDEK 
0.1 Hz 0.08±0.01 Pa 0.14 ±0.01 Pa **
1 Hz 0.27±0.09 Pa 0.57 ±0.14 Pa *
10 Hz 0.13±0.09 Pa 0.17 ±0.09 Pa
Table 6-4 Loss modulus (G") of WT and single variants
G"
Frequency WT γD297N γE323Q γK356Q 
0.1 Hz 0.10±0.01 Pa 0.19±0.03 Pa 0.19±0.04 Pa 0.19±0.07 Pa
1 Hz 0.78±0.16 Pa 1.15 ±0.07 Pa 1.22 ±0.15 Pa 1.30±0.39 Pa
10 Hz 0.78±0.28 Pa 0.52 ±0.15 Pa 0.68 ±0.23 Pa 1.38±0.51 Pa
As shown in Table 6-3 significant differences were observed for γDEK at 0.1 Hz 
and 1Hz, no significant differences were observed for the single mutant variants,
Table 6-4.
As fibrin clots are neither solely elastic or solely viscous, but visco-elastic
polymers, the tanδ parameter (ratio of G"/G') was calculated, Table 6-5 and 
Table 6-6.  Although not statically significant, these tanδ values show that when 
the overall visco-elastic properties are considered there is only noticeable
changes at 0.1Hz in γDEK. Indicating that each residue appears to be 
contributing to an additive overall effect.
Table 6-5 Overall deformability (tanδ) of WT and γDEK variant 
Tanδ
Frequency WT γDEK 
0.1 Hz 0.19±0.04 Pa 0.40±0.11 Pa *
1 Hz 0.38±0.11 Pa 0.56±0.05 Pa
10 Hz 0.11±0.06 Pa 0.10±0.04 Pa
Table 6-6 Overall deformability (tanδ) of WT and single variants 
Tanδ
Frequency WT γD297N γE323Q γK356Q 
0.1 Hz 0.16±0.04 Pa 0.22±0.01 Pa 0.21±0.07 Pa 0.12±0.03 Pa
1 Hz 0.81±0.21 Pa 0.70±0.09 Pa 0.75±0.16 Pa 0.58±0.09 Pa
10 Hz 0.26±0.12 Pa 0.15±0.04 Pa 0.17±0.06 Pa 0.26±0.12 Pa
150
Figure 6-1 Complete G’ and G’’ curves for WT and γDEK G' is represented by a solid line and G" is represented by a dotted line. WT
in blue and γDEK in red, very short frequencies 0.01Hz-1Hz represent deformation events occurring at branch points and along 
fibrin fibers no change is observed for G' but a significant increase is found for G". Frequencies at 1Hz represent deformation events
at the fiber level such as twisting and stretching, and high frequencies an increase for yDEK is seen here for both G' and G". <10
Hz represents deformation events occurring at the molecular level there are no significant differences at this frequency for γDEK. 
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Figure 6-2 Complete G’ and G’’ curves for the single mutant variants WT , γD297N, γE323Q and γK356QG' is represented by a
solid line and G" is represented by a dotted line. WT in blue and γD297N in red, γE323Q in green and γK356Q in purple. Very short 
frequencies 0.01Hz-1Hz represent deformation events occurring at branch points and along fibrin fibers yK356Q is significantly
increased for G' but no change is observed for G". Frequencies at 1Hz represent deformation events at the fiber level such as
twisting and stretching γK356Q is significantly increased for G' but no change is observed for G".<10 Hz represents deformation 
events occurring at the molecular level γK356Q is significantly increased for G' but no change is observed for G". 
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Figure 6-3 The storage modulus (G') for all fibrin variants. For γDEK, there was no difference in G' at 0.1Hz (A), there was a significant 
increase in G' at 1Hz (B) and a non-significant increase of G' at 10Hz (C) when compared to WT. For the single fibrin variants there
was a trend of an increased G' at 0.1Hz (D) that was significantly different for γK356Q, p<0.05. Measurements conducted at 1Hz 
(E) also showed an increase of G' for all single variants with a significant difference for γK356Q p<0.05. Single mutant variants were 
also increased at 10Hz (F), significantly for γK356Q. 
153
Figure 6-4 The loss modulus (G") for all fibrin variantsFor γDEK G" was increased across all frequencies (A-C) but only significantly 
at 0.1Hz and 1Hz, p<0.05. At 0.1Hz (D) and 1Hz (E) all single mutants had a non-significant increase in G", however at 10Hz (F)
γD297N and γE323Q had a non-significant reduction in G" whereas γK356Q had a non-significant increase in G". 
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Figure 6-5 The visco-elastic ratio of G"/G' (tanδ). For γDEK, at 0.1Hz and 10Hz there was an non-significant increase in the tanδ, 
however at 10Hz no change was observed. For the single variants, at 0.1Hz there was an insignificant increase for γD297N and 
γE323Q whereas there was a non-significant decrease for γK356Q. At 1Hz there was a slight reduction in tan delta for γD297N and 
γE323Q followed by a greater decrease in tan delta by γK356Q. At 10Hz both yD297N and yE323Q were non significantly reduced 
whereas γK356Q was similar to the WT. 
*
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6.3 Discussion
In this chapter, the effects of the extended D-E interactions on clot mechanics
were investigated using an in-house magnetic tweezers apparatus. Due to
material limitations at the time, two sets of experiments have been conducted,
the first set is a comparison of the triple mutant variant γDEK to the WT. A second 
set of experiments comparing mechanics between single fibrin variants and the
WT was performed later within the project. The same batch of WT was used to
perform the experiments for both data sets, however the magnetic rheology
equipment was calibrated before both data sets were collected. The frequencies
selected (0.1Hz, 1H and 10Hz) are representative of deformation events
happening within the clot, 0.1Hz observes deformation at whole clot scale where
large scale motions of the fibers and branches align, fibers bending and twisting
occur at 1Hz, whilst at 10Hz molecular deformation events occur such as
stretching of the molecular domains. This was shown by the Ariëns group
(Allan.P, 2012) based on a previous model of rheology of semi flexible fibers
(Morse, 1998b).
When WT is compared to γDEK one can see an increase in G' for γDEK at 1Hz 
(significant) and 10Hz (insignificant). This is unexpected as one would think that
the γDEK fibrinogen would lead to clots that are less stiff and more deformable 
due to weaker electrostatic interactions and less stable A:a knob-hole bonds.
However as demonstrated in the Ariëns laboratory (Allan.P, 2012) the
deformation events that occur at these intermediate and short frequencies are in
the order of fibrin fibers, therefore it is possible that due to the nature of the
γDEK’s denser clot network the fibers are less able to rotate and the clot is more 
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stiff overall. This hypothesis does agree with the literature as clots that are
denser have previously reported to be more stiff, (Ryan et al., 1999b; Weisel,
2004a). It is difficult to postulate why this difference is not seen at 0.1Hz but it
could be that 0.1Hz is at the early stages of this unfolding event therefore not all
of the deformation from the pulling experiments has taken place. This hypothesis
also fits for the single fibrin variants as they are different density to the WT but
also have significantly thinner fibers. Interestingly γK356Q is the least dense 
mutant however, it is the most significantly different for G' compared to the WT.
Perhaps this residue is more influential on packing arrangements within the fiber.
Furthermore, when introduced to the triple mutant this residue may contribute to
an increase in clot stiffness more than γD297N and γE323Q.   
As for the loss modulus (G") the γDEK triple mutant is significantly increased at 
0.1Hz and 1Hz suggesting that more deformation is occurring. The single mutant
variants have an increased (G") at these frequencies however they are not
significantly different to the WT. This suggests that the abolition of just one
electrostatic bond introduced by the single variants is not enough to cause a
significant change in the loss modulus, but all three amino acid changes are
required for there to be an effect. At 10Hz there is a small increase in G" between
the WT and γDEK which is also reflected in the single variant experiments, as 
there is a small decrease for γD297N and γE323Q and an non-significant 
increase with γK356Q, so there is no change overall. The higher deformation 
observed for the variants at 0.1Hz and 1Hz could be attributed to thinner fibers
that are less densely packed. Chapter 5 demonstrates that all variant clots are
made of significantly thinner fibers, that have an approximate 30-50% reduction
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in the number of protofibrils. This would indicate that when pulled there are fewer
protofibrils to bear the stress applied.
Tanδ , a ratio of G"/G', was calculated as fibrin clots do not have the mechanical 
properties of purely elastic or purely viscous materials, fibrin clots are visco-
elastic. When a material has a tanδ =1 the elastic and viscous components are 
acting by the same magnitude, when the tanδ is <1 then the elastic component 
is dominating and when tanδ >1 the viscous component is dominating. The 
experiments in this thesis observed that all of the tanδ values are <1, which is to 
be expected because pulling was conducted at 40pN. Pulling at 40pN allows
multiple beads to be measured without permanent deformation of the clot. At
0.1Hz γDEK had a large 2 fold (although not significant) increase compared to 
WT in the tanδ, however there were only small changes for the single mutant 
variants, suggesting again that all three single mutations are required for an
effect. A similar observation was also made for 1Hz as there was a moderate
increase in tanδ for γDEK but when comparing the single fibrin variants there 
was little change. At 10Hz there is no significant change for any of the variants
albeit there is a decrease in tanδ for γD297N and γE323Q suggesting that there 
is less deformation for these two variants. The data is very difficult to interpret
within this range because, at frequencies of 10-25Hz limitations of the micro-
rheometer are being reached, more specifically the CCD camera. A replacement
of the current camera with one that could measure higher rates up to 100Hz
would give more insight to if/and how many deformation events are occurring in
fibrin networks at the molecular domain level.
The technique utilises an in-house micro-rheometer and therefore there is
currently very little data for a comparison to be made to other studies, however
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there have been two publications from the Ariëns group. It was demonstrated
that protofibril packing had an effect on clot mechanics (Domingues et al., 2016).
Here the authors observed that plasma depleted affinity purified fibrin clots
increased in decreased in rigidity when made with higher thrombin
concentrations at 1Hz (only this frequency was measured using the micro-
rheology device by the authors). A non-significant decrease in protofibril number
did not have an effect on the overall visco-elastic properties of the clot.
Unfortunately due to limitations in material, γDEK was not measured for 
protofibril packing therefore I can only postulate that γDEK would have even 
fewer protofibrils than the single variants which gives arise to the increase in
tanδ. 
Another work (Duval et al., 2014) showed that the microrheological properties of
fibrin is regulated by fibrin α-chain crosslinking. The values for WT(-FXIII) G’, G’’ 
and tanδ are in the same order of magnitude between the studies showing that 
the method is somewhat consistent.
To summarise, the clot stiffness (G') is increased for all variants for the majority
of frequencies, the increase in G' is due to the increase in clot density that is
observed in the previous chapter. The clot viscosity (G") is increased at 0.1Hz
and 1Hz but not at 10Hz, this signifies that more deformation events are
occurring at the fiber level and is attributed this to a decrease in protofibril number
which leads to thinner fibers as described in the previous chapter. When both G'
and G" are taken into consideration in the form of tanδ, there is no significant 
difference in the micro-rheological properties of the fibrin clots.
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Chapter 7 - Discussion
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7.1 Summary of data
The work presented in this thesis has used a wide range of biochemical and
biophysical experimental methods to study fibrin polymerisation, clot structure
and clot mechanics. A large proportion of this work focused on the successful
expression and purification of recombinant human fibrinogen with chosen
mutation(s) in the γ-chain, γDEK, γD297N, γE323Q and γK356Q. These 
fibrinogen variants were studied using turbidity for polymerisation kinetic
analysis. Confocal microscopy and scanning electron microscopy were used to
probe the structure of the fibrin clots, and a light scattering method was used to
investigate internal fiber structure. Atomic force microscopy was used to study
early polymerisation methods and clot mechanics were investigated using an in-
house micro-rheology device.
CHO cells were used to successfully produce recombinant proteins. Following
purification by affinity chromatography, SDS-PAGE analysis showed no signs of
degradation of the three fibrinogen chains (Aαβbγ) with no unexpected 
contaminating bands. When investigating the local confirmation in the far-UV
range using CD spectroscopy small differences between the variants and the
WT were observed.
Early polymerisation kinetics by AFM showed that at the earliest time point
measured (10minutes) all variants except γK356Q had shorter protofibrils 
indicating that the alteration of the extended D-E interactions hinders the
polymerisation process. While indeed protofibrils were shorter after 10 minutes
for the γD297N, γE323Q and γDEK variants, no difference in protofibril length 
distribution was seen at the 20 and 30 minute time points between the variants
and the WT, suggesting that the rate of longitudinal growth ‘catches up’ with the
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WT. Turbidity was used to measure progressively later stages of polymerisation
(lateral aggregation of the protofibrils). A significant reduction in Vmax for the
variants along with a large reduction in maximum OD was observed. The
maximum OD was the most different for γDEK followed by the single point 
mutation variants. Overall, it therefore appears that the extended D-E
interactions have some effect during the initiation of longitudinal protofibril growth
at the early stages of polymerisation. Shorter protofibrils at 10 minute timepoints
in AFM studies were observed for the majority of variants, and an effect of the
mutations resulting in an extended lag phase as seen in turbidity for γDEK. The 
disruption in longitudinal growth later impacts on lateral fiber growth as can be
seen from the reduction in Vmax and MaxOD in the turbidity assay, which is an
indication of altered fiber thickness.
This large reduction in the ability to laterally aggregate effectively as shown by
the Max OD results indicated that the overall clot structures could be different.
To investigate this further, clot micrographs using both laser scanning confocal
microscopy (LSCM) and scanning electron microscopy (SEM) were produced.
Visual inspection of SEM micrographs and quantitative analysis of confocal
micrographs showed that the γDEK clot is significantly denser and the single 
mutants were more dense than WT, but not to the same extent as γDEK, this 
confirmed the pattern seen in maximum optical density results. In confocal lysis
experiments all variants were slower to lyse compared to WT, with the exception
of γD297N. 
Next, it was investigated whether the abnormal structures had an impact on clot
mechanics, as the structures were denser and the fibers were thinner, as seen
by SEM, and therefore it remained to be seen whether these clots would behave
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in a more elastic or a more viscous behaviour. The results from the micro-
rheometer studies showed that there were increases in storage modulus for
γDEK at the fiber level. γK356Q was the only single variant with an increase in 
storage modulus (all frequencies), perhaps suggesting that the interaction
mediated by γK356Q is required during polymerisation somewhat more so in 
order to produce fibers of the correct elasticity. For the loss modulus, γDEK was 
the only variant to significantly dissipate energy, both at the whole clot (0.1Hz)
and fiber level (1Hz). This indicates that alterations of all three extended D-E
residues are required for permanent deformation to take place. When taking both
the elastic and viscous properties of the clot into consideration, the tanδ is 
increased for γDEK at 0.1Hz and 1Hz but remains similar across all frequencies 
for the single mutants. This could be due to the reduction in D-E binding in γDEK 
variant resulting in less stable knob-hole bonds resulting in protofibrils that are
more easily deformable.
To conclude, the data summarised shows that the fibrinogen variants produced
in this thesis lead to slower forming, denser clots that are harder to lyse (with the
exception of γD297N) and γDEK is more readily deformable at lower 
frequencies.
7.2 Discussion
The results as summarised in section 7.1 show that there were altered
polymerisation kinetics, structures and clot mechanics, even for the single fibrin
variants, this suggests that each of the extended D-E interactions has an effect
and culminate into a larger effect in triple mutant γDEK. Unfortunately due to time 
and material limitations I was unable to probe further to the sub-molecular
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mechanistic reasoning as to why these variants have an effect on polymerisation,
however residues and stretches of residues containing the mutations have
previously been investigated in the literature.
7.2.1 γD297N 
Fibrinogen has a total of four calcium binding sites, two of which are low affinity
binding sites (γ2 and β2) and two of which are high affinity binding sites (γ1 and 
β1) (Marguerie et al., 1977). The γ1 and γ2 sites are located on the γ-chain of 
fibrinogen, whereas sites β1 and β2 are located on the β-chain of the molecule.  
It was previously unclear whether the γ2 calcium binding site was present or not 
in fibrinogen solution or if it was a result of molecular packing interactions
(Kostelansky et al., 2004b; Kostelansky et al., 2004a). Studies with
γD298A/D301A recombinant variant (which is adjacent to γD297 residue of 
interest) was made to probe and confirm the presence of the γ2 calcium binding 
site (Kostelansky et al., 2007). It was observed that the binding site is located
within a loop spanning residues γ294-301. The authors found that polymerisation 
differed slightly with the D298A/D301A variant meaning that the γ2 calcium 
binding site has a small role in fibrin polymerisation but attributed their observed
differences to “subtle structural changes in the hole-a polymerisation site”. Their
data and other work (Varadi and Scheraga, 1986) also indicated that it is the γ1 
site (331-336) which has greater affinity for calcium, and therefore a more crucial
for A:a knob-hole interactions. Due to its’ proximity, the γD297N mutant could 
affect the γ2 calcium binding site and therefore it would be difficult to interpret 
whether the observed effects would be because of altered calcium binding or the
abolishment of D-E interactions. However, considering that the study discussed
above mutated the γ2 calcium binding site and observed a small change in 
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polymerisation, I cannot rule out that the altered polymerisation profile, clot
structure and thinner fibers for γD297N that are observed are due to the abolition 
of the extended D-E electrostatic interactions, and not from a potentially affected
calcium binding site. Unfortunately, there was not enough material available to
perform experiments with and without calcium ions for this variant.
Interestingly very recent advances in molecular dynamic simulations and optical
trap methodologies have implicated residue γD297 in catch-slip bond regulation 
in fibrin(ogen) (Litvinov et al., 2018). Catch-slip bonds are bonds that strengthen
under acute tension (catch) but then dissociate at higher forces (slip). Catch-slip
bonds have also been discovered in other biological systems, for example
between the adhesion molecules P-Selectin and PSLG-1 in rolling cells such as
leukocytes (McEver and Zhu, 2010; Marshall et al., 2003).
In this publication the authors have used optical trap microscopy in combination
with molecular dynamic simulations to investigate the rupture forces of knob-hole
bonds. A:a bonds are non-covalent and can rupture by force pulling experiments.
In brief, beads functionalised with either fibrinogen or fragment D (contains
holes-a) were flowed into a compartment where ‘pedestals’ were functionalised
with fibrin. The beads are trapped using a laser and the immobilised single
molecules on the pedestal are put into proximity with the beads and the two fibrin
fragments interact. Pulling experiments are then performed by increasing the
distance of the pedestal from the bead. In their pulling experiments the authors
discovered that the knob-hole bonds behave differently to most non covalent
bonds, they noticed that initially the average bond lifetime increases with force,
then decreases with force displaying a catch-slip mechanism. They further
investigate this interesting finding using molecular dynamic simulations of the γ 
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nodule of human fibrin(ogen). In their model they postulate that a moveable flap
containing residues γ295 to γ305 regulates the γ2 calcium binding site, when 
calcium is bound, γD297 along with γD301 undergo spatial reorientation and 
interact with the calcium ion therefore hindering catch-slip bonds, when calcium
is unbound they are able to interact with knob A and mediate the catch- slip
bond mechanism.
7.2.2 E323Q
For the γE323Q variant, one study (Pratt et al., 1997), in addition to the molecular
simulations previously mentioned (Kononova et al., 2013) did elucidate a
potential role for γE323 in polymerisation. They show through the use of crystal 
structures that several amino acid residues in the hole-a polymerisation pocket
re-adjust to accommodate the binding of the GPRP peptide, resulting in the
rearrangement of hydrogen bonds and salt links that stabilise the A:a
interactions. They predicted that γK338 and γE323 form a salt link when GPRP 
is unbound. When bound there is a slight shift resulting in the interaction of K338
with the peptide. γE323Q could have a local effect by the disruption of extended 
D-E electrostatic interactions and therefore could lead to changes to other
residues that interact directly with knob-A leading to the delayed polymerisation,
thinner fibrin fibers, and denser clot network observed in the results. Interestingly
studies have shown that the γ1 calcium binding site is consists of residues γ311-
336 (Varadi and Scheraga, 1986; Dang et al., 1985; Yee et al., 1997), which is
immediately next to the A:a binding pocket, residues γ337-379 (Shimizu et al.,
1992). This suggests that the stretch of residues encompassing both this calcium
binding site and the polymerisation site are extremely important, which is
supported in the literature where three residues (318-320) are deleted leading to
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delayed polymerisation and reduced calcium binding (Koopman et al., 1991).
The γE323Q mutant could additionally play a role in the binding and unbinding 
of the γ2 binding site but more work would need to be performed to confirm this. 
7.2.3 K356Q
As observed in the literature, the variant K356Q has also been implicated in
packing interactions. It was originally thought that cleavage of FpA and formation
of A:a interactions drive the longitudinal protofibril formation, whereas FpB is
responsible for lateral aggregation, and ultimately packing of the fibrin fiber along
with the αC domains. However, work utilising different snake enzymes have been 
used instead of thrombin to cleave fibrinopeptide A only (Blomback et al., 1958)
and showed that fibrin networks are still able to form. It is known that B:b
interactions still do occur physiologically due to the existence of
dysfibrinogenaemia Metz where only FpB can be cleaved from the patient’s
fibrinogen (Galanakis et al., 1993). Ultimately, even though only FpB is cleaved
from these clots the monomers are still able to form fibers (Mosesson et al.,
1987). More recent work was performed by Professor Doolittle’s laboratory, who
is a pioneer in analysis of fibrin crystals and relating them to polymerisation and
protofibril packing (Yang et al., 2000), here they investigated whether or not there
were extra residues/domains facilitating in the lateral aggregation of fibrin
protofibrils. In this selected paper the authors created four D:D structures; DD-
GP (DD with GPRP ligand bound to hole-a) DD-GH (DD with GHRP ligand bound
to b-holes) DD-BOTH (DD with GPRP ligand bound to hole-a and GHRP bound
to b-holes), and DD-NL (Both holes empty, no ligands). Through the creation of
these four crystal variants the authors found that structures that had ligand(s)
occupying the holes ‘a’ and/or ‘b’ had very different lateral packing interactions
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to crystals where holes were left empty. Two stretches of residues were
proposed by the authors to be responsible for lateral packing interactions, these
were γ350-360 and γ370-380 (termed γC-γC contacts), which also contains the 
γK356Q variant. With this in mind, it is difficult to say without further work whether 
the results such as slower kinetics, reduced fiber thickness, reduced network
density and increased G’ (stiffness) are the result of abolition of extended D-E
interaction or a disruption of lateral packing mechanisms proposed by Doolittle
et al., or perhaps a combination of both.
Congenital dysfibrinogenaemia, fibrinogen Detroit, contains a substitution at
Arginine 19 on the Aα-chain to a serine residue, changing the knob A sequence, 
and causing interference with the binding with hole-a. When the patient’s plasma
was added to ‘normal’ purified fibrinogen a delay in polymerisation was observed
resulting in an delay in polymerisation initiation, indicating that the fibrinogen
molecules were defective (Blomback et al., 1968). A new fibrin variant
R19S/R17S recently produced in the Ariëns laboratory, which mutates the α- and 
β-chain knob sequences yields fibrinogen that does not polymerise at all upon 
cleavage by thrombin (Duval, unpublished). Interestingly, a dysfibrinogenaemia
named Fibrinogen Miami (Bβ D61G) has been described, this variant contains a 
mutation in the opposite interacting residue to γK356 that is being investigated. 
This dysfibrinogenaemia also showed delayed polymerisation kinetics,
(Galanakis et al., 1996) suggesting that the K356 and BβD61 ion pair interaction 
may be more important than originally thought for the polymerisation of fibrin.
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To summarise, the data shows abnormal polymerisation kinetics, clot structures
and some differences in clot stiffness for γDEK and γK356Q. Due to the 
additional potential functions of residues γD297N, γE323 and γK356 it is difficult 
to say with confidence if the aberrant results are due to the fact that extended D-
E interactions are negated, or if other mechanisms are involved. For example,
D297 could play a role in catch slip bonds, γE323 could destabilise salt links to 
other residues in the binding pocket and γK356 may be involved in the alteration 
of γC-γC contacts. As each of these single variants may contribute differently to 
the overall effect of the triple mutant γDEK, I have tried to simplify the 
contributions of each single variant into a ranking system in Table 7-1. This table
ranks the percentage change of all mutants (positive or negative) with regards to
the WT. Only experimental data where all variants were compared were
included, therefore discounting protofibril packing and turbidity with reptilase as
there was not enough material for these assays. The clot mechanic data at
0.1Hz, 1Hz and 10Hz were compared for tanδ only as clots are visco-elastic 
materials as I would like to compare the overall deformability of the variant clots.
At earlier stages of polymerisation single mutants γD297N and γK356Q, are 
more different compared with the WT than γDEK. It is expected that γDEK is the 
most different because it has altered residues in all positions, so this was
somewhat surprising. Later stages of polymerisation (lateral aggregation) is
measured by rate of lateral aggregation. The abolition of the extended D-E
interactions has an effect on lateral aggregation γDEK is the most reduced 
followed by γE323Q then the two other single mutants γD297N and γK356Q. 
Maximum optical density is mathematically relatable to fiber thickness and to
some extent clot density (Carr and Hermans, 1978), therefore it is no surprise
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that γDEK is the most dense and has the thinnest fibers to WT, again this seems 
to be followed by γE323Q, γD297N and γK356Q. As seen in Table 7-1 clot 
mechanics are most different for γDEK at 0.1Hz and 1Hz. Clot density for γDEK 
is significantly higher than WT, therefore clot density is likely having an effect on
the tanδ, +111% at 0.1Hz. These lower frequencies detect changes in mechanics 
at a whole clot level. At 10Hz however (molecular deformation events), the
pattern is completely changed, γDEK has a smaller tanδ than that of γD297N 
and γE323Q. This is unusual because I would expect that when all three residues 
are altered in γDEK, fewer interactions are able to occur between monomers and 
therefore easier to deform molecular domains. Lastly, γD297N appears to be 
fastest to lyse (even faster than WT) in the lysis experiments, although initially I
would not expect this to be the case. It maybe that perhaps protofibril packing
could be responsible for this, as larger spacing between protofibrils could allow
faster diffusing of lytic proteins. γD297N has the largest reduction in protofibril 
number (-45%) which would fit with this hypothesis, but other single variants
γE323Q and γK356Q also had similar reduction in protofibril number (-28% and 
-32.5%, respectively). As the latter were slower to lyse, this does not concur with
this hypothesis and hence further investigations need to be done to explain why
D297N is the fastest to lyse.
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Table 7-1 Ranking of overall percentage difference of recombinant variants
compared to WT.  γDEK in orange, γD297N in green, γE323Q in blue and 
γK356Q in yellow. Percentage differences most different from the WT were 
ranked (1) whereas the variants with the lowest percentage differences
were ranked (4). Red boxes indicate a significantly different result.
(Most different) Ranking (Least different)
1 2 3 4
Polymerisation
Early Stages
Protofibril
Length 10min
γK356Q 
(+)
γD297N 
(-)
γDEK   
(-)
γE323Q 
(-)
Protofibril
Length 20min
γD297N 
(+)
γK356Q 
(+)
γDEK   
(-)
γE323Q 
(+)
Protofibril
Length 30min
γK356Q 
(+)
γE323Q 
(+)
γD297N 
(+)
γDEK   
(+)
Polymerisation
Later Stages
Maximum OD
γDEK 
(-)
γE323Q 
(-)
γK356Q 
(-)
γD297N 
(-)
Lag Phase
γDEK    
(+)
γE323Q 
(+)
γK356Q 
(-)
γD297N 
(-)
Max
polymerisation
Rate
γDEK    
(-)
γE323Q 
(-)
γD297N 
(-)
γK356Q 
(-)
Structure
Fiber
Thickness
γDEK
(-)
γE323Q 
(-)
γK356Q 
(-)
γD297N 
(-)
Density
γDEK
(+)
γE323Q 
(+)
γK356Q 
(-)
γD297N 
(+)
Lysis
γD297N 
(+)
γDEK
(-)
γK356Q 
(-)
γE323Q 
(-)
Mechanics
Tanδ 0.1Hz 
γDEK    
(+)
γD297N 
(+)
γE323Q 
(+)
γK356Q 
(-)
Tanδ 1Hz 
γDEK    
(+)
γK356Q 
(-)
γD297N 
(-)
γE323Q 
(-)
Tanδ 10Hz 
γD297N 
(-)
γE323Q 
(-)
γDEK   
(-)
γK356Q 
(+)
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7.3 Limitations
7.3.1 CD spectroscopy
As previously discussed in section 3.3.4 it is surprising there is a small amount
of data available for CD spectroscopy of fibrinogen, making it more difficult to
confirm the result. Additionally CD requires strict cross calibration and validation
of reference CD spectra of proteins that have been fully or almost fully
crystallised, fibrinogen has many disordered regions and therefore this must be
taken into consideration when interpreting the CD result. The data shows that
across all types of secondary structures that γDEK is different to the WT. It is 
worth noting that the protein concentration has a significant effect on the output
spectra and therefore even though all precautionary measures and practices
were performed one cannot negate the possibility that in fact protein aggregates
were present or the protein concentration slightly varied for γDEK compared to 
WT. Due to the high sensitivity of the equipment, the small concentration change
perturbed the CD output slightly. This is a possibility as when the raw CD curves
of WT and γDEK are analysed all peaks are shifted to the same degree, which 
is a reflection upon a difference in concentration rather than a change in the
secondary structure.
7.3.2 Cell culture
In this work, the yield for some of the variants was limiting the amount of work
that could be performed. Yields ranged from 1.5mg total protein (γDEK) to 15mg 
total protein (γD297N). To improve on this a greater number of clones could be 
selected for, increasing the number of clones from 48 to 100, therefore it would
be more likely to select for a highly expressing clone. However, this obviously
would impact on the cost and the time required for clone selection.
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7.3.3 Micro-rheology
At present, the magnetic tweezers set up does not completely measure
intramolecular deformation events due to the limitations of the frequency of the
CCD camera. To gather more data using the current micro-rheology setup I could
replace the current camera with a camera that performs at a higher frequency
(e.g. 100Hz). Collecting data at higher frequencies would enable me to
completely measure the G', G" and tanδ of molecular unfolding events. Optical 
trap methods could also be used to support the data. Pulling of individual fibrin
monomers from fibrinogen could be performed to investigate the magnitude of
molecular unfolding events in the variants compared with WT.
7.3.3.1 Factor XIII
The crosslinking of fibrin chains with FXIII influences overall clot density
(Hethershaw et al., 2014), but more importantly FXIII changes the mechanical
properties of the blood clot by increasing the elastic modulus (Dorgalaleh and
Rashidpanah, 2016) (Shen and Lorand, 1983). Lateral force single fiber pulling
experiments have shown that the storage modulus is significantly increased by
factor XIII crosslinked fibrin (Liu et al., 2010), suggesting that the crosslinks form
at early stages during protofibril and fiber formation rather than FXIII permeating
through pores in the network following clot formation.
Unfortunately, due to material and time constraints, factor XIII experiments were
not performed. Factor XIII γ-chain crosslinking sites are localised to residues 
398/399 and K406 therefore, it is unlikely that the variants would disrupt the
crosslinking process. The fibrin variants are denser than the WT with more fibers,
albeit thinner. It would be interesting to know what impact FXIII has on the
mechanics of the mutants, due to material limitations I did not prioritise FXIIIa
173
experiments as I do not expect factor XIIIa to introduce a significant effect to the
variants compared to the WT. I suspect that each mutant will be cross-linked to
a similar extent by factor XIIIa leading to a similar increase in G’ and G’’, however
further experimentation would be needed to test this.
7.3.4 Limitations of turbidity measurements
Turbidity, a light scattering method, can be performed to investigate the kinetics
of fibrin polymerisation. However, turbidity profiles do not represent the full extent
of the kinetics as early stages of polymerisation such as longitudinal protofibril
growth. This is because the turbidity technique is not sensitive enough to
measure these small changes in protofibril formation, however the method is
particularly useful for measuring fiber growth (lateral aggregation). To
complement the turbidity method atomic force microscopy was used to image
early stages of protofibril formation.
7.3.5 Limitations of confocal microscopy
Confocal microscopy was used in this work to quantify the density and lysis rates
of fibrin clots. Confocal microscopy is particularly useful because it allows the
formation of a fibrin clot in hydrated conditions. However, confocal microscopy
does not have the resolving power of a scanning electron microscope and
therefore one cannot image beyond the detail of fibrin fibers, nor can one
accurately determine fibre diameter using confocal microscopy. In this work, clot
structure experiments were supported with scanning electron microscopy to
obtain greater detail of the fibrin fibers. Images taken at x20,000
Another limitation of the confocal experiments is that the addition of the Alexa
488 fluorophore could affect the fibrin polymerisation and clot formation. The
label reacts with primary amines and forms stable dye-protein conjugates. I must
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consider that the labelling of fibrinogen had an effect on the clot structure
observed in the confocal experiments because the degree of labelling (moles per
dye per moles of protein) between the WT and the variants varied between the
WT (18.66) and the variants γDEK (24.07) γD297N (20.24), γE323Q (21.47) 
γK356Q (20.3). Although the recommended degree of labelling using the Alexa 
Fluor Labelling kit is in the range of 4-9 moles of dye per moles of protein,
meaning that the protein is over labelled, I did not observe aggregation of protein
conjugates. Due to material limitations it was not possible to relabel the proteins.
However, previous turbidity experiments have been conducted in the Ariëns
laboratory (data not shown) where labelled recombinant WT fibrinogen has been
incorporated and the formation of a clot has been observed. No differences were
seen between clots formed with labelled fibrinogen compared to those made
without. If enough material was available turbidity profile experiments should also
have been be conducted on the variants in the presence of labelled fibrinogen.
The effect of labelled fibrinogen on longitudinal protofibril formation using atomic
force microscopy could also be performed, to support the turbidity result.
7.3.6 Limitations of scanning electron microscopy
Scanning electron microscopy has been used to highlight in detail the fiber
composition of the variant clots. However, scanning electron microscopy does
have its limitations, the most crucial being that clots for SEM are dehydrated to
allow for imaging. Dehydration of the clots could lead to inaccurate measuring of
fibrin fiber diameters. Additionally, due to the multiple processing and handling
procedures, fibrin clots have to be made with a higher concentration of thrombin
(1U/mL compared to 0.1U/mL used for turbidity) to create a meshwork that is
sufficiently stable and does not collapse during clot processing.
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7.3.7 Limitations of atomic force microscopy
Although AFM experiments have been particularly insightful with regards to early
protofibril formation, the method does have its limitations. One has to be careful
when interpreting the AFM data, as one cannot know for certain whether all
protofibrils that form during the polymerisation process and transferred to the
mica surface, remain at the surface during the washing and drying process (see
section 4.3.2). An assumption was made that the WT and all the variants were
absorbed to the mica surface in equal amounts. To investigate this further one
could study whether changing the surface to another substrate or using chemical
modifiers to change the mica surface has an impact on number of protofibrils
attaching. Further work as described in 7.4.2 could also be performed to increase
the robustness of the method.
7.4 Future Work
7.4.1 Clot mechanics
It is known that altered clot structures have an impact on the mechanical
measurements taken, especially clot stiffness (Weisel, 2004a). This makes
rheology data difficult to interpret when comparing the variants to WT because
differences observed may be ultrastructure related. To provide additional insight
single fiber lateral force AFM could be performed and this would allow me to
further assess whether there is any mechanical differences at the single fiber
level without clot density influencing the outcome. In the future, I would like to
perform lateral force single fiber pulling experiments to test the hypothesis that
the thinner variant fibers are mechanically weaker than WT fibers. Detailed
explanations of experimental equipment used and experimental procedures for
lateral force AFM can be found in the literature (Carlisle et al., 2009). In brief,
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fibrin fibers are formed and are suspended between two ridges, as demonstrated
in Figure 7-1, it is then possible to pull the suspended fibers with an AFM
cantilever tip. When the AFM cantilever pulls on the fibrin fiber it is possible to
calculate strain-stress curves. Additionally, SEM and light scattering studies
would need to be performed to measure fiber thickness and protofibril packing
as these may impact on the single fiber mechanics.
Figure 7-1 Cartoon representation of lateral force AFM experiments. Fibrin
fibers (solid red line) are suspended between grooves (blue), the fiber can
be pulled with an AFM cantilever tip (represented by a green circle). During
pulling the fibers stretch and eventually rupture.
7.4.2 AFM studies
AFM experiments were previously conducted with 0.5mg/mL Fibrinogen, 2.5mM
CaCl2 and 0.1U/mL thrombin, and imaged a 5µm x 5µm window size. However
the resolution of the protofibrils was poor because it was apparent that there was
too much material to distinguish between monomers and protofibrils. The current
setup using 0.02mg/mL fibrinogen and 0.05U/mL thrombin as described in
section 2.14 was optimised by Stephen Baker, University of Leeds and based
on the method published by Protopopova et al. (Protopopova et al., 2015). As an
improvement I would like to optimise and develop a new method using a FAST-
SCAN AFM this will allow me to image much larger window sizes 50µmx50µm
Before Pulling During Pulling
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to 100µmx100µm encapsulating more protofibrils in an image and making the
overall count more robust.
7.4.3 Interactions with other blood components
7.4.3.1 αIIbβ3
In this thesis, all of the studies into polymerisation, clot structure and clot
mechanics were in a purified in vitro system. In physiology however there is an
abundance of plasma proteins, not to mention other cell types such as platelets
and red blood cells. Fibrinogen has other functions such as aiding platelet
aggregation through the platelet αIIbβ3 receptor (Bennett, 2005), therefore would
the mutants still perform other functions such as fibrin platelet interactions? In
the case of αIIbβ3 it is likely that normal fibrin function would be intact as αIIbβ3
interactions with fibrin are localised to residues α95-97 and γ400-411, far away 
from the residues of interest. To test this in the future platelet aggregometry could
be performed similar to as described in (Farrell et al., 1992), in the presence of
variant and WT fibrinogen.
7.4.3.2 GPVI
Glycoprotein VI (GPVI) is a platelet receptor and typically binds to collagen at a
gly-pro-hydroxypro (GPO) sequence, this subsequently activates the platelet
through the dimerisation of GPVI (Nieswandt and Watson, 2003). it has recently
been shown that GPVI can also bind fibrinogen (Mangin et al., 2018).
GPVI binds to fibrin and also fibrin degradation product D-dimer, and this induces
platelet activation (Induruwa et al., 2018). The exact binding interface of GPVI
and fibrin has not yet been described, so it is difficult to say whether the
recombinant variants would have an effect of the intensity of platelet binding and
platelet aggregation. With the production of additional recombinant fibrinogen I
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could perform surface plasmon resonance (SPR) and isothermal titration
calorimetry (ITC) to investigate the binding intensities of the fibrinogen variants
with GPVI.
7.4.3.3  Plasminogen, tPA and α2-Antiplasmin 
The results demonstrate that the rate of lysis is mainly influenced by the final
architecture of the clot, with the fiber density and fiber thickness being the most
prevalent of factors. Plasminogen and tPA both bind via kringle domains and
bind to exposed lysine residues, (Mutch et al., 2010). Other fibrin interaction sites
(not fibrin) have also been identified. Firstly a stretch of residues in the α-chain 
spanning from α148-160 binds both tPA and plasminogen to low affinity 
(Schielen et al., 1990), but it is unlikely that the recombinant variants will impact
on this interaction as the residues are located away from this region on the γ-
chain. Another additional plasminogen binding site includes residues γ311-336 
and γ337-379 (Yonekawa et al., 1992). These regions do encompass the
residues where two of the variants are, γE323Q and γK356Q. Further work such 
as binding assays would need to be conducted to investigate whether the
mutations enhance or reduce plasminogen binding.
The enzyme α2-Antiplasmin plays a key role in the fibrinolytic process by 
inhibiting plasmin. FXIII crosslinks α2-Antiplasmin to the fibrin clot at residue 
α303K (Rijken and Uitte de Willige, 2017). As the point mutations in the variants 
are not in proximity to this region it is unlikely that the variants will have an impact
on α2-Antiplasmin binding. 
7.4.3.4 αMβ2
Fibrinogen also binds to the leukocyte receptor αMβ2 (Forsyth et al., 2001), which
has implicated fibrinogen in leukocyte adhesion and the overall inflammatory
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response. Fibrinogen binds αMβ2 receptor via residues γ190-202 and γ377-395 
(Ugarova et al., 1998). The γE323Q and γK356Q mutated residues in these 
variants are somewhat closely located to the αMβ2 site. It is therefore possible
that the variants would have abnormal leukocyte adhesion functionality, however
further study would be required to confirm this.
7.4.4 Complement protein C3
Complement protein 3 (C3) is an important protein in the initiation of innate
immunity and is involved in inflammatory response (Sahu and Lambris, 2001). In
addition to these roles, it has been shown that complement C3 can effect turbidity
and clot structure (Howes et al., 2012). The data shows that a difference in clot
structure can influence clot mechanics and therefore the presence of C3 could
also influence clot mechanics. Howes et al. also showed that C3 can bind to
immobilised fibrinogen using SPR. The recombinant variants could affect the
amount of C3 that is able to integrate into fibrin clots, however further work would
need to be completed because these articles do not describe where C3
specifically binds to fibrin.
7.4.5 Role of calcium binding
As discussed in section 7.2, fibrinogen has a total of four calcium binding sites,
two of which are low affinity binding sites (γ2 and β2) and two of which are high 
affinity binding sites (γ1 and β1).  
Variant γD297N interestingly resides within the low affinity γ2 calcium binding 
site, whereas the variant γE323Q resides within the high affinity γ1 binding site. 
In the case of the γ2 binding site recombinant variant Kostelansky et al.,
developed recombinant variant γD298A/D301A to investigate the role of calcium 
binding on polymerisation (Kostelansky et al., 2007). The authors found that
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polymerisation differed slightly with the D298A/D301A variant meaning that the
γ2 calcium binding site has a small role in fibrin polymerisation. I observe much 
larger changes in the γD297N variant which is closely related to the calcium 
binding site.
Therefore to confirm that my results are from the lack of catch bonds and not
through the loss of calcium binding, it would be necessary to test the variants,
with and without calcium throughout all of the biophysical in vitro assays.
Interestingly a recent publication has proposed that in fact the catch-slip bonds
are regulated by the presence of calcium (Litvinov et al., 2018), this makes it very
difficult to predict on what are observed changes are from as catch-slip may
actually be dependent on calcium binding. An additional caveat is that the β2 
calcium binding sites also play a role polymerisation and clot formation, mainly
lateral aggregation of protofibrils (Kostelansky et al., 2004b), making it even
more difficult to assess the effects of each individual calcium binding on
polymerisation and clot formation.
7.4.6 Molecular dynamic simulations
In the past, X-ray crystallography studies of fibrin(ogen) have provided a
tremendous amount of information in regards to the structure of fibrinogen, some
groups have co-crystalised the synthetic knob (GPRP) with the D-region in order
to produce fibrin crystals (Yang et al., 2000)
On my behalf, my collaborators at University of Massachusetts, (Lowell) are
currently performing molecular dynamic simulations using available fibrin crystal
structure 3GHG in the protein data bank (Kollman et al., 2009).
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I am interested in discovering the dynamic binding contacts formed in and near
A:a binding pocket during fibrin polymerisation that lead to the striking
differences observed in this work. Molecular pulling simulations (Kononova et al.,
2013) of GPRP peptide from γC nodule will map the binding and unbinding 
transitions for the variants, allowing the assessment of the importance of
individual residues and their dissociation kinetics. The simulations will identify
the role of the variants in three distinct regions of the γC nodule, γD297N in the 
moveable flap, γE323Q in loop I and γK356Q in the interior region. The force 
required to rupture the A:a bond as a function of time for each variant will be
simulated. The number of residues that are actively participating in the extended
knob-hole binding pocket will also be analysed, WT fibrinogen will also be
simulated.
7.5 Physiological importance and relevance
Interestingly, a dysfibrinogenaemia named Fibrinogen Miami (Bβ D61G) has 
been described in the literature. The variant described contained a mutation of
the opposite interacting residue to γK356 that is being investigated in my work. 
The current hypothesis is that ββD61 interacts with γK356. The patient who had 
this dysfibrinogenaemia also showed tendency to bleed and delayed
polymerisation kinetics, (Galanakis et al., 1996) providing evidence that the K356
and BβD61 extended knob-hole interaction also plays an important role in clot 
formation in a physiological setting and may be extremely important in the clinic.
Based on the literature I predict that small changes within the side chains of these
key extended knob-hole residues will influence catch-slip bonds and reduce the
unbinding force of knob A from hole-a, which later amplifies into significant
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changes in polymerisation kinetics and overall clot structure. In physiological
circumstances this could be extremely important during development of
thrombosis as the catch mechanism allows the bonds to counterintuitively
strengthen under shear stresses such as blood flow, possibly preventing
embolization, providing more evidence of the importance of this extended knob-
hole interactions.
The work in this thesis is somewhat limited in terms of scope as it only explores
the role of these residues in fibrin polymerisation and clot formation in vitro and
in silico (data still processing). The next stage to take this research further would
be to explore the role of these variants in fibrinogen deficient plasma to determine
whether the effects of denser clots and thinner fibers observed in the in vitro
studies are still evident when other blood components are involved. FXIIIa
crosslinking, platelet contraction and red blood cell retention are all mechanisms
that are influenced by the final clot structure and mechanics.
Additionally, it was also initially planned that I would investigate the role of these
extended knob-hole interactions on clot formation and stability in vivo. To do this,
an in vivo murine model of thrombosis was proposed. Briefly, in fibrinogen
knockout mice (Fib-/-) a carotid artery would be cannulated to allow for
administration of anaesthetic and injection of recombinant fibrinogen mutants
labelled with Alexa Fluor 488, for 5 minutes prior to exposure of the femoral vein
and application of 10% FeCl3 filter paper for 3 minutes to induce thrombosis.
Real time observation of the clots would have been made using an intra-vital
microscope where clot formation and final clot size would have been measured.
However, due to limitations with the yield of the recombinant variants it was not
possible to conduct such experiments. Power calculations were performed by
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Marco Domingues of the Ariëns laboratory on my behalf and predicted that 5-6
mice would be required to perform a in vivo murine model of thrombosis and
therefore to complete these type of experiments 20-30mg total protein would be
required. Although this would be possible with further protein expression of the
extended knob-hole variants. Therefore, without further studies in ex vivo
(plasma) and in vivo (mouse model) data it is difficult to correlate the effects of
extended knob-hole interactions to DVT risk in patients. However, the results
observed especially in regards to mechanics does show that clots become more
readily deformable when these interactions are abolished, showing that the
mechanical properties of clots could potentially be regulated through extended
knob-hole interactions in additional to traditional mechanisms such as factor XIIIa
crosslinking.
7.6 Conclusions
To conclude, I have used well characterised CHO cell expression and purification
systems to produce pure, and intact recombinant human fibrinogen with
mutations at the extended knob-hole binding sites. I have explored the functional
consequence of these mutations during polymerisation using biophysical light
scattering and atomic force microscopy imaging methods where I observed
delayed polymerisation kinetics. I further probed the role of these variants on
fibrin clot structure using light scattering, laser scanning confocal microscopy and
scanning electron microscopy and observed variant clots that were denser with
thinner fibers. The effects on clot mechanics were also investigated where I
observed that tanδ was mainly increased at 0.1Hz and 1Hz indicating that all 
point mutations are required to have a mechanical effect on the clots. This work
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has exclusively been completed using in vitro biochemical and biophysical in
vitro assays, I recommend that further work should be completed in the future to
test the effects of the variants in the presence of cells and other blood
components.
Although the experiments performed in this thesis are not directly clinically
relevant, the additional understanding of the mechanisms that regulate extended
D-E interactions in fibrin polymerisation, clot formation and clot mechanics may
have future implications for the understanding and prevention of thromboembolic
diseases.
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9.1 - The DNA sequence of the pMLP-γA 
>pMLP-γA. Primer binding sites highlighted in blue, start and stop codons of fibrinogen 
in yellow, target codons during mutagenesis highlighted in red.
CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGT
TTGTGACGTGGCGCGGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGT
GATGTTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTTTG
GTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTAGGCGGATGTTGTAG
TAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAGAGGA
AGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAATATTTGTCTAGGGCCCAAGC
TTGTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGA
GGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGA
ATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGT
TGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTT
TCCACACCTGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGA
GCCTGGGGACTTTCCACACCCTAACTGACACACATTCCACAGCTGGTTCTTTCCGCCTCA
GAAGGGTACCCGGTCCTCCTCGTATAGAAACTCGGACCACTCTGAGACGAAGGCTCGCGT
CCAGGCCAGCACGAAGGAGGCTAAGTGGGAGGGGTAGCGGTCGTTGTCCACTAGGGGGTC
CACTCGCTCCAGGGTGTGAAGACACATGTCGCCCTCTTCGGCATCAAGGAAGGTGATTGG
TTTATAGGTGTAGGCCACGTGACCGGGTGTTCCTGAAGGGGGGCTATAAAAGGGGGTGGG
GGCGCGTTCGTCCTCACTCTCTTCCGCATCGCTGTCTGCGAGGGCCAGCTGTTGGGCTCG
CGGTTGAGGACAAACTCTTCGCGGTCTTTCCAGTACTCTTGGATCGGAAACCCGTCGGCC
TCCGAACGTACTCCGCCACCGAGGGACCTGAGCGAGTCCGCATCGACCGGATCGGAAAAC
CTCTCGAGAAAGGCGTCTAACCAGTCACAGTCGCAAGGTAGGCTGAGCACCGTGGCGGGC
GGCAGCGGGTGGCGGTCGGGGTTGTTTCTGGCGGAGGTGCTGCTGATGATGTAATTAAAG
TAGGCCGTCTTGAGACGGCGGATGGTCGAGCTTGAGGTGTGGCAGGCTTCAGATCTGGCC
ATACACTTGAGTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCCCAG
GTCCAACCTGATCAGAATTGCGCCGCTCTCGAGTGAATTGTCGACCGCGGCCCCAGCTCC
GGGCACTCAGACATCATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTAT
GCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGC
ATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTG
TCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAA
GTTGAAAACAAAACATCAGAAGTCAAACAGCTGATAAAAGCAATCCAACTCACTTATAAT
CCTGATGAATCATCAAAACCAAATATGATAGACGCTGCTACTTTGAAGTCCAGGAAAATG
TTAGAAGAAATTATGAAATATGAAGCATCGATTTTAACACATGACTCAAGTATTCGATAT
TTGCAGGAAATATATAATTCAAATAATCAAAAGATTGTTAACCTGAAAGAGAAGGTAGCC
CAGCTTGAAGCACAGTGCCAGGAACCTTGCAAAGACACGGTGCAAATCCATGATATCACT
GGGAAAGATTGTCAAGACATTGCCAATAAGGGAGCTAAACAGAGCGGGCTTTACTTTATT
AAACCTCTGAAAGCTAACCAGCAATTCTTAGTCTACTGTGAAATCGATGGGTCTGGAAAT
GGATGGACTGTGTTTCAGAAGAGACTTGATGGCAGTGTAGATTTCAAGAAAAACTGGATT
CAATATAAAGAAGGATTTGGACATCTGTCTCCTACTGGCACAACAGAATTTTGGCTGGGA
AATGAGAAGATTCATTTGATAAGCACACAGTCTGCCATCCCATATGCATTAAGAGTGGAA
CTGGAAGACTGGAATGGCAGAACCAGTACTGCAGACTATGCCATGTTCAAGGTGGGACCT
GAAGCTGACAAGTACCGCCTAACATATGCCTACTTCGCTGGTGGGGATGCTGGAGATGCC
TTTGATGGCTTTGATTTTGGCGATGATCCTAGTGACAAGTTTTTCACATCCCATAATGGC
ATGCAGTTCAGTACCTGGGACAATGACAATGATAAGTTTGAAGGCAACTGTGCTGAACAG
GATGGATCTGGTTGGTGGATGAACAAGTGTCACGCTGGCCATCTCAATGGAGTTTATTAC
CAAGGTGGCACTTACTCAAAAGCATCTACTCCTAATGGTTATGATAATGGCATTATTTGG
GCCACTTGGAAAACCCGGTGGTATTCCATGAAGAAAACCACTATGAAGATAATCCCATTC
AACAGACTCACAATTGGAGAAGGACAGCAACACCACCTGGGGGGAGCCAAACAGGCTGGA
GACGTTTAAAAGACCGTTTCAAAAGAGATTTACTTTTTTAAAGGACTTTATCTGAACAGA
GAGATATAATGGGCGGCCGCAATTCTGATCATAATCAGCCATACCACATTTGTAGAGGTT
TTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCA
ATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATC
ACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTC
pMLP-F1
FbgGg-F1
FbgGg-F2
pMLP-R1
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ATCAATGTATCTTATCATGTCTGGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACC
GGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGG
GCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTG
GCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTC
AACGGCCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGGGCTC
TAGACGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATG
ACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCG
GCAGCGCTCTGGGTCATTTTCGGCGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGGC
CTGTCGCTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCC
GCCACCAAACGTTTCGGCGAGAAGCAGGCCATTATCGCCGGCATGGCGGCCGACGCGCTG
GGCTACGTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTCCCCATTATGATTCTT
CTCGCTTCCGGCGGCATCGGGATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGAT
GACGACCATCAGGGACAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGT
TGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAA
GTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCT
CCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCC
CTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGG
TCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCT
TATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAG
CAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGA
AGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTXXTGA
AGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTG
GTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAG
AAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAG
GGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAAT
GAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCT
TAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGAC
TCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAA
TGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCG
GAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATT
GTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCA
TTGCTGCAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTT
CCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCT
TCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGG
CAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTG
AGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGG
CGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAA
AACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGGTCGATGT
AACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGT
GAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTT
GAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCA
TGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACAT
TTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATA
AAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGA
204
9.2 - Sequence alignments of WT with recombinant variants
D297N variant
>pMLP+Fbg-γ WT compared to pMLP+Fbg-γ D297N 
WT ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTC 60
D297N ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTC 60
************************************************************
WT TCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGA 120
D297N TCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGA 120
************************************************************
WT TTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACC 180
D297N TTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACC 180
************************************************************
WT AAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACA 240
D297N AAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACA 240
************************************************************
WT TCAGAAGTCAAACAGCTGATAAAAGCAATCCAACTCACTTATAATCCTGATGAATCATCA 300
D297N TCAGAAGTCAAACAGCTGATAAAAGCAATCCAACTCACTTATAATCCTGATGAATCATCA 300
************************************************************
WT AAACCAAATATGATAGACGCTGCTACTTTGAAGTCCAGGAAAATGTTAGAAGAAATTATG 360
D297N AAACCAAATATGATAGACGCTGCTACTTTGAAGTCCAGGAAAATGTTAGAAGAAATTATG 360
************************************************************
WT AAATATGAAGCATCGATTTTAACACATGACTCAAGTATTCGATATTTGCAGGAAATATAT 420
D297N AAATATGAAGCATCGATTTTAACACATGACTCAAGTATTCGATATTTGCAGGAAATATAT 420
************************************************************
WT AATTCAAATAATCAAAAGATTGTTAACCTGAAAGAGAAGGTAGCCCAGCTTGAAGCACAG 480
D297N AATTCAAATAATCAAAAGATTGTTAACCTGAAAGAGAAGGTAGCCCAGCTTGAAGCACAG 480
************************************************************
WT TGCCAGGAACCTTGCAAAGACACGGTGCAAATCCATGATATCACTGGGAAAGATTGTCAA 540
D297N TGCCAGGAACCTTGCAAAGACACGGTGCAAATCCATGATATCACTGGGAAAGATTGTCAA 540
************************************************************
WT GACATTGCCAATAAGGGAGCTAAACAGAGCGGGCTTTACTTTATTAAACCTCTGAAAGCT 600
D297N GACATTGCCAATAAGGGAGCTAAACAGAGCGGGCTTTACTTTATTAAACCTCTGAAAGCT 600
************************************************************
WT AACCAGCAATTCTTAGTCTACTGTGAAATCGATGGGTCTGGAAATGGATGGACTGTGTTT 660
D297N AACCAGCAATTCTTAGTCTACTGTGAAATCGATGGGTCTGGAAATGGATGGACTGTGTTT 660
************************************************************
WT CAGAAGAGACTTGATGGCAGTGTAGATTTCAAGAAAAACTGGATTCAATATAAAGAAGGA 720
D297N CAGAAGAGACTTGATGGCAGTGTAGATTTCAAGAAAAACTGGATTCAATATAAAGAAGGA 720
************************************************************
WT TTTGGACATCTGTCTCCTACTGGCACAACAGAATTTTGGCTGGGAAATGAGAAGATTCAT 780
D297N TTTGGACATCTGTCTCCTACTGGCACAACAGAATTTTGGCTGGGAAATGAGAAGATTCAT 780
************************************************************
WT TTGATAAGCACACAGTCTGCCATCCCATATGCATTAAGAGTGGAACTGGAAGACTGGAAT 840
D297N TTGATAAGCACACAGTCTGCCATCCCATATGCATTAAGAGTGGAACTGGAAGACTGGAAT 840
************************************************************
WT GGCAGAACCAGTACTGCAGACTATGCCATGTTCAAGGTGGGACCTGAAGCTGACAAGTAC 900
D297N GGCAGAACCAGTACTGCAGACTATGCCATGTTCAAGGTGGGACCTGAAGCTGACAAGTAC 900
************************************************************
WT CGCCTAACATATGCCTACTTCGCTGGTGGGGATGCTGGAGATGCCTTTGATGGCTTTGAT 960
D297N CGCCTAACATATGCCTACTTCGCTGGTGGGGATGCTGGAGATGCCTTTGATGGCTTTGAT 960
************************************************************
WT TTTGGCGATGATCCTAGTGACAAGTTTTTCACATCCCATAATGGCATGCAGTTCAGTACC 1020
D297N TTTGGCAATGATCCTAGTGACAAGTTTTTCACATCCCATAATGGCATGCAGTTCAGTACC 1020
****** *****************************************************
205
WT TGGGACAATGACAATGATAAGTTTGAAGGCAACTGTGCTGAACAGGATGGATCTGGTTGG 1080
D297N TGGGACAATGACAATGATAAGTTTGAAGGCAACTGTGCTGAACAGGATGGATCTGGTTGG 1080
************************************************************
WT TGGATGAACAAGTGTCACGCTGGCCATCTCAATGGAGTTTATTACCAAGGTGGCACTTAC 1140
D297N TGGATGAACAAGTGTCACGCTGGCCATCTCAATGGAGTTTATTACCAAGGTGGCACTTAC 1140
************************************************************
WT TCAAAAGCATCTACTCCTAATGGTTATGATAATGGCATTATTTGGGCCACTTGGAAAACC 1200
D297N TCAAAAGCATCTACTCCTAATGGTTATGATAATGGCATTATTTGGGCCACTTGGAAAACC 1200
************************************************************
WT CGGTGGTATTCCATGAAGAAAACCACTATGAAGATAATCCCATTCAACAGACTCACAATT 1260
D297N CGGTGGTATTCCATGAAGAAAACCACTATGAAGATAATCCCATTCAACAGACTCACAATT 1260
************************************************************
WT GGAGAAGGACAGCAACACCACCTGGGGGGAGCCAAACAGGCTGGAGACGTTTAA1314
D297N GGAGAAGGACAGCAACACCACCTGGGGGGAGCCAAACAGGCTGGAGACGTTTAA1314
******************************************************
E323Q variant
>pMLP+Fbg-γ WT compared to pMLP+Fbg-γ E323Q 
WT ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTC 60
E323Q ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTC 60
************************************************************
WT TCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGA 120
E323Q TCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGA 120
************************************************************
WT TTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACC 180
E323Q TTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACC 180
************************************************************
WT AAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACA 240
E323Q AAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACA 240
************************************************************
WT TCAGAAGTCAAACAGCTGATAAAAGCAATCCAACTCACTTATAATCCTGATGAATCATCA 300
E323Q TCAGAAGTCAAACAGCTGATAAAAGCAATCCAACTCACTTATAATCCTGATGAATCATCA 300
************************************************************
WT AAACCAAATATGATAGACGCTGCTACTTTGAAGTCCAGGAAAATGTTAGAAGAAATTATG 360
E323Q AAACCAAATATGATAGACGCTGCTACTTTGAAGTCCAGGAAAATGTTAGAAGAAATTATG 360
************************************************************
WT AAATATGAAGCATCGATTTTAACACATGACTCAAGTATTCGATATTTGCAGGAAATATAT 420
E323Q AAATATGAAGCATCGATTTTAACACATGACTCAAGTATTCGATATTTGCAGGAAATATAT 420
************************************************************
WT AATTCAAATAATCAAAAGATTGTTAACCTGAAAGAGAAGGTAGCCCAGCTTGAAGCACAG 480
E323Q AATTCAAATAATCAAAAGATTGTTAACCTGAAAGAGAAGGTAGCCCAGCTTGAAGCACAG 480
************************************************************
WT TGCCAGGAACCTTGCAAAGACACGGTGCAAATCCATGATATCACTGGGAAAGATTGTCAA 540
E323Q TGCCAGGAACCTTGCAAAGACACGGTGCAAATCCATGATATCACTGGGAAAGATTGTCAA 540
************************************************************
WT GACATTGCCAATAAGGGAGCTAAACAGAGCGGGCTTTACTTTATTAAACCTCTGAAAGCT 600
E323Q GACATTGCCAATAAGGGAGCTAAACAGAGCGGGCTTTACTTTATTAAACCTCTGAAAGCT 600
************************************************************
WT AACCAGCAATTCTTAGTCTACTGTGAAATCGATGGGTCTGGAAATGGATGGACTGTGTTT 660
E323Q AACCAGCAATTCTTAGTCTACTGTGAAATCGATGGGTCTGGAAATGGATGGACTGTGTTT 660
************************************************************
WT CAGAAGAGACTTGATGGCAGTGTAGATTTCAAGAAAAACTGGATTCAATATAAAGAAGGA 720
E323Q CAGAAGAGACTTGATGGCAGTGTAGATTTCAAGAAAAACTGGATTCAATATAAAGAAGGA 720
************************************************************
WT TTTGGACATCTGTCTCCTACTGGCACAACAGAATTTTGGCTGGGAAATGAGAAGATTCAT 780
E323Q TTTGGACATCTGTCTCCTACTGGCACAACAGAATTTTGGCTGGGAAATGAGAAGATTCAT 780
************************************************************
206
WT TTGATAAGCACACAGTCTGCCATCCCATATGCATTAAGAGTGGAACTGGAAGACTGGAAT 840
E323Q TTGATAAGCACACAGTCTGCCATCCCATATGCATTAAGAGTGGAACTGGAAGACTGGAAT 840
************************************************************
WT GGCAGAACCAGTACTGCAGACTATGCCATGTTCAAGGTGGGACCTGAAGCTGACAAGTAC 900
E323Q GGCAGAACCAGTACTGCAGACTATGCCATGTTCAAGGTGGGACCTGAAGCTGACAAGTAC 900
************************************************************
WT CGCCTAACATATGCCTACTTCGCTGGTGGGGATGCTGGAGATGCCTTTGATGGCTTTGAT 960
E323Q CGCCTAACATATGCCTACTTCGCTGGTGGGGATGCTGGAGATGCCTTTGATGGCTTTGAT 960
************************************************************
WT TTTGGCGATGATCCTAGTGACAAGTTTTTCACATCCCATAATGGCATGCAGTTCAGTACC 1020
E323Q TTTGGCGATGATCCTAGTGACAAGTTTTTCACATCCCATAATGGCATGCAGTTCAGTACC 1020
************************************************************
WT TGGGACAATGACAATGATAAGTTTGAAGGCAACTGTGCTGAACAGGATGGATCTGGTTGG 1080
E323Q TGGGACAATGACAATGATAAGTTTCAAGGCAACTGTGCTGAACAGGATGGATCTGGTTGG 1080
************************ ***********************************
WT TGGATGAACAAGTGTCACGCTGGCCATCTCAATGGAGTTTATTACCAAGGTGGCACTTAC 1140
E323Q TGGATGAACAAGTGTCACGCTGGCCATCTCAATGGAGTTTATTACCAAGGTGGCACTTAC 1140
************************************************************
WT TCAAAAGCATCTACTCCTAATGGTTATGATAATGGCATTATTTGGGCCACTTGGAAAACC 1200
E323Q TCAAAAGCATCTACTCCTAATGGTTATGATAATGGCATTATTTGGGCCACTTGGAAAACC 1200
************************************************************
WT CGGTGGTATTCCATGAAGAAAACCACTATGAAGATAATCCCATTCAACAGACTCACAATT 1260
E323Q CGGTGGTATTCCATGAAGAAAACCACTATGAAGATAATCCCATTCAACAGACTCACAATT 1260
************************************************************
WT GGAGAAGGACAGCAACACCACCTGGGGGGAGCCAAACAGGCTGGAGACGTTTAA1314
E323Q GGAGAAGGACAGCAACACCACCTGGGGGGAGCCAAACAGGCTGGAGACGTTTAA1314
******************************************************
K356Q variant
>pMLP+Fbg-γ WT compared to pMLP+Fbg-γ K356Q 
WT ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTC 60
K356Q ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTC 60
************************************************************
WT TCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGA 120
K356Q TCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGA 120
************************************************************
WT TTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACC 180
K356Q TTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACC 180
************************************************************
WT AAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACA 240
K356Q AAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACA 240
************************************************************
WT TCAGAAGTCAAACAGCTGATAAAAGCAATCCAACTCACTTATAATCCTGATGAATCATCA 300
K356Q TCAGAAGTCAAACAGCTGATAAAAGCAATCCAACTCACTTATAATCCTGATGAATCATCA 300
************************************************************
WT AAACCAAATATGATAGACGCTGCTACTTTGAAGTCCAGGAAAATGTTAGAAGAAATTATG 360
K356Q AAACCAAATATGATAGACGCTGCTACTTTGAAGTCCAGGAAAATGTTAGAAGAAATTATG 360
************************************************************
WT AAATATGAAGCATCGATTTTAACACATGACTCAAGTATTCGATATTTGCAGGAAATATAT 420
K356Q AAATATGAAGCATCGATTTTAACACATGACTCAAGTATTCGATATTTGCAGGAAATATAT 420
************************************************************
WT AATTCAAATAATCAAAAGATTGTTAACCTGAAAGAGAAGGTAGCCCAGCTTGAAGCACAG 480
K356Q AATTCAAATAATCAAAAGATTGTTAACCTGAAAGAGAAGGTAGCCCAGCTTGAAGCACAG 480
************************************************************
WT TGCCAGGAACCTTGCAAAGACACGGTGCAAATCCATGATATCACTGGGAAAGATTGTCAA 540
K356Q TGCCAGGAACCTTGCAAAGACACGGTGCAAATCCATGATATCACTGGGAAAGATTGTCAA 540
************************************************************
207
WT GACATTGCCAATAAGGGAGCTAAACAGAGCGGGCTTTACTTTATTAAACCTCTGAAAGCT 600
K356Q GACATTGCCAATAAGGGAGCTAAACAGAGCGGGCTTTACTTTATTAAACCTCTGAAAGCT 600
************************************************************
WT AACCAGCAATTCTTAGTCTACTGTGAAATCGATGGGTCTGGAAATGGATGGACTGTGTTT 660
K356Q AACCAGCAATTCTTAGTCTACTGTGAAATCGATGGGTCTGGAAATGGATGGACTGTGTTT 660
************************************************************
WT CAGAAGAGACTTGATGGCAGTGTAGATTTCAAGAAAAACTGGATTCAATATAAAGAAGGA 720
K356Q CAGAAGAGACTTGATGGCAGTGTAGATTTCAAGAAAAACTGGATTCAATATAAAGAAGGA 720
************************************************************
WT TTTGGACATCTGTCTCCTACTGGCACAACAGAATTTTGGCTGGGAAATGAGAAGATTCAT 780
K356Q TTTGGACATCTGTCTCCTACTGGCACAACAGAATTTTGGCTGGGAAATGAGAAGATTCAT 780
************************************************************
WT TTGATAAGCACACAGTCTGCCATCCCATATGCATTAAGAGTGGAACTGGAAGACTGGAAT 840
K356Q TTGATAAGCACACAGTCTGCCATCCCATATGCATTAAGAGTGGAACTGGAAGACTGGAAT 840
************************************************************
WT GGCAGAACCAGTACTGCAGACTATGCCATGTTCAAGGTGGGACCTGAAGCTGACAAGTAC 900
K356Q GGCAGAACCAGTACTGCAGACTATGCCATGTTCAAGGTGGGACCTGAAGCTGACAAGTAC 900
************************************************************
WT CGCCTAACATATGCCTACTTCGCTGGTGGGGATGCTGGAGATGCCTTTGATGGCTTTGAT 960
K356Q CGCCTAACATATGCCTACTTCGCTGGTGGGGATGCTGGAGATGCCTTTGATGGCTTTGAT 960
************************************************************
WT TTTGGCGATGATCCTAGTGACAAGTTTTTCACATCCCATAATGGCATGCAGTTCAGTACC 1020
K356Q TTTGGCGATGATCCTAGTGACAAGTTTTTCACATCCCATAATGGCATGCAGTTCAGTACC 1020
************************************************************
WT TGGGACAATGACAATGATAAGTTTGAAGGCAACTGTGCTGAACAGGATGGATCTGGTTGG 1080
K356Q TGGGACAATGACAATGATAAGTTTGAAGGCAACTGTGCTGAACAGGATGGATCTGGTTGG 1080
************************************************************
WT TGGATGAACAAGTGTCACGCTGGCCATCTCAATGGAGTTTATTACCAAGGTGGCACTTAC 1140
K356Q TGGATGAACAAGTGTCACGCTGGCCATCTCAATGGAGTTTATTACCAAGGTGGCACTTAC 1140
************************************************************
WT TCAAAAGCATCTACTCCTAATGGTTATGATAATGGCATTATTTGGGCCACTTGGAAAACC 1200
K356Q TCACAAGCATCTACTCCTAATGGTTATGATAATGGCATTATTTGGGCCACTTGGAAAACC 1200
*** ********************************************************
WT CGGTGGTATTCCATGAAGAAAACCACTATGAAGATAATCCCATTCAACAGACTCACAATT 1260
K356Q CGGTGGTATTCCATGAAGAAAACCACTATGAAGATAATCCCATTCAACAGACTCACAATT 1260
************************************************************
WT GGAGAAGGACAGCAACACCACCTGGGGGGAGCCAAACAGGCTGGAGACGTTTAA1314
K356Q GGAGAAGGACAGCAACACCACCTGGGGGGAGCCAAACAGGCTGGAGACGTTTAA1314
******************************************************
γDEK (triple mutant) variant
>pMLP+Fbg-γ WT compared to pMLP+Fbg-γ D297N-E323Q-K356Q (γDEK) 
WT ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTC 60
yD297N-E323Q-K356Q ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTC 60
************************************************************
WT TCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGA 120
yD297N-E323Q-K356Q TCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGA 120
************************************************************
WT TTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACC 180
yD297N-E323Q-K356Q TTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACC 180
************************************************************
WT AAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACA 240
yD297N-E323Q-K356Q AAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACA 240
************************************************************
WT TCAGAAGTCAAACAGCTGATAAAAGCAATCCAACTCACTTATAATCCTGATGAATCATCA 300
yD297N-E323Q-K356Q TCAGAAGTCAAACAGCTGATAAAAGCAATCCAACTCACTTATAATCCTGATGAATCATCA 300
************************************************************
WT AAACCAAATATGATAGACGCTGCTACTTTGAAGTCCAGGAAAATGTTAGAAGAAATTATG 360
yD297N-E323Q-K356Q AAACCAAATATGATAGACGCTGCTACTTTGAAGTCCAGGAAAATGTTAGAAGAAATTATG 360
************************************************************
208
WT AAATATGAAGCATCGATTTTAACACATGACTCAAGTATTCGATATTTGCAGGAAATATAT 420
yD297N-E323Q-K356Q AAATATGAAGCATCGATTTTAACACATGACTCAAGTATTCGATATTTGCAGGAAATATAT 420
************************************************************
WT AATTCAAATAATCAAAAGATTGTTAACCTGAAAGAGAAGGTAGCCCAGCTTGAAGCACAG 480
yD297N-E323Q-K356Q AATTCAAATAATCAAAAGATTGTTAACCTGAAAGAGAAGGTAGCCCAGCTTGAAGCACAG 480
************************************************************
WT TGCCAGGAACCTTGCAAAGACACGGTGCAAATCCATGATATCACTGGGAAAGATTGTCAA 540
yD297N-E323Q-K356Q TGCCAGGAACCTTGCAAAGACACGGTGCAAATCCATGATATCACTGGGAAAGATTGTCAA 540
************************************************************
WT GACATTGCCAATAAGGGAGCTAAACAGAGCGGGCTTTACTTTATTAAACCTCTGAAAGCT 600
yD297N-E323Q-K356Q GACATTGCCAATAAGGGAGCTAAACAGAGCGGGCTTTACTTTATTAAACCTCTGAAAGCT 600
************************************************************
WT AACCAGCAATTCTTAGTCTACTGTGAAATCGATGGGTCTGGAAATGGATGGACTGTGTTT 660
yD297N-E323Q-K356Q AACCAGCAATTCTTAGTCTACTGTGAAATCGATGGGTCTGGAAATGGATGGACTGTGTTT 660
************************************************************
WT CAGAAGAGACTTGATGGCAGTGTAGATTTCAAGAAAAACTGGATTCAATATAAAGAAGGA 720
yD297N-E323Q-K356Q CAGAAGAGACTTGATGGCAGTGTAGATTTCAAGAAAAACTGGATTCAATATAAAGAAGGA 720
************************************************************
WT TTTGGACATCTGTCTCCTACTGGCACAACAGAATTTTGGCTGGGAAATGAGAAGATTCAT 780
yD297N-E323Q-K356Q TTTGGACATCTGTCTCCTACTGGCACAACAGAATTTTGGCTGGGAAATGAGAAGATTCAT 780
************************************************************
WT TTGATAAGCACACAGTCTGCCATCCCATATGCATTAAGAGTGGAACTGGAAGACTGGAAT 840
yD297N-E323Q-K356Q TTGATAAGCACACAGTCTGCCATCCCATATGCATTAAGAGTGGAACTGGAAGACTGGAAT 840
************************************************************
WT GGCAGAACCAGTACTGCAGACTATGCCATGTTCAAGGTGGGACCTGAAGCTGACAAGTAC 900
yD297N-E323Q-K356Q GGCAGAACCAGTACTGCAGACTATGCCATGTTCAAGGTGGGACCTGAAGCTGACAAGTAC 900
************************************************************
WT CGCCTAACATATGCCTACTTCGCTGGTGGGGATGCTGGAGATGCCTTTGATGGCTTTGAT 960
yD297N-E323Q-K356Q CGCCTAACATATGCCTACTTCGCTGGTGGGGATGCTGGAGATGCCTTTGATGGCTTTGAT 960
************************************************************
WT TTTGGCGATGATCCTAGTGACAAGTTTTTCACATCCCATAATGGCATGCAGTTCAGTACC 1020
yD297N-E323Q-K356Q TTTGGCAATGATCCTAGTGACAAGTTTTTCACATCCCATAATGGCATGCAGTTCAGTACC 1020
******.*****************************************************
WT TGGGACAATGACAATGATAAGTTTGAAGGCAACTGTGCTGAACAGGATGGATCTGGTTGG 1080
yD297N-E323Q-K356Q TGGGACAATGACAATGATAAGTTTCAAGGCAACTGTGCTGAACAGGATGGATCTGGTTGG 1080
************************ ***********************************
WT TGGATGAACAAGTGTCACGCTGGCCATCTCAATGGAGTTTATTACCAAGGTGGCACTTAC 1140
yD297N-E323Q-K356Q TGGATGAACAAGTGTCACGCTGGCCATCTCAATGGAGTTTATTACCAAGGTGGCACTTAC 1140
************************************************************
WT TCAAAAGCATCTACTCCTAATGGTTATGATAATGGCATTATTTGGGCCACTTGGAAAACC 1200
yD297N-E323Q-K356Q TCACAAGCATCTACTCCTAATGGTTATGATAATGGCATTATTTGGGCCACTTGGAAAACC 1200
***.********************************************************
WT CGGTGGTATTCCATGAAGAAAACCACTATGAAGATAATCCCATTCAACAGACTCACAATT 1260
yD297N-E323Q-K356Q CGGTGGTATTCCATGAAGAAAACCACTATGAAGATAATCCCATTCAACAGACTCACAATT 1260
************************************************************
WT GGAGAAGGACAGCAACACCACCTGGGGGGAGCCAAACAGGCTGGAGACGTTTAA 1314
yD297N-E323Q-K356Q GGAGAAGGACAGCAACACCACCTGGGGGGAGCCAAACAGGCTGGAGACGTTTAA 1314
******************************************************
209
9.3 - Representative SEM Images at x2000 magnification
WT
γK356QγE323Q
γD297NγDEK
210
9.4 - Representative SEM images at x5000 magnification
γK356Q
WT γDEK γD297N
γE323Q
211
9.5 - Representative SEM images at x10000 magnification
γK356Q
WT γDEK γD297N
γE323Q
212
9.6 - Representative SEM images at x50000 magnification
γK356Q
WT γDEK γD297N
γE323Q
213
9.7 - Abstracts
XXVIth Congress International Society of Thrombosis and Haemostasis Congress,
Berlin, Germany, 2017
Extended D-E interaction sites near the classical knob-hole binding site play an important
role in fibrin polymerisation and clot formation
Asquith N.L.1, Duval C.1, Domingues M.M.1,2, McPherson H.R.1, Macrae F.L.1, Connell S.D.3,
Barsegov V.4, Ariëns R.A.S.1
1 Thrombosis and Tissue Repair Group; Division of Cardiovascular and Diabetes Research;
Leeds Institute of Cardiovascular And Metabolic Medicine; University of Leeds; UK
2 Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal
3 Molecular and Nanoscale Physics group, School of Physics and Astronomy, University of
Leeds, UK
4 Department of Chemistry, University of Massachusetts, Lowell, Massachusetts, USA
BACKGROUND: Molecular simulations indicate the presence of an extended binding interface
beyond the traditional knob-hole interactions that occur when thrombin converts fibrinogen to
fibrin (Kononova, JBC 2013). Within this extended binding interface, γAsp297, γGlu323 and 
γLys356 in the D-region of one fibrin molecule interact with βLys58, βAsp61 and βHis67 in the 
E-region of another, respectively. The effects of these novel electrostatic interactions on fibrin
polymerisation and clot structure are unknown.
AIMS: To study the role of the extended knob-hole interface in polymerisation kinetics, clot
structure and clot mechanics.
METHODS: Recombinant human fibrinogen γDEK variant (γD297N/E323Q/K356Q) and wild-
type (WT) were produced in CHO cells and purified by affinity chromatography. Clot
polymerisation kinetics were studied by turbidity. Clot visco-elastic properties were determined
by magnetic tweezers. Confocal microscopy was used to study clot formation, clot structure and
clot lysis.
RESULTS: γDEK showed extended lag phase (+30%), slower clotting rate (-45%) and lower 
maximum OD (-41%) compared to WT. This variant produced a denser clot network (+41%) in
hydrated conditions compared to WT, which resulted in slower lysis rates (-37%). Frequency
dependent moduli were calculated and G’ (elastic modulus), was similar at 0.1Hz but higher at 1
and 10Hz, compared to WT. G” (energy loss modulus) was increased at 0.1Hz 1Hz and 10Hz,
compared to WT. The loss tangent (tanδ, visco-elasticity) was increased at 0.1Hz and 1Hz but 
similar at 10Hz.
CONCLUSIONS: The abolition of electrostatic interactions responsible for the extended binding
interface results in altered polymerisation kinetics (prolonged protofibril formation), clot structure
and viscoelastic properties. Our findings support previous molecular simulations and
demonstrate that the D-E binding interface extends beyond the classical knob-hole interaction to
reinforce fibrin polymerisation.
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Extended D-E interactions near the classical knob-hole binding site play an important role
in fibrin polymerisation and clot stability
Asquith N.L.1, Duval C.1, Baker S.1, Domingues M.M.1,2, McPherson H.R.1, Macrae F.L.1, Connell
S.D.3, Barsegov V.4, Ariëns R.A.S.1
1 Thrombosis and Tissue Repair Group; Division of Cardiovascular and Diabetes Research;
Leeds Institute of Cardiovascular and Metabolic Medicine; University of Leeds; UK
2 Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal
3 Molecular and Nanoscale Physics group, School of Physics and Astronomy, University of
Leeds, UK
4 Department of Chemistry, University of Massachusetts, Lowell, Massachusetts, USA
BACKGROUND: Molecular simulations indicate a role for extended electrostatic binding beyond
the classical knob-hole polymerisation sites generated during fibrinogen to fibrin conversion. The
effects of these novel electrostatic interactions on fibrin polymerisation and stability are unknown.
RESULTS: Recombinant γDEK-fibrinogen, created to eliminate extended binding, showed 
altered polymerisation compared to WT. γDEK-fibrinogen produced a denser clot with thinner 
fibres. Frequency dependent moduli were calculated to study clot mechanics, the loss tangent
(tanδ) was increased, indicating a more viscous clot. 
CONCLUSIONS: Our findings demonstrate that the D-E binding interface extends beyond the
classical knob-hole interaction during fibrin polymerisation and reinforces clot stability.
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Extended D-E interactions near the classical knob-hole binding site play an important role
in fibrin polymerisation and clot stability
Asquith N.L.1, Duval C.1, Baker S.1, Domingues M.M.1,2, McPherson H.R.1, Macrae F.L.1, Connell
S.D.3, Barsegov V.4, Ariëns R.A.S.1
1 Thrombosis and Tissue Repair Group; Division of Cardiovascular and Diabetes Research;
Leeds Institute of Cardiovascular and Metabolic Medicine; University of Leeds; UK
2 Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal
3 Molecular and Nanoscale Physics group, School of Physics and Astronomy, University of
Leeds, UK
4 Department of Chemistry, University of Massachusetts, Lowell, Massachusetts, USA
BACKGROUND: Molecular simulations indicate the presence of an extended binding interface
beyond the traditional knob-hole interactions that occur when thrombin converts fibrinogen to
fibrin (Kononova, JBC 2013). Within this extended binding interface, γAsp297, γGlu323 and 
γLys356 in the D-region of one fibrin molecule interact with βLys58, βAsp61 and βHis67 in the 
E-region of another, respectively. The effects of these novel electrostatic interactions on fibrin
polymerisation and clot structure are unknown.
AIMS: To study the role of the extended knob-hole interface in polymerisation kinetics, clot
structure and clot mechanics.
METHODS: Recombinant human fibrinogen γDEK variant (γD297N/E323Q/K356Q) and wild-
type (WT) were produced in CHO cells and purified by affinity chromatography. Clot
polymerisation kinetics were studied by turbidity. Clot visco-elastic properties were determined
by magnetic tweezers. Confocal microscopy was used to study clot formation, clot structure and
clot lysis. Single γD297N, γE323Q and γK356Q fibrinogen mutants were also produced and 
characterised.
RESULTS: γDEK showed extended lag phase (+30%), slower clotting rate (-45%) and lower 
maximum OD (-41%) compared to WT. This variant produced a denser clot network (+41%) in
hydrated conditions compared to WT, which resulted in slower lysis rates (-37%). Frequency
dependent moduli were calculated and G’ (elastic modulus), was similar at 0.1Hz but higher at 1
and 10Hz, compared to WT. G” (energy loss modulus) was increased at 0.1Hz 1Hz and 10Hz,
compared to WT. The loss tangent (tanδ, visco-elasticity) was increased at 0.1Hz and 1Hz but 
similar at 10Hz. Preliminary turbidity data for γD297N γE323Q and γK356Q fibrinogen variants 
show reduced maximum OD similar to yDEK.
CONCLUSIONS: The abolition of electrostatic interactions responsible for the extended binding
interface results in altered polymerisation kinetics (prolonged protofibril formation), clot structure
and viscoelastic properties. Our findings support previous molecular simulations and
demonstrate that the D-E binding interface extends beyond the classical knob-hole interaction to
reinforce fibrin polymerisation.
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Extended D-E interactions near the classical knob-hole binding site play an important role
in fibrin polymerisation and clot stability
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S.D.3, Barsegov V.4, Ariëns R.A.S.1
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Leeds Institute of Cardiovascular and Metabolic Medicine; University of Leeds; UK
2 Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal
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BACKGROUND: Previous studies indicate the presence of an extended binding interface beyond
the traditional knob-hole interactions that occur when thrombin converts fibrinogen to fibrin
(Kononova, JBC 2013): γAsp297, γGlu323 and γLys356 in the D-region interact with βLys58, 
βAsp61 and βHis67 in the E-region from another adjacent fibrin monomer. 
AIMS: To investigate the role of the extended knob-hole interface in polymerisation kinetics, clot
structure and mechanics.
METHODS: Four recombinant human fibrinogen variants and WT were produced: γDEK 
(γD297N/E323Q/K356Q) with mutations in all γ-chain residues involved in extended knob-hole 
binding, and variants with single mutations at γD297N, γE323Q or γK356Q.   
RESULTS: Maximum OD for all variants was reduced compared to WT, whereas lag phase was
only extended for γDEK. γDEK was more readily deformable (loss tangent, tanδ), but single 
mutant variants were unchanged compared to WT. Electron microscopy showed γDEK forming 
the densest clots, followed by the single mutants, then WT. Fibers for all variants were thinner
than WT, with γDEK being the thinnest. Variants γDEK and γE323Q produced a denser clot 
network in hydrated conditions, whereas γD297N and γK356Q were similar to WT, and all were 
slower to lyse, except γD297N. There were no differences in clot size between γD297N and WT 
fibrinogen in an in vivo model of murine femoral thrombosis.
CONCLUSIONS: The abolition of electrostatic interactions responsible for extended binding
results in altered polymerisation kinetics, clot structure and viscoelastic properties. Our findings
demonstrate that the D-E binding interface extends beyond the classical knob-hole interaction to
reinforce fibrin polymerisation.
